PEPTIDE DEFORMYLASE INHIBITORS FIELD OF THE INVENTION The present invention relates to the use of novel antibacterial compounds, and pharmaceutical compositions containing these compounds as peptide deformylase inhibitors.

BACKGROUND OF THE INVENTION Bacterial initiator methionyl tRNA is modified by methionyl tRNA formyltransferase (FMT) to produce formyl-methionyl tRNA. The formyl methionine (f-met) is then incorporated at the N-termini of newly synthesized polypeptides. Polypeptide deformylase (PDF or Def) then deformylates primary translation products to produce N-methionyl polypeptides. Most intracellular proteins are further processed by methionine amino peptidase (MAP) to yield the mature peptide and free methionine, which is recycled. PDF and MAP are both essential for bacterial growth, and PDF is required for MAP activity. This series of reactions is referred to as the methionine cycle (Figure 1). Polypeptide Met . Met- -,., Met-tRNA Polypeptide Dey'' DEF T 1 FMT FMT F-M et- Polypeptide Figure 1. The methionine cycle.

To date, polypeptide deformylase homologous genes have been found in bacteria, in chloroplast-containing plants, in mice and in human. The plant proteins are nuclear encoded

but appear to carry a chloroplast localisation signal. This is consistent with the observation that chloroplast RNA and protein synthesis processes are highly similar to those of eubacteria.

While there is limited information on protein expression of mammalian PDF gene homologs (Bayer Aktiengesellschaft, Pat. W02001/42431), no functional role for such proteins has been demonstrated to date (Meinnel, T. , Parasitology Today 16 (4), 165-168, 2000).

Polypeptide deformylase is found in all eubacteria for which high coverage genomic sequence information is available. Sequence diversity among PDF homologs is high, with as little as 20% identity between distantly related sequences. However, conservation around the active site is very high, with several completely conserved residue, including one cystine and two histidines which are required to coordinate the active site metal (Meinnel, T. et al. , J. Mol.

Biol. 267,749-761, 1997).

PDF is recognized to be an attractive antibacterial target, as this enzyme has been demonstrated to be essential for bacterial growth in vitro (Mazel, D. et al. , EMBO J. 13 (4), 914-923,1994), is not believed to be involved in eukaryotic protein synthesis (Rajagopalan et al. , J. Am. Chem. Soc. 119,12418-12419, 1997), and is universally conserved in prokaryotes (Kozak, M. , Microbiol. Rev. 47,1-45, 1983). Therefore PDF inhibitors can potentially serve as broad spectrum antibacterial agents.

SUMMARY OF THE INVENTION The present invention involves novel antibacterial compounds represented by Formula (1) hereinbelow and their use as PDF inhibitors.

DETAILED DESCRIPTION OF THE INVENTION In one aspect of the present invention, there is provided a compound of formula (1) : wherein:

R is selected from the group consisting of : C2 6 alkyl (optionally substituted by alkoxy, halogen, or CI-3 alkylsulfanyl); C2 6 alkenyl (optionally substituted by alkoxy, halogen, or Cl-3 alkylsulfanyl); C2 6 alkynyl (optionally substituted by alkoxy, halogen, or C1 3 alkylsulfanyl); (CH2) n- C3-6 carbocycle (optionally substituted by alkoxy, halogen, or C1-3 alkylsulfanyl); and (CH2) nR4, wherein R4 is selected from the group consisting of phenyl, furan, benzofuran, thiophene, benzothiophene, tetrahydrofuran, tetrahydropyran, dioxane, 1,4- benzodioxane or benzo [1, 3] dioxole; R4 is optionally substituted by one or more substituent selected from Cl, Br, I, C1-3 alkyl (optionally substituted by one to three F) and C1 2 alkoxy (optionally substituted by one to three F); Rl and R2 are independently selected from the group consisting of : hydrogen, Ci. g substituted alkyl, C2 3 substituted alkenyl, C2 3 substituted alkynyl, (CH2)n-C3-6 substituted carbocycle, aryl, heteroaryl, and heterocyclic; Y represents O, CH2 or a covalent bond; and n is an integer from 0 to 2; or a salt, solvate, or physiologically functional derivative thereof.

In this invention the most preferred R2 group is hydrogen. In this invention the most preferred absolute configuration of compounds of the formula (1) is indicated below: As used herein, the term"alkyl"refers to a straight or branched chain saturated hydrocarbon radical. Examples of"alkyl"as used herein include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, hexyl and the like.

As used herein, the term"substituted alkyl"refers to a straight or branched chain saturated hydrocarbon radical, optionally substituted with substituents selected from the group that includes Cl-3 alkyl (optionally substituted by one to three fluorines), C2 3 alkenyl, C2 3 alkynyl, Cl-2 alkoxy (optionally substituted by one to three fluorines), sulfanyl, sulfinyl,

sulfonyl, oxo, hydroxy, mercapto, amino, guanidino, carboxy, aminocarbonyl, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, aminosulfonyl, sulfonylamino, carboxyamide, ureido, nitro, cyano and halogen, multiple degrees of substitution being allowed.

As used herein, the term"alkenyl"refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond. Examples of"alkenyl"as used herein include, but are not limited to, ethenyl and propenyl.

As used herein, the term"substituted alkenyl"refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond, optionally substituted with substituents selected from the group which includes C1 3 alkyl (optionally substituted' by one to three F), amino, aryl, cyano and halogen, multiple degrees of substitution being allowed.

As used herein, the term"alkynyl"refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond. Examples of"alkynyl"as used herein include, but are not limited to, acetylenyl and 1-propynyl.

As used herein, the term"substituted alkynyl"refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond, optionally substituted with substituents selected from the group which includes C1 3 alkyl (optionally substituted by one to three F), amino, aryl and halogen, multiple degrees of substitution being allowed.

As used herein, the term"halogen"refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I), and"halo"refers to the halogen radicals fluoro, chloro, bromo and iodo.

As used herein, the term"carbocycle"refers to a non-aromatic cyclic hydrocarbon radical having from three to seven carbon atoms. For carbocycles with five-to seven- membered rings, a ring double bond is allowed. Exemplary"carbocycle"groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, and cycloheptyl.

As used herein, the term"substituted carbocycle"refers to a non-aromatic cyclic hydrocarbon radical having from three to seven carbon atoms, and which is optionally substituted with substituents selected from the group which includes C1 3 alkyl (optionally substituted by one to three F), C2 3 alkenyl, C2 3 alkynyl, Cl-2 alkoxy (optionally substituted by one to three F), sulfanyl, sulfinyl, sulfonyl, oxo, hydroxy, mercapto, amino, guanidino, carboxy, aminocarbonyl, aryl, aryloxy, heteroaryl, heterocyclic, aminosulfonyl, sulfonylamino,

carboxyamide, nitro, ureido, cyano and halogen, multiple degrees of substitution being allowed. For carbocycles with five-to seven-membered rings, a ring double bond is allowed.

As used herein, the term"aryl"refers to an optionally substituted benzene ring or to an optionally substituted benzene ring fused to one or more optionally substituted benzene rings to form a ring system. Exemplary optional substituents include C1 3 substituted alkyl, C2 3 substituted alkenyl, C2 3 substituted alkynyl, heteroaryl, heterocyclic, aryl, C1 3 alkoxy (optionally substituted by one to three F), aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl ; sulfonylamino, carboxyamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen, or ureido, multiple degrees of substitution being allowed. Such a ring or ring system may be optionally fused to one or more optionally substituted aryl rings (including benzene rings), carbocycle rings or heterocyclic rings. Examples of"aryl"groups include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, biphenyl, indanyl, anthracyl or phenanthryl, as well as substituted derivatives thereof.

As used herein, the term"heteroaryl"refers to an optionally substituted monocyclic five to six membered aromatic ring containing one or more heteroatomic substitutions selected from S, SO, SO2, O, N, or N-oxide, or to such an aromatic ring fused to one or more optionally substituted rings, such as heteroaryl rings, aryl rings, heterocyclic rings, or carbocycle rings (e. g. , a bicyclic or tricyclic ring system). Examples of optional substituents are selected from the group which includes Cul-3 substituted alkyl, C2 3 substituted alkenyl, C2 3 substituted alkynyl, heteroaryl, heterocyclic, aryl, Cul-3 alkoxy (optionally substituted by one to three F), aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, carboxyamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen or ureido, multiple degrees of substitution being allowed. Examples of"heteroaryl"groups used herein include, but are not limited to, benzoimidazolyl, benzothiazolyl, benzoisothiazolyl, benzothiophenyl, benzopyrazinyl, benzotriazolyl, benzotriazinyl, benzo [1, 4] dioxanyl, benzofuranyl, 9H-a- carbolinyl, cinnolinyl, 2,3-dihydro- [1, 4] dioxino [2, 3-b]-pyridinyl, furanyl, furo [2,3-b] pyridinyl, imidazolyl, imidazolidinyl, imidazopyridinyl, isoxazolyl, isothiazolyl, isoquinolinyl, indolyl, indazolyl, indolizinyl, naphthyridinyl, oxazolyl, oxothiadiazolyl, oxadiazolyl, phthalazinyl, pyridyl, pyrrolyl, purinyl, pteridinyl, phenazinyl, pyrazolyl, pyridyl, pyrazolopyrimidinyl,

pyrazolopyridinyl, pyrrolizinyl, pyridazyl, pyrazinyl, pyrimidyl, 4-oxo-1, 2-dihydro-4H- pyrrolo [3,2, 1-ij]-quinolin-4-yl, quinoxalinyl, quinazolinyl, quinolinyl, quinolizinyl, thiophenyl, triazolyl, triazinyl, tetrazolopyrimidinyl, triazolopyrimidinyl, tetrazolyl, thiazolyl, thiazolidinyl, and substituted versions thereof.

As used herein, the term"heterocyclic"refers to a three to seven-membered ring containing one or more heteroatomic moieties selected from S, SO, SO2, O, N, or N-oxide, optionally substituted with substituents selected from the group which includes Ci. g substituted alkyl, C2 3 substituted alkenyl, C2 3 substituted alkynyl, heteroaryl, heterocyclic, aryl, Cl-3 alkoxy (optionally substituted by one to three F), aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, carboxyamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen, or ureido, multiple degrees of substitution being allowed. Such a ring can be saturated or have one or more degrees of unsaturation. Such a ring may be optionally fused to one or more other optionally substituted"heterocyclic"ring (s), aryl ring (s), heteroaryl ring (s), or carbocycle ring (s). Examples of"heterocyclic"moieties include, but are not limited to, 1, 4-dioxanyl, 1,3-dioxanyl, pyrrolidinyl, pyrrolidin-2-onyl, piperidinyl, imidazolidine-2,4- dionepiperidinyl, piperazinyl, piperazine-2,5-dionyl, morpholinyl, dihydropyranyl, dihydrocinnolinyl, 2,3-dihydrobenzo [1, 4] dioxinyl, 3, 4-dihydro-2H-benzo [b] [1, 4] -dioxepinyl, tetrahydropyranyl, 2,3-dihydrofuranyl, 2,3-dihydrobenzofuranyl, dihydroisoxazolyl, tetrahydrobenzodiazepinyl, tetrahydroquinolinyl, tetrahydrofuranyl, tetrahydronaphthyridinyl, tetrahydropurinyl, tetrahydrothiopyranyl, tetrahydrothiophenyl, dihydroquinoxalinyl, tetrahydroquinoxalinyl, tetrahydropyridinyl, tetrahydrocarbolinyl, 4H-benzo [1, 3] -dioxinyl, benzo [1, 3] dioxonyl, 2, 2-difluorobenzo- [1, 3] -dioxonyl, 2,3-dihydro-phthalazine-1, 4-dionyl, isoindole-1, 3-dionyl, and the like.

As used herein, the term"alkoxy"refers to the group-OR,, where Ra is alkyl as defined above. Exemplary alkoxy groups useful in the present invention include, but are not limited to, methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, and t-butoxy.

As used herein the term"aralkoxy"refers to the group-ORaRb, where Ra is alkyl and Rb is aryl as defined above.

As used herein the term"aryloxy"refers to the group-ORa, where Ra is aryl as defined above.

As used herein, the term"mercapto"refers to the group-SH.

As used herein, the term"sulfanyl"refers to the group-SRa, where Ra is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term"sulfinyl"refers to the group-S (O) Ra, where Ra is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term"sulfonyl"refers to the group-S (O) 2Ra, where Ra is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term"oxo"refers to the group =O.

As used herein, the term"hydroxy"refers to the group-OH.

As used herein, the term"amino"refers to the group-NH2. The amino group is optionally substituted by substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term"cyano"refers to the group-CN.

As used herein, the term"aminosulfonyl"refers to the group-S (O) 2NH2. The aminosulfonyl group is optionally substituted by substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term"sulfonylamino"refers to the group-NHS (O) Ra where Ra is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term"carboxyamide"refers to the group-NHC (O) Ra where Ra is substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term"carboxy"refers to the group-C (O) OH. The carboxy group is optionally substituted by substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term"aminocarbonyl"refers to the group-C (O) NH2. The aminocarbonyl group is optionally substituted by substituted alkyl, substituted carbocycle, aryl, heteroaryl or heterocyclic, as defined above.

As used herein, the term"ureido"refers to the group-NHC (O) NHRa wherein Ra is hydrogen, alkyl, carbocycle or aryl as defined above.

As used herein, the term"guanidino"refers to the group-NHC (=NH) NH2.

As used herein, the term"acyl"refers to the group-C (O) Ra, where Ra is alkyl, carbocycle, or heterocyclic as defined herein.

As used herein, the term"aroyl"refers to the group-C (O) Ra, where Ra is aryl as defined herein.

As used herein, the term"heteroaroyl"refers to the group-C (O) Ra, where Ra is heteroaryl as defined herein.

As used herein, the term"acyloxy"refers to the group-OC (O) Ra, where Ra is alkyl, carbocycle, or heterocyclic as defined herein.

As used herein, the term"aroyloxy"refers to the group-OC (O) Ra, where Ra is aryl as defined herein.

As used herein, the term"heteroaroyloxy"refers to the group-OC (O) Ra, where Ra is heteroaryl as defined herein.

Also included in the present invention are pharmaceutically acceptable salts and complexes, such as the hydrochloride, hydrobromide and trifluoroacetate salts and the sodium, potassium and magnesium salts. The compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds and diastereomers are contemplated to be within the scope of the present invention.

Preferred compounds useful in the present invention are selected from the group consisting of : N-Hydroxy-N- [ (R)-2- (N'-pyridin-2-yl-hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N- { (R) -2- [N'- (3-methoxy-phenyl)-hydrazinocarbonyl]-heptyl}- formamide. <BR> <BR> <BR> <BR> <P> N-Hydroxy-N- { (R)-2- [N'- (4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-<BR > <BR> <BR> <BR> <BR> <BR> heptyl}-formamide.

N- { (R)-2- [N'- (4-Cyano-phenyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy-formam ide.

N- { (R)-2- [N'-(2, 6-Dimethyl-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}-N-hydr oxy- formamide. <BR> <BR> <BR> <P> N-Hydroxy-N-[(R)-2-(N'-quinoxalin-2-yl-hydrazinocarbonyl)-he ptyl]-formamide.<BR> <BR> <BR> <BR> <BR> <BR> <P> N-Hydroxy-N-((2R)-2- {N'-(3, 4-dihydro-quinoxalin-2-yl)-hydrazinocarbonyl}-<BR> <BR> <BR> <BR> <BR> <BR> heptyl)-formamide.

N-Hydroxy-N-{(R)-2-[N'-(1, 3, 4-trimethyl-lH-pyrazolo [3,4-b] pyridin-6-yl)- <BR> <BR> <BR> hydrazinocarbonyl]-heptyl}-formamide.<BR> <BR> <BR> <BR> <BR> <P>4-(N'-{ (R) -2- [(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)- benzenesulfonamide.

N-Hydroxy-N- [(2R)-2-(cyclohexylmethyl)-3-oxo-3-{N'[4-(trifluoroemthyl)- <BR> <BR> <BR> pyrimidin-2-yl]-hydrazino}-propyl]-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N- [ (2R)-2- (cyclopentylmethyl)-3-oxo-3- { N'- [4- (trifluoromethyl)-<BR> <BR> <BR> <BR> <BR> <BR> pyrimidin-2-yl]-hydrazino}-propyl]-formamide.<BR> <BR> <BR> <BR> <BR> <P>N- { (R) -2- [N'-(Dimethyl-trifluoromethyl-pyrimidin-4-yl)-hydrazinocarbo nyl]-heptyl}- N-hydroxy-formamide. <BR> <BR> <BR> <P>N-Hydroxy-N- { (R) -2- [N'- (6-trifluoromethyl-pyridazin-3-yl)-hydrazinocarbonyl]-<BR > <BR> <BR> <BR> heptyl}-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N- { (R)-2-[N'-(6-trifluoromethyl-pyrimidin-4-yl)-hydrazinocarbon yl]-<BR> <BR> <BR> <BR> <BR> heptyl}-formamide.

N-Hydroxy-N- { (R)-2- [N'- (5-methyl- [1, 2,4] triazolo [1, 5-a] pyrimidin-7-yl)- <BR> <BR> <BR> hydrazinocarbonyl]-heptyl}-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N- { (R) -2- [N'- (9H-purin-6-yl)-hydrazinocarbonyl]-heptyl}-formamide.

N-{(R)-2-[N'-(5-Cyano-pyrimidin-2-yl)-hydrazinocarbonyl]- heptyl}-N-hydroxy- formamide.

N-Hydroxy-N-((2R)-2-{[N'-(pyrimidin-2-yl)-hydrazino]carbo nyl}-heptyl)-formamide.

N-Hydroxy-N-((2R)-2-(cyclobutylmethyl)-3-oxo-3-{N'-[4-(tr ifluoroemthyl)- <BR> <BR> <BR> pyrimidin-2-yl]-hydrazino}-propyl)-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N- { (R)-2-[N'-(6-imidazol-1-yl-pyrimidin-4-yl)-hydrazinocarbonyl ]-<BR> <BR> <BR> <BR> <BR> heptyl}-formamide.

N-[(R)-2-(N'-ZBenzo[1, 2,4] triazin-3-yl-hydrazinocarbonyl)-heptyl]-N-hydroxy- formamide.

N-Hydroxy-N- { (R)-2- [N'- (7-methoxy-benzo [1, 2,4] triazin-3-yl) -hydrazinocarbonyl]- <BR> <BR> <BR> heptyl}-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N- { (R) -2- [N'- (l-methyl-lH-pyrazolo [3,4-d] pyrimidin-6-yl) -<BR> <BR> <BR> <BR> <BR> hydrazinocarbonyl]-heptyl}-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-((R)-2-{N'-[6-(5-Chloro-pyridin-3-yl-oxy)-pyridaz in-3-yl]-hydrazinocarbonyl}-<BR> <BR> <BR> <BR> <BR> heptyl)-N-hydroxy-formamide.

N-Hydroxy-N- [(2R)-2-({N'-[6-(1H-pyrrol-1-yl)-3-pyridazinyl]-hydrazino}-c arbonyl)- heptyl]-formamide.

N-Hydroxy-N-((2R)-2-{[N'-(9-methyl-9H-prin-6-yl)-hydrazin o]-carbonyl}-heptyl)- formamide.

N-Hydroxy-N- { (R)-2- [N- ( {6-morpholm-4-yl}-9H-purin-2-yl)-hydrazinocarbonyl]-<BR&g t; <BR> <BR> <BR> <BR> heptyl}-formamide.

N- { (R) -2- [N'-(6-Fluoro-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hyd roxy- formamide.

N-Hydroxy-N-((2R)-2-{ [N'-(1-methyl-lH-pyrazolo [3, 4-d] pyrimidin-4-yl)-hydrazino]- carbonyl}-heptyl)-formamide.

N-{(R)-2-[N'-(4-Amino-6-isopropyl-[1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-heptyl}- N-hydroxy-formamide. <BR> <BR> <BR> <P>N- { (R)-2- [N'- (2, 5-Dimethyl-4-nitro-2H-pyrazol-3-yl)-hydrazinocarbonyl]-hepty l}-N- hydroxy-formamide.

N- { (R)-2-[N'-(3-Chloro-1-methyl-lH-pyrazolo [3,4-d] pyrimidin-6-yl)- hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N- { (R) -2- [N'-(6-Dimethylamino-9H-purin-2-yl)-hydrazinocarbonyl]-hepty l}-N- hydroxy-formamide.

N-Hydroxy-N- [(2R)-4-cyclopropyl-2-( {N'- [4-(trifluoromethyl)-pyrimidin-2-yl]- <BR> <BR> <BR> hydrazino}-carbonyl)-butyl]-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N- ( (2R)-2- (cyclopropylmethyl)-3-oxo-3- { N'- [4- (trifluoromethyl)-<BR> <BR> <BR> <BR> <BR> pyrimidin-2-yl]-hydrazino}-propyl)-formamide.

N-Hydroxy-N-{(R)-2-[N'-methyl-N'-(4-trifluoroemthyl-pyrim idin-2-yl)- hydrazinocarbonyl]-heptyl}-formamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-h ydrazino)-4- trifluoromethyl-pyrimidine-5-carboxylic acid methyl ester.

2-(N'- { (R)-2- [(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4- trifluoromethyl-pyrimidine-5-carboxylic acid.

N-{(R)-2-[N'-(5-Fluoro-4-methoxy-pyrimidin-2-yl)-hydrazin ocarbonyl]-heptyl}-N- hydroxy-formamide.

N- { (R) -2- [N'- (4-Dimethylamino-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}- N- hydroxy-formamide. <BR> <BR> <BR> <P>N-Hydroxy-N-{ (2R)-2-[(N'-{6-[(2-hydroxyethyl) amino]-1, 3-dihydro-2H-purin-2-<BR> <BR> <BR> <BR> <BR> ylidene}-hydrazino)-carbonyl]-heptyl}-formamide.<BR> <BR> <BR> <BR> <BR> <P>N- { (R) -2- [N'- (5-Fluoro-4-morpholin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl ]-<BR> <BR> <BR> <BR> <BR> heptyl}-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <P>N- { (R)-2- [N'- (5-Fluoro-4-methylamino-pyrimidin-2-yl)-hydrazinocarbonyl]-h eptyl}- N-hydroxy-formamide.

2- (N'- { (R) -2- [(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4- trifluoromethyl-pyrimidine-5-carboxylic acid dimethylamide.

N-Hydroxy-N- { (R) -2- [N'- (3-oxo-3, 4-dihydro-quinoxalin-2-yl)-hydrazinocarbonyl]-<BR> <BR> <BR> heptyl}-formamide.<BR> <BR> <BR> <P>N- { (R) -2-Butoxy-2- [N'- (4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-<BR > <BR> <BR> ethyl}-N-hydroxy-formamide.<BR> <BR> <BR> <P>2-(N'-{ (R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)- 4- trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoro-phenyl)-amide.

2- (N'- { (R)-2- [ (Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-4- trifluoromethyl-pyrimidine-5-carboxylic acid tert-butylamide. <BR> <BR> <P>N-Hydroxy-N-((R)-2- {N'- [(1-piperidin-1-yl-methanoyl)-trifluoromethyl-pyrimidin-2-&l t;BR> <BR> <BR> yl]-hydrazinocarbonyl}-heptyl)-formamide.<BR> <BR> <BR> <P>N- { (R)-2- [N'- (5-Cyano-4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl ]-<BR> <BR> <BR> heptyl}-N-hydroxy-formamide.

N-Hydroxy-N- [ (2R)-2- ( {N'- [9- (4, 4, 4-trifluorobutyl)-1, 9-dihydro-2H-purin-2-ylidene]- <BR> <BR> hydrazino}-carbonyl)-heptyl]-formamide.<BR> <BR> <BR> <P>N-Hydroxy-N-((R)-2- {N'- [(1-morpholin-4-yl-methanoyl)-trifluoromethyl-pyrimidin-< BR> <BR> <BR> 2-yl]-hydrazinocarbonyl}-heptyl)-formamide.<BR> <BR> <BR> <P>2-(N'- { (R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)- 4- trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide.

N-Hydroxy-N-[(2R)-3-[N'-(1, 2, 4-benzotriazin-3-yl)-hydrazino]-2-(cyclohexylmethyl)- 3-oxopropyl]-formamide.

N-Hydroxy-N- ( (2R)-2- (cyclohexylmethyl)-3- {N'- [7- (methyloxy)-1, 2,4-benzotriazin- 3-yl]-hydrazino}-3-oxopropyl)-formamide.

2-[2-((2R)-2-{ [Formyl (hydroxy) amino] methyl} heptanoyl) hydrazino]-N-methyl-N-2- pyridinyl-4- (trifluoromethyl)-5-pyrimidinecarboxamide.

2- [2-((2R)-2- { [Formyl (hydroxy) amino] methyl} heptanoyl) hydrazino]-N-methyl-N- phenyl-4- (trifluoromethyl)-5-pyrimidinecarboxamide.

2-(N'- { (R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)- 4- trifluoromethyl-pyrimidine-5-carboxylic acid morpholin-4-ylamide. <BR> <BR> <P>N-Hydroxy-N-((R)-2- {N'-[(N'-phenyl-hydrazinocarbonyl)-trifluoromethyl-pyrimidin -<BR> <BR> <BR> 2-yl]-hydrazinocarbonyl}-heptyl)-formamide.<BR> <BR> <BR> <P>2-(N'- { (R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)- 4- trifluoromethyl-pyrimidine-5-carboxylic acid piperidin-1-ylamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-h ydrazino)-4- trifluoromethyl-pyrimidine-5-carboxylic acid pyrrol-1-ylamide. <BR> <BR> <P>N- { (R)-2-[N'-(Dimethylamino-fluoro-pyrimidin-2-yl)-hydrazinocar bonyl]-heptyl}-N- hydroxy-formamide.

N-((R)-2- {N'- [(Ethyl-methyl-amino)-fluoro-pyrimidin-2-yl]-hydrazinocarbon yl}-<BR> <BR> <BR> heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[7-(methylo xy)-1, 2, 4-benzotriazin- <BR> <BR> 3-yl]-hydrazino}-3-oxopropyl)-formamide.<BR> <BR> <BR> <P>N-Hydroxy-N- { (R)-2- [N'- (l-methyl-lH-benzoimidazol-2-yl)-hydrazinocarbonyl]-<BR&g t; <BR> <BR> heptyl}-formamide.

N- { (R)-2- [N'-(4-Azetidin-1-yl-5-fluoro-pyrimidin-2-yl)-hydrazinocarbo nyl]-heptyl} N-hydroxy-formamide.

N- { (R)-2- [N'- (4-Cyclopropylamino-5-fluoro-pyrimidin-2-yl)-hydrazinocarbon yl]- heptyl}-N-hydroxy-formamide.

N-[(R)-2-(N-Benzo[1, 2,4] triazin-3-yl-hydrazinocarbonyl) -3-cyclopentyl-propyl]-N- hydroxy-formamide. <BR> <BR> <P>N-Hydroxy-N- { (R) -2- [N'- (morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl) -<BR> <BR> <BR> hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N-[(R)-2-(N'-{[(2-hydroxy-ethyl)-methyl-amino]- trifluoromethyl- <BR> <BR> pyrimidin-2-yl}-hydrazinocarbonyl)-heptyl]-formamide.<BR& gt; <BR> <BR> <P>N-Hydroxy-N-((R)-2- {N'- [(4-methyl-piperazin-1-yl)-trifluoromethyl-pyrimidin-2-yl]-& lt;BR> <BR> <BR> hydrazinocarbonyl}-heptyl)-formamide.<BR> <BR> <BR> <P>N-Hydroxy-N- ( (2R)-2- (cyclohexylmethyl)-3- {N'- [4- (cyclopropylamino)-5-fluoro-<BR> <BR> <BR> pyrimidin-2-yl] hydrazino}-3-oxopropyl)-formamide.<BR> <BR> <BR> <P>N-Hydroxy-N- ( (2R)-2- (cyclopentylmethyl)-3- {N'- [4- (cyclopropylamino)-5-fluoro- pyrimidin-2-yl] hydrazino}-3-oxopropyl)-formamide. <BR> <BR> <P>N-Hydroxy-N- [ (2R)-3- {N'- [4- (azetidin-1-yl)-5-fluoro-pyrimidin-2-yl]-hydrazino}-2-<BR > <BR> <BR> (cyclopentylmethyl)-3-oxopropyl]-formamide.

N-Hydroxy-N- [(2R)-5-methyl-2-( {N'- [4-(trifluoromethyl)-pyrimidin-2-yl]- hydrazino}-carbonyl)-hexyl]-formamide.

N-[(R)-2-(N'-Benzo[1, 2,4] triazin-3-yl-hydrazinocarbonyl)-5-methyl-hexyl]-N- hydroxy-formamide.

N-Hydroxy-N-[(2R)-5-methyl-2-({N'-[7-(methyloxy)-1, 2,4-benzotriazin-3-yl]- hydrazino}-carbonyl)-hexyl]-formamide.

N- { (R)-2- [N'- (7-Chloro-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide. <BR> <BR> <P>N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3- {N'- [4-(morpholin-4-yl)-6-<BR> <BR> <BR> (trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-3 : oxopropyl)-formamide.

N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3- {N'- [4- [ (2-hydroxyethyl)- (methyl)- amino]-6-(trifluoroemthyl)-pyrimidin-2-yl]-hydrazino}-3-oxop ropyl)- formamide.

N-Hydroxy-N- [(2R)-6-methyl-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]- hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-((2R)-2-{[N'-(1, 2, 4-benzotriazin-3-yl)-hydrazino]-carbonyl}-6- methylheptyl)-formamide.

N-Hydroxy-N- { (R)-2- [N'- (5-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- <BR> <BR> <BR> heptyl}-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-((R)-2- {N'- [(4-Ethyl-piperazin-1-yl)-trifluoromethyl-pyrimidin-2-yl]-&l t;BR> <BR> <BR> <BR> <BR> hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N- { (R) -2- [N'-(piperazin-1-yl-trifluoromethyl-pyrimidin-2-yl)<BR> ; <BR> <BR> <BR> <BR> hydrazinocarbonyl]-heptyl}-formamide.

N- { (R) -2- [N'- (7-Fluoro-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

N-Hydroxy-N- [(2R)-2-( {N'- [4-(4-ethyl-1-piperazinyl)-6-(trifluoromethyl)-pyrimidin- <BR> <BR> <BR> 2-yl]-hydrazino}-carbonyl)-6-methylheptyl]-formamide.<BR& gt; <BR> <BR> <BR> <P>N-Hydroxy-N- [ (2R)-6-methyl-2- ( {N'- [4- (piperazin-1-yl)-6- (trifluoromethyl)-<BR> <BR> <BR> <BR> <BR> pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.<B R> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N- [ (2R)-6-methyl-2- ( {N'- [4- (4-methyl-piperazin-1-yl)-6-<BR> <BR> <BR> <BR> <BR> (trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-hepty l]-formamide.

N-Hydroxy-N-((2R)-2-{[N'-(7-chloro-1, 2,4-benzotriazin-3-yl) hydrazino] carbonyl}-6- methylheptyl)-formamide.

N-Hydroxy-N- ( (2R)-6-methyl-2- { [N'- (5-methyl-1, 2, 4-benzotriazin-3-yl)-hydrazino]- carbonyl}-heptyl)-formamide.

N-Hydroxy-N- ( (2R)-2- { [N'- (7-fluoro-1, 2, 4-benzotriazin-3-yl)-hydrazino]-carbonyl}- <BR> <BR> <BR> 6-methylheptyl)-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N-((R)-2-{N'-[(2-methoxy-ethylamino)-trif luoromethyl-pyrimidin-2-yl]<BR> <BR> <BR> <BR> <BR> hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N- [(2R)-6-methyl-2-({N'-[7-(methyloxy)-1, 2,4-benzotriazin-3-yl]- <BR> <BR> <BR> hydrazino}-carbonyl)-heptyl]-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N-[(R)-2-(N'-{ [4-(2-hydroxy-ethyl)-piperazin-1-yl]-trifluoromethyl-<BR& gt; <BR> <BR> <BR> <BR> pyrimidin-2-yl}-hydrazinocarbonyl)-heptyl]-formamide.<BR& gt; <BR> <BR> <BR> <BR> <P>N-Hydroxy-N-((R)-2-{N'-[(4-pyrimidin-2-yl-piperazin -1-yl)-trifluoromethyl-<BR> <BR> <BR> <BR> <BR> pyrimidin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.<BR& gt; <BR> <BR> <BR> <BR> <P>N-Hydroxy-N-((R)-2- {N'- [(2-hydroxy-ethylamino)-trifluoromethyl-pyrimidin-2-yl]-< BR> <BR> <BR> <BR> <BR> hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N- { (R)-2-[N'-(7-trifluoromethyl-benzo [1, 2,4] triazin-3-yl)- hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N- { (R)-2- [N'- (6-methyl-benzo [l, 2,4] triazin-3-yl)-hydrazinocarbonyl]- heptyl}-formamide.

N-Hydroxy-N-{(2R)-2-(cyclopentylmethyl)-3-[N'-(5-methyl-1 , 2,4-benzotriazin-3- yl) hydrazino]-3-oxopropyl}-formamide.

N-Hydroxy-N-[(2R)-2-({N'-[4-(trifluoroemthyl)-pyrimidin-2 -yl]-hydrazino}- carbonyl)-octyl]-formamide.

N-Hydroxy-N-((2R)-2-{[N'-(1, 2,4-benzotriazin-3-yl) hydrazino]-carbonyl}-octyl)- formamide.

N-Hydroxy-N- [ (2R)-2- ( {N'- [7- (methyloxy)-l, 2, 4-benzotriazin-3-yl]-hydrazino}- carbonyl)-octyl]-formamide.

N-Hydroxy-N- { (R)-2- [N'- (7-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- heptyl}-formamide.

N-{(R)-2-[N'-(6-Chloro-benzo[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide. <BR> <BR> <BR> <P>N-Hydroxy-N- { (R) -2- [N'- (5-methoxy-benzo [1,2, 4] triazin-3-yl)-hydrazinocarbonyl]-<BR> <BR> <BR> <BR> <BR> heptyl}-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N- { (R) -2- [N'-(1-methyl-2-oxo-1, 2-dihydro-pyridin-4-yl)-<BR> <BR> <BR> <BR> <BR> hydrazinocarbonyl]-heptyl}-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N-((R)-2- {N'-[(N'-pyridin-2-yl-hydrazino)-trifluoromethyl-pyrimidin-2 -<BR> <BR> <BR> <BR> <BR> yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-morpholin-4-yl-pyrimid in-2-yl)- <BR> <BR> <BR> hydrazinocarbonyl]-heptyl}-formamide.<BR> <BR> <BR> <BR> <BR> <P>N- ( (R)-2- {N'- [4- (4-Ethyl-piperazin-1-yl)-6-methyl-pyrimidin-2-yl]-<BR> <BR> <BR> <BR> <BR> hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <P>N- { (R)-2- [N'- (4, 6-Dimethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydr oxy- formamide. <BR> <BR> <BR> <BR> <P>N-Hydroxy-N- { (R) -2- [N'- (4-trifluoromethyl-pyridin-2-yl)-hydrazinocarbonyl]-<BR&g t; <BR> <BR> <BR> <BR> heptyl}-formamide.

N-Hydroxy-N- [(R)-2-(N'-isoquinolin-1-yl-hydrazinocarbonyl)-heptyl]-forma mide. <BR> <BR> <BR> <P>N-Hydroxy-N-[(R)-2-(N'-quinolin-2-yl-hydrazinocarbo nyl)-heptyl]-formamide.<BR> <BR> <BR> <BR> <BR> <P>N- { (R)-2-[N'-(l-Benzyl-2-oxo-1, 2-dihydro-pyridin-4-yl)-hydrazinocarbonyl]-heptyl}- N-hydroxy-formamide.

N-Hydroxy-N- { (R)-2- [N'- (4-oxo-4H-pyrido [l, 2-a] [1, 3,5] triazin-2-yl)- <BR> <BR> <BR> hydrazinocarbonyl]-heptyl}-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N- { (R)-2-[N'-(4-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-hepty l}- formamide.

N- { (R) -2- [N'- (l-Butyl-2-oxo-1, 2-dihydro-pyridin-4-yl)-hydrazinocarbonyl]-heptyl}- N-hydroxy-formamide.

N-Hydroxy-N- { (R)-2- [N'- (9-methyl-4-oxo-4H-pyrido [1, 2-a] [1, 3,5] triazin-2-yl)- hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N- { (R)-2- [N'- (6-oxo-4-trifluoromethyl-1, 6-dihydro-pyrimidin-2-yl) - hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N- { (R) -2- [N'-(methyl-trifluoromethyl-pyrimidin-2-yl)- hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N- { (R)-2- [N'- (5-trifluoromethyl-pyridin-2-yl)-hydrazinocarbonyl]- <BR> <BR> heptyl}-formamide.<BR> <BR> <BR> <P>N- { (R)-2- [N'- (6-Ethoxy-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy - formamide.

N-Hydroxy-N-[(R)-2-(N'-pyrido [2, 3-e]- [1, 2,4] triazin-3-yl-hydrazinocarbonyl)- heptyl]-formamide.

N-((R)-2-{N'-[1-(1-Ethyl-propyl)-2-oxo-1,2-dihydro-pyridi n-4-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N- ( (R)-2- {N'- [2-oxo-1- (3-trifluoromethyl-benzyl)-1, 2-dihydro-pyridin-4- yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N- { (R) -2- [N'- (4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}- formamide.

N-Hydroxy-N- { (R) -2- [N'-(6-methoxy-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}- formamide. <BR> <BR> <BR> <P>N-Hydroxy-N- { (R) -2- [N'-(2-oxo-1-quinolin-8-yl-methyl-1, 2-dihydro-pyridin-4-yl)-<BR> <BR> <BR> hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N- [ (R)-2- (N'- { 2-oxo-1- [2- (5, 6,7, 8-tetrahydro-[1, 8] naphthyridin-2-yl)- ethyl]-dihydro-pyridin-4-yl}-hydrazinocarbonyl)-heptyl]-form amide.

N-{ (R)-2-[N'-(4, 6-Bis-ethylamino-[1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

N- {(R)-2-[N'-(Bis-dimethylamino-[1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

N- { (R)-2- [N'- (4, 6-Di-morpholin-4-yl- [1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-heptyl}- N-hydroxy-formamide.

N-Hydroxy-N-((R)-2-{N'-[4-(4-methyl-piperazin-1-yl)-6-pro pylamino-[1, 3,5] triazin- 2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N- { (R)-2-[N7-(Dimethylamino-morpholin-4-yl-[l, 3, 5] triazin-2-yl)- hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N- { (R) -2- [N'- (6-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}- formamide.

N-Hydroxy-N-((R)-2-{N'-[5-(5-phenyl-[1, 3,4] oxadiazol-2-yl) -pyridin-2-yl]- hydrazinocarbonyl}-heptyl)-formamide.

N- { (R)-2- [N'- (7-tert-Butyl-1, 4-dioxo-1, 2,3, 4-tetrahydro-pyrido [3,4-d] pyridazin-5-yl) - hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N- ( (R)-2- {N'- [4-Ethylamino-6- (4-methyl- [ 1, 4] diazepan-1-yl)- [1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N- ( (R)-2- {N'- [4-Ethylamino-6- (4-ethyl-piperazin-1-yl)- [1, 3,5] triazin-2-yl]- <BR> <BR> hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.<BR> <BR> <BR> <P>N-Hydroxy-N- { (R) -2- [N'- (6-trifluoromethyl-pyridin-2-yl)-hydrazinocarbonyl]-<BR&g t; <BR> <BR> heptyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-morpholin-4-yl-methyl- pyrimiein-2-yl)- hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N- { (R)-2- [N'- (4-methyl-6-morpholin-4-yl- [1, 3,5] triazin-2-yl) - hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N- { (2R)-2- (cyclopentylmethyl)-3- [N'- (4, 6-dimethyl-2-pyrimidinyl)- hydrazino]-3-oxopropyl}-formamide.

N-Hydroxy-N- { (R)-2- [N'- (4-methyl-6-pyrrolidin-1-yl-methyl-pyrimidin-2-yl)- hydrazinocarbonyl]-heptyl}-formamide.

N- { (R)-2- [N'- (4-Dimethylaminomethyl-6-methyl-pyrimidin-2-yl)- <BR> <BR> hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.<BR> <BR> <BR> <P>N-Hydroxy-N- ( (R)-2- {N'- [4-methyl-6- (4-methyl-piperazin-1-yl-methyl)-pyrimidin-2-<BR> <BR> <BR> yl]-hydrazinocarbonyl}-heptyl)-formamide.<BR> <BR> <BR> <P>N-Hydroxy-N- { (R) -2- [N'- (5-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}- formamide.

N- ( (R)-2- {N'- [Dimethylamino- (4-methyl- [1,4] diazepan-1-yl)- [1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N- { (R)-2-[N'-(4-methyl-6-pyrrolidin-l-yl- [1, 3,5] triazin-2-yl)- <BR> <BR> hydrazinocarbonyl]-heptyl}-formamide.<BR> <BR> <BR> <P>N-Hydroxy-N- ( (R)-2- {N'- [4-methyl-6-) 4-pyrrolidin-l-yl-piperidin-1-yl)- [1,3, 5] triazin-2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-((R)-2- {N'[(Ethyl-methyl-amino)-methyl-[1, 3, 5] triazin-2-yl]-hydrazinocarbonyl}- heptyl)-N-hydroxy-formamide.

N- ( (R)-2- {N'- [ (4- (4-Ethyl-piperazin-1-yl)-6-methyl- [1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N- [ (2R)-7, 7, 7-trifluoro-2- ( {N'- [4- (trifluoromethyl)-pyrimidin-2-yl]- hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N- ( (2R)-7, 7, 7-trifluoro-2-{[N'-(5-methyl-1, 2,4-benzotriazin-3-yl)- hydrazino]-carbonyl}-heptyl)-formamide.

N-Hydroxy-N- ( (2R)-7, 7, 7-trifluoro-2-{[N'-(7-methyl-1, 2, 4-benzotriazin-3-yl)- hydrazino]-carbonyl}-heptyl) f-ormamide.

N-Hydroxy-N-{(R)-2-[N'-(4-methylamino-6-morpholin-4-yl-[1 , 3,5]-2-yl)- hydrazinocarbonyl]-heptyl}-formamide.

N- ( (R)-2-IN- [4- (4-Ethyl-piperazin-1-yl)-6-methylamino- [1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Ethylamino-6-morpholin-4-yl-[1, 3,5] triazin-2-yl) - hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4, 6,7-trimethyl-7, 8-dihydro-pterin-2-yl)- hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N- { (R)-2- [N'- (4, 6, 7-trimethyl-pteridin-2-yl)-hydrazinocarbonyl]-heptyl}- formamide. <BR> <BR> <BR> <P>N-Hydroxy-N- { (R) -2- [N'- (methoxymethoxymethyl-trifluoromethyl-pyrimidin-2-yl)-<BR > <BR> <BR> hydrazinocarbonyl]-heptyl}-formamide.<BR> <BR> <BR> <P>N-Hydroxy-N- ( (R)-2- {N'- [4-methyl-6- (1-piperidin-1-yl-methanoyl)-pyrimidin 2-yl]-<BR> <BR> <BR> hydrazinocarbonyl}-heptyl)-formamide.

2- (N'- { (R) -2- [(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-6-meth yl- pyrimidine-4-carboxylic acid cyclopropylamide.

2-(N'-{ (R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)- 6-methyl- pyrimidine-4-carboxylic acid diisopropylamide.

N- { (R)-2- [N'- (5-Cyano-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy- formamide.

N- { (R)-2- [N'- (4, 6-Diethyl- [1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

N- { (R)-4-Cyclopentyl-2- [N'- (4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]- butyl}-N-hydroxy-formamide.

N- { (R)-4-Cyclopentyl-2- [N'- (7-methyl-benzo [l, 2,4] triazin-3-yl)-hydrazinocarbonyl]- butyl}-N-hydroxy-formamide.

N- { (R)-4-Cyclopentyl-2- [N'- (5-methyl-benzo [l, 2,4] triazin-3-yl)-hydrazinocarbonyl]- <BR> <BR> butyl}-N-hydroxy-formamide.<BR> <BR> <BR> <P>N-Hydroxy-N-((R)-2-{N'-[6-(4-methyl-piperazin-1-yl- methyl)-pyridin-2-yl]-<BR> <BR> <BR> hydrazinocarbonyl}-heptyl)-formamide.

N- ( (R)-2- {N'- [5- (4, 6-Dimethoxy-pyrimidin-2-yl)-pyridin-2-yl]-hydrazinocarbonyl} - heptyl)-N-hydroxy-formamide.

N- { (R) -2- [N'-(Diethylamino-methyl-[1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-heptyl}- N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-(N'-{[(2-methyl-ethyl)-methyl-amino]-m ethyl-[1, 3,5] triazin-2- yl}-hydrazinocarbonyl)-heptyl]-formamide.

N- ( (R)-1- {N'- [4- (2, 6-Dimethyl-morpholin-4-yl)-6-methyl- [1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(5-Fluoro-4-methyl-6-morpholin-4-yl-pyrimidi n-2-yl)- hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Ethyl-6-morpholin-4-yl-[1, 3,5] triazin-2-yl)-hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

N-{(R)-2-[N'-(Ethyl-methyl-amino)-[1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-heptyl}- N-hydroxy-formamide.

N- ( (R)-2- {N'- [4-Ethyl-6- (4-ethyl-piperazin-1-yl)- [1, 3,5] triazin-2-yl]- <BR> <BR> hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.<BR> <BR> <BR> <P>N- ( (R)-2- { N'- [5-Fluoro-4-methyl-6- (4-methyl-piperazin-1-yl)-pyrimidin-2-yl]-<BR> <BR> <BR> hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N- { (R)-2- [N'- (Dimethylamino-ethyl- [1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-heptyl}- N-hydroxy-formamide.

N-((R)-2-{N'-[5-Fluoro-4-methyl-6-(4-methyl-[1, 4] diazepan-1-yl)-pyrimidin-2-yl]- <BR> <BR> hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.<BR> <BR> <BR> <P>N- { (R) -4-Cyclopentyl-2- [N'- (morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)-<BR> <BR> <BR> hydrazinocarbonyl]-butyl}-N-hydroxy-formamide.

N-[(R)-2-(N'-{Ethyl-[(2-methoxy-ethyl)-methyl-amino]-[1, 3,5] triazin-2-yl} - <BR> <BR> hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.<BR> <BR> <BR> <P>N- { (R)-2-[N'-(Dimethylamino-methyl-pyrimidin-2-yl)-hydrazinocar bonyl]-heptyl}- N-hydroxy-formamide.

N- (R)-2- [N'- (4-Cyclopropylamino-6-methyl-pyrimidin-2-yl)-hydrazinocarbon yl]- <BR> <BR> heptyl}-N-hydroxy-formamide.<BR> <BR> <BR> <P>N- { (R)-2-Cyclohexyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hy drazinocarbonyl]-<BR> <BR> <BR> ethyl}-N-hydroxy-formamide.

N- { (R)-2-CycloheXyl-2-[N'-(7-methoxy-benzo [1, 2,4] triazin-3-yl)- hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N- { (R)-2-Cyclohexyl-2- [N'- (5-methyl-benzo [l, 2,4] triazin-3-yl)-hydrazinocarbonyl]- ethyl}-N-hydroxy-formamide.

N- { (R)-4, 4-Dimethyl-2- [N'- (4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]- pentyl}-N-hydroxy-formamide.

N- {(R)-4,4-Dimethyl-2-[N'-(7-methyl-benzo[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- pentyl}-N-hydroxy-formamide.

N- { (R)-4, 4-Dimethyl-2- [N'- (5-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- pentyl}-N-hydroxy-formamide.

N- { (R)-4, 4-Dimethyl-2- [N'-(morpholin-4-yl-trifluoroemthyl-pyrimidin-2-yl)- hydrazinocarbonyl]-pentyl}-N-hydroxy-formamide.

N-((R)-2- {N'- [Ethyl-(methyl-pyridin-2-yl-amino)- [1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-{(R)-2-[N'-(4-Cyclopropylamino-6-ethyl-[1, 3,5] triazin-2-yl)-hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-[N'-(5-methyl-benzo[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-3- (1-methyl-cyclopentyl)-propyl]-formamide.

N-Hydroxy-N- [(R)-2- [N'-(7-methoxy-benzo [1, 2,4] triazin-3-yl) -hydrazinocarbonyl]-3- (1-methyl-cyclopentyl)-propyl]-formamide.

N-Hydroxy-N-{(R)-3-(1-methyl-cyclopentyl)-2-[N'-(4-triflu oromethyl-pyrimidin-2- yl)-hydrazinocarbonyl]-propyl}-formamide.

N-Hydroxy-N-{(R)-2-[N'-(4-isopropyl-6-morpholin-4-yl-[1, 3,5] triazin-2-yl) - <BR> <BR> hydrazinocarbonyl]-heptyl}-formamide.<BR> <BR> <BR> <P>N-Hydroxy-N- { (2R)-2- (cyclopentylmethyl)-3- [N'- (4-methyl-2-pyrimidinyl)-<BR> <BR> <BR> hydrazino]-3-oxopropyl}-formamide.

N-Hydroxy-N- [ (2R)-6, 6, 6-trifluoro-2- ( {N'- [4- (trifluoromethyl)-pyrimidin-2-yl]- hydrazino}-carbonyl)-hexyl]-formamide.

N- { (R) -2- [N'- (5, 7-Dimethyl-benzo [ 1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide. <BR> <BR> <P>N- { (R)-2-[N'-(3, 6-Dimethyl-pyrazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydrox y- formamide.

N-((R)-2-{N'[4-(4-Ethyl-piperazine-1-yl)-6-isopropyl-[1, 3,5] triazin-2-yl] - hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N- { (R)-2- [N'- (4-Dimethylamino-6-isopropyl- [1, 3,5] triazin-2-yl)-hydrazinocarbonyl]- <BR> <BR> heptyl}-N-hydroxy-formamide.<BR> <BR> <BR> <P>N-Hydroxy-N- { (R) -2- [N'- (methyl-trifluoromethyl-pyridin-2-yl) -hydrazinocarbonyl]-<BR> <BR> <BR> heptyl}-formamide.

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-h ydrazino)-6, N, N- trimethyl-isonicotinamide.

N-Hydroxy-N [ (2R)-2- ( {N'- [3-amino-6- (trifluoromethyl)-pyridin-2-yl]-hydrazino}- carbonyl)-heptyl]-formamide.

N-Hydroxy-N- [(R)-2- (N'- {4-isopropyl-6- [(2-methoxy-ethyl)-methyl-amino]- [1,3, 5] triazin-2-yl}-hydrazinocarbonyl)-heptyl]-formamide. <BR> <BR> <P>N- { (R) -3-Cyclopentyl-2- [N'- (4-ethyl-6-morpholin-4-yl- [1,3, 5] triazin-2-yl)-<BR> <BR> <BR> hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.

N-Hydroxy-N- { (R)-2- [N'- (4-morpholin-4-yl-6-propyl- [ 1, 3,5] triazin-2-yl) - hydrazinocarbonyl]-heptyl}-formamide.

N-((R)-2-{N'-[4-(4-Ethyl-piperazin-1-yl)-6-propyl-[1, 3,5] triazin-2-yl]- <BR> <BR> hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.<BR> <BR> <BR> <P>N- { (R) -5,5-Dimethyl-2- [N'(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-< ;BR> <BR> <BR> hexyl}-N-hydroxy-formamide.<BR> <BR> <BR> <P>N- { (R) -5, 5-Dimethyl-2- [N'- (7-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-<BR> <BR> <BR> hexyl}-N-hydroxy-formamide.

N- { (R) -5, 5-Dimethyl-2- [N'- (5-methyl-benzo [1, 2,4] triazin-3-yl) -hydrazinocarbonyl]- hexyl}-N-hydroxy-formamide.

N- { (R) -5,5-Dimethyl-2- [N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)- hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N- { (R) -4-Ethyl-2- [N'- (4-trifluoromethyl-pyrimidin-2-yl)-hydrazino carbonyl]-hexyl}- N-hydroxy-formamide.

N- { (R) -4-Ethyl-2- [N'- (7-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-hexyl}- N-hydroxy-formamide.

N- { (R) -4-Ethyl-2- [N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)- hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N- ( (R)-3-Cyclopentyl-2- {N'- [4-ethyl-6- (4-ethyl-piperazin-1-yl)- [ 1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-propyl)-N-hydroxy-formamide.

N- { (R)-3-Cyclopentyl-2- [N'- (4-cyclopropylamino-6-ethyl- [1, 3, 5] triazin-2-yl)- hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.

N- { (R) -4-Ethyl-2- [N'- (5-methyl-benzo [ 1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-hexyl}- N-hydroxy-formamide.

N-Hydroxy-N- [ (R)-2- (N'- { [ (2-methoxy-ethyl)-methyl-amino]-propyl- [1, 3,5] triazin-2- yl}-hydrazinocarbonyl)-heptyl]-formamide.

N- { (R)-2- [N'- (Dimethylamino-propyl- [ 1, 3,5] triazin-2-yl)-hydrazinocarbonyl]- <BR> <BR> heptyl}-N-hydroxy-formamide.<BR> <BR> <BR> <P>N- { (R)-2- [N'- (4-Ethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydrox y- formamide.

N-Hydroxy-N- { (R)-2- [N'- (4-isopropyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}- formamide.

N- { (R)-2- [N'- (4-Cyclopropyl-6-morpholin-4-yl- [1, 3,5] triazin-2-yl)- <BR> <BR> hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.<BR> <BR> <BR> <P>N-Hydroxy-N- [ (2R)-2- ( {N'- [4- (pyridm-2-yl)-pyrimidin-2-yl]-hydrazino}-carbonyl)- heptyl]-formamide.

N- ( (R)-2- {N'- [4-Cyclopropyl-6- (4-ethyl-piperazin-1-yl)- [1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N- { (R)-2- [N'- (Cyclopropyl-dimethylamino- [1, 3,5] triazin-2-yl) -hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

N-((R)-2-{N'-[Cyclopropyl-(ethyl-methyl-amino)-[1, 3,5] triazin-2-yl] - hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N- { (R)-2- [N'- (4-Cyclopropyl-6-pyrrolidin-1-yl [1, 3,5] triazin-2-yl)- hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N- { (R)-2- [N'- (4, 6-Dicyclopropyl- [1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

N-Hydroxy-N- [ (R)-2- [N'- (5-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-3- (2-methyl-cyclopentyl)-propyl]-formamide.

N-[(R)-2-[N'-(Dimethylamino-ethyl-[1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-3- (2- methyl-cyclopentyl)-propyl]-N-hydroxy-formamide.

N-Hydroxy-N- [(R)-2- [N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-3- (2-methyl-cyclopentyl)-propyl]-formamide.

N- { (R) -2- [N'- (5-Ethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydrox y- formamide.

N-Hydroxy-N- { (2R)-2- (cyclopentylmethyl)-3- [N'- (7-methyl-1, 2, 4-benzotriazin-3-yl)- hydrazino]-3-oxopropyl}-formamide.

N-Hydroxy-N-[(2R)-2-(cyclopentylmethyl)-3-(N'- {4-ethyl-6-[ethyl (methyl) amino]- 1, 3, 5-triazin-2-yl}-hydrazino)-3-oxopropyl]-formamide.

N-Hydroxy-N- ( (2R)-2- (cyclopentylmethyl)-3- {N'- [4- (dimethylamino)-6-ethyl-1, 3,5- triazin-2-yl]-hydrazino}-3-oxopropyl)-formamide.

N- ( (R)-2- {N'- [4-Ethyl-6- (4-isopropyl-piperazin-1-yl)- [ 1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-[(2R)-3-[N'-(6-chloro-1, 2, 4-benzotriazin-3-yl)-hydrazino]-2- <BR> <BR> (cyclopentylmethyl)-3-oxopropyl]-formamide.<BR> <BR> <BR> <P>N- { (R) -4,4-Dimethyl-2- [N'- (4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-<BR > <BR> <BR> hexyl}-N-hydroxy-formamide.

N- { (R)-4, 4-Dimethyl-2- [N'- (7-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- hexyl}-N-hydroxy-formamide.

N- { (R)-4, 4-Dimethyl-2- [N'- (5-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- <BR> <BR> hexyl}-N-hydroxy-formamide.<BR> <BR> <BR> <P>N- { (R) -4, 4-Dimethyl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2 -yl)-<BR> <BR> <BR> hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(5-phenyl-[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-heptyl}- formamide. <BR> <BR> <BR> <P>N- { (R)-2- [N'- (4-Ethyl-6-morpholin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl] -heptyl}- N-hydroxy-formamide. <BR> <BR> <P>N-((R)-2- {N'- [4-Ethyl-6-(4-methyl-piperazin-1-yl)-pyrimidin-2-yl]-<BR& gt; <BR> <BR> hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.<BR> <BR> <BR> <P>N- { (R) -2- [N'- (5-Ethyl-4-methyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl} -N- hydroxy-formamide.

N- ( (R)-2- { N'- [4-Ethyl-6- (4-propyl-piperazin-1-yl)- [ 1, 3,5] triazin-2-yl]- <BR> <BR> hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.<BR> <BR> <BR> <P>N-Hydroxy-N-((R)-2- {N'- [6-(4-pyrimidin-2-yl-piperazin-1-yl-methyl)-pyridin-2-yl]-&l t;BR> <BR> <BR> hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-((R)-2-{N'-[6-(3-[1, 2,4] triazol-l-yl-methyl- [l, 2,4] triazol-1-yl)-pyridin- 2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

N-{ (R) -3-Bicyclo [2.2. 1] hept-7-yl-2- [N'- (4-trifluoromethyl-pyrimidin-2-yl)- hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.

N- { (R)-3-Bicyclo [2.2. 1] hept-7-yl-2- [N'- (morpholin-4-yl-trifluoromethyl-pyrimidin-2- <BR> <BR> yl)-hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.<BR> ; <BR> <BR> <P>N-hydroxy-N-[(R)-2-(N'-pyridin-3-yl-hydrazinocarbon yl)-heptyl]-formamide.

4- {4-Ethyl-6- [2- ( (2R)-2- { [formyl (hydroxy) amino]-methyl}-heptanoyl)-hydrazino]- 1,3, 5-triazin-2-yl}-1-methyl-1-propylpiperazin-1-ium iodide.

N- { (R) -3-Bicyclo [2.2. 1] hept-7-yl-2-[N'-(5-methyl-benzo [1, 2,4] triazin-3-yl) - hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.

N-{ (R)-2-[N'-(4-Azetidin-l-yl-6-ethyl-[1, 3,5] triazin-2-yl)-hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

N- { (R)-2-Cyclopentyl-2- [N'- (4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]- ethyl}-N-hydroxy-formamide.

N- { (R)-2-Cyclopentyl-2- [N'- (morpholin-4-yl-4-trifluoromethyl-pyrimidin-2-yl)- <BR> <BR> hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.<BR> <BR> <BR> <P>N- { (R)-2-Cyclopentyl-2- [N'- (4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-ethyl}-N- hydroxy-formamide.

N- { (R)-2-Cyclopentyl-2- [N'- (dimethylamino-ethyl- [1, 3,5] triazin-2-yl) - hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cyclopentyl-2-[N'-(7-methyl-benzo[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- ethyl}-N-hydroxy-formamide.

N-{(R)-2-Cyclopentyl-2-[N'-(5-methyl-benzo[1, 2,4] triazin-3-yl) -hydrazinocarbonyl]- ethyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(5-methyl-benoz[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-2- (4-methyl-cyclohexyl)-ethyl}-formamide.

N-Hydroxy-N- { (R)-2-[N'-(7-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-2- (4-methyl-cyclohexyl)-ethyl}-formamide.

N-Hydroxy-N-{(R)-2-(4-methyl-cyclohexyl)-2-[N'-(4-triflur omethyl-pyrimidin-2- <BR> <BR> <BR> yl)-hydrazinocarbonyl]-ethyl}-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N- { (R)-2-(4-methyl-cyclohexyl)-2- [N'-(morpholin-4-yl-trifluoromethyl-<BR> <BR> <BR> <BR> <BR> pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-formamide.

N-Hydroxy-N-{(R)-2-(4-methyl-cyclohexyl)-2-[N'-(4-methyl- pyridin-2-yl)- hydrazinocarbonyl]-ethyl}-formamide.

N-{(R)-2-[N'-(Dimethylamino-ethyl-[1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-2- (4- methyl-cyclohexyl)-ethyl}-N-Hydroxy-formamide.

N-{(R)-2-[N'-(6, 7-Dihydro-5 H-cyclopentapyrimidin-2-yl)-hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

N- ( (R)-2- [N- [4-Ethyl-6- ( (S)-2-hydroxymethyl-pyrrolidin-1-yl)- [1, 3,5] triazin-2-yl] - <BR> <BR> <BR> hydrazinocarbonyl]-heptyl)-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <P>N- { (R)-2- [N'- (Dimethylamino-pyridin-3-yl-pyrimidin-2-yl)-hydrazinocarbony l]-<BR> <BR> <BR> <BR> <BR> heptyl}-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <P>N- { (R) -2- [N'- (Dimethylamino-pyridin-4-yl-pyrimidin-2-yl)-hydrazinocarbony l]-<BR> <BR> <BR> <BR> <BR> heptyl}-N-hydroxy-formamide.

N-Hydroxy-N- { (R)-2-N'- (5, 6,7, 8-tetrahydro-benzo [1, 2,4] triazin-3-yl)- hydrazinocarbonyl]-heptyl}-formamide.

N- { (R)-2- [N'- (5, 6-Diethyl- [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

N-Hydroxy-N- { (R)-2- [N'- [5- (4-hydroxy-phenyl)- [l, 2,4] triazin-3-yl] - hydrazinocarbonyl}-heptyl)-formamide.

N- [(R)-2-(N'-{[(2-Dimethylamino-ethyl)-methyl-amino]-ethyl-[1, 3,5] triazin-2-yl}- <BR> <BR> <BR> hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <P>N- { (R) -2- [N'- (2-Dimethylamino-quinazolin-4-yl)-hydrazinocarbonyl]-heptyl} -N- hydroxy-formamide.

N-Hydroxy-N- { (R) -2- [N'- (3-methanesulfonyl-4, 6-dimethyl-pyridin-2-yl) - hydrazinocarbonyl]-heptyl}-formamide.

N-((R)-2-{N'-[4-Ethyl-6-(3-hydroxy-piperidin-1-yl)-[1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-[(R)-2-(N'-[4,5']Bipyrimidinyl-2-yl-hydrazinocarbonyl)- heptyl]-N-hydroxy- formamide.

N-((R)-2- {N'-[(Cyclopropyl-methyl-amino)-ethyl-[1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N- ((R)-2-{N'-[4-Ethyl-6-((R)-3-hydroxy-pyrrolidin-1-yl)-[1, 3,5] triazin-2-yl] - hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N-[(R)-2-(N'-[3,3']Bipyridnyl-5-yl-hydrazinocar bonyl)-heptyl]- formamide.

N-Hydroxy-N- [(R)-2-(N'-(5-morpholin-4-yl-pyridin-3-yl)-hydrazinocarbonyl )- heptyl]-formamide. <BR> <BR> <BR> <P>N-Hydroxy-N- { (R)-2- [N'- (4-pyridin-3-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-<BR> ; <BR> <BR> <BR> heptyl}-formamide.

N-Hydroxy-N- { (R)-2- [N'- (5, 6,7, 8-tetrahydro-quinazolin-2-yl)-hydrazinocarbonyl]- heptyl}-formamide.

N- [ (R)-2- (N-I [Cyclopropyl-1- (l-methyl-piperidin-4-yl)-ainino]-ethyl- [1, 3,5] triazin- 2-yl}-hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

N-((R)-2-{N'-[4-((R)-3-Diemthylamino-pyrrolidin-1-yl)-6-e thyl-[1, 3,5] triazin-2-yl]- <BR> <BR> <BR> hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N- [ (R)-2- (N'- [5- (lH-pyrrol-2-yl)-pyridin-3-yl]-hydrazinocarbonyl)- heptyl]-formamide.

N-Hydroxy-N- [(R)-2-(N'-[(4-methyl-piperazin-1-l)-trifluoromethyl-pyrimid in-4-yl]- hydrazinocarbonyl)-heptyl]-formamide.

N-Hydroxy-N- [(R)-2-(N'-(5-Furan-3-yl-pyridin-3-yl)-hydrazinocarbonyl)-he ptyl]- formamide. <BR> <BR> <BR> <BR> <P>N- { (R) -5, 5-Dimethyl-2- [N'- (4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-<BR > <BR> <BR> <BR> <BR> heptyl}-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <P>N- { (R) -5, 5-Dimethyl-2- [N'- (7-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-<BR> <BR> <BR> <BR> <BR> heptyl}-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <P>N- { (R) -5, 5-Dimethyl-2- (4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide. <BR> <BR> <P>N- { (R) -2-Cycloheptyl-2- [N'- (4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-<BR > <BR> <BR> <BR> <BR> ethyl}-N-hydroxy-formamide.

N- { (R)-2-Cycloheptyl-2- [N'- (4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-ethyl}-N- hydroxy-formamide.

N- { (R)-2-Cycloheptyl-2- [N'- (dimethylamino-ethyl- [1, 3,5] triazin-2-yl) - hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

N- { (R)-2-Cycloheptyl-2- [N'- (7-methyl-benzo [ 1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- ethyl}-N-hydroxy-formamide.

N- ( (R)-2- {N'- [4-Ethyl-6- (4-hydroxy-piperidin-1-yl)- [1, 3,5] triazin-2-yl] - hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N- { (R)-5, 5-Dimethyl-2- [N'- (5-methyl-benzo [ 1, 2,4] triazin-3-yl) -hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

N- { (R)-2- [N'- (4-Dimethylamino-quinazolin-2-yl)-hydrazinocarbonyl]-heptyl} -N- hydroxy-formamide. <BR> <BR> <BR> <P>N-Hydroxy-N- { (R) -2- [N'- (4-pyridin-4-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-<BR> ; <BR> <BR> <BR> <BR> heptyl}-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N- ( (R)-2- {N'- [4- (3-hydroxymethyl-phenyl)-pyrimidin-2-yl]-<BR> <BR> <BR> <BR> <BR> hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N-((R)-2-{N'-[4-(4-hydroxymethyl-phenyl)-pyrimi din-2-yl]- hydrazinocarbonyl}-heptyl)-formamide.

N- ( (R)-2- { N'- [4-Ethyl-6- (3-methoxy-piperidin-1-yl)- [ 1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N- { (R)-2- [N'- (7-methyl-benzo [1, 2,4] triazin-3-yl) -hydrazinocarbonyl]-2- (4-methyl-cyclohexyl)-ethyl}-formamide.

N- {N'-[Ethyl-(ethyl-methylamino)-[1, 3,5] triazin-2-yl]-hydrazinocarbonyl}-2- (4-methyl-cyclohexyl)-ethyl}-N-hydroxy-formamide.

N-[(R)-2-{N'-[Ethyl-(ethyl-methylamino)-[1, 3,5] triazin-2-yl]-hydrazinocarbonyl}-2- (4-methyl-cyclohexyl)-ethyl}-N-hydroxy-formamide.

N-Hydroxy-N- { (R)-2- [N'- (7-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-2- <BR> <BR> <BR> (4-methyl-cyclohexyl)-ethyl}-formamide.<BR> <BR> <BR> <BR> <BR> <P>N- ( (R)-2- { N'- [4- (2, 6-Dimethoxy-phenyl)-pyrimidin-2-yl]-hydrazinocarbonyl}-<B R> <BR> <BR> <BR> <BR> heptyl)-N-hydroxy-formamide.

N-((R)-2-{N'-[4-Ethyl-6-((R)-3-methoxy-pyrrolidin-1-yl)-[ 1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N- ( (R)-2- {N'- [4-Ethyl-6- (4-methoxy-piperidm-l-yl)- [l, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

N-Hydroxy-N- [(R)-2-(N'-(6-pyrrolidin-1-yl-pyrimidin-4-yl)-hydrazinocarbo nyl)- heptyl]-formamide.

N-Hydroxy-N- [ (R)-2- (N'- [6- (4-methyl-piperazin-1-yl)-pyrimidin-4-yl])-<BR> <BR> <BR> hydrazinocarbonyl)-heptyl]-formamide.<BR> <BR> <BR> <P>N- { (R)-2- [N'- (6-Dimethylamino-pyrimidin-4-yl)-hydrazinocarbonyl]-heptyl}- N- hydroxy-formamide. <BR> <BR> <P>N- { (R)-2-[N'-(Pyridin-4-yl-trifluoromethyl-pyrimidin-4-yl)-hydr azinocarbonyl]-<BR> <BR> <BR> heptyl}-N-hydroxy-formamide.<BR> <BR> <BR> <P>N- { (R)-2- [N'- (Pyridin-3-yl-trifluoromethyl-pyrimidin-4-yl)-hydrazinocarbo nyl]-<BR> <BR> <BR> heptyl}-N-hydroxy-formamide.

N- { (R) -2- [N'-(2-Ethylamino-6-trifluoromethyl-pyrimidin-4-yl)-hydrazin ocarbonyl]- heptyl}-N-hydroxy-formamide.

N-Hydroxy-N- ( (R)-2- {N'- [5- (4-methoxy-phenyl)- [ 1, 2,4] triazin-3-yl] - hydrazinocarbonyl}-heptyl)-formamide.

N-Hydroxy-N- ( (R)-2- {N'- [4- (2, 3, 4-trimethoxy-phenyl)-pyrimidin-2-yl]- hydrazinocarbonyl}-heptyl)-formamide.

N- { (R)-4, 4-Dimethyl-2- [N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

N- { (R)-4, 4-Dimethyl-2- [N'- (7-methyl-benzo [ 1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

N- { (R)-4, 4-Dimethyl-2- [N'- (5-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

N- { (R)-4, 4-Dimethyl-2- [N'- (4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

N-Hydroxy-N- { (R) -2- [N'-(6-morpholin-4-yl-pyrimidin-4-yl)-hydrazinocarbonyl]- heptyl}-formamide.

N-Hydroxy-N- [ (R)-2- (N'- { 5- [4- (2-hydroxy-ethoxy)-phenyl]- [1, 2,4] triazin-3-yl}- hydrazinocarbonyl)-heptyl]-formamide.

N- { (R)-2- [N'- (4-Furan-2-yl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}-N-h ydroxy- formamide. <BR> <BR> <BR> <P>N- ( (R)-2- {N'- [4- (3, 5-Dimethyl-isoxazol-4-yl)-pyrimidin-2-yl]-hydrazinocarbonyl} -<BR> <BR> <BR> heptyl)-N-hydroxy-formamide.<BR> <BR> <BR> <P>N-Hydroxy-N- { (R)-2- [N'- (4-methyl-1-oxy-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}- formamide.

2- (N'- { (R) -2- [(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydrazino)-6-meth yl- nicotinic acid.

N-Hydroxy-N- { (R) -2- [N'- (3-methoxy-pyridin-2-yl)-hydrazinocarbonyl]-heptyl}- formamide.

N-Hydroxy-N- { (2R)-2- [ (N'- {4- [4- (methylsulfonyl) phenyl]-pyrimi din-2-yl}-<BR> <BR> <BR> <BR> hydrazino)-carbonyl]-heptyl}-formamide.

N-Hydroxy-N- [(2R)-2-( {N'- [4-(furan-3-yl)-pyrimidin-2-yl]-hydrazino}-carbonyl)- heptyl]-formamide.

N-[(2R)-2-({N'-[4-(2-aminophenyl)-pyrimidin-2-yl]-hydrazi no}-carbonyl)-heptyl]-N- hydroxy-formamide.

N-Hydroxy-N- [ (2R)-2- ( {N'- [5- (5-methyl-1, 3, 4-oxadiazol-2-yl)-4- (trifluoromethyl)- pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3- {N'- [5-(5-methyl-1, 3,4-oxadiazol-2-yl)- 4-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-3-oxopropyl)- formamide.

N-[(2R)-2-({N'-[6-(diemthylamino)-2-methyl-pyrimidin-4-yl ]-hydrazino}-carbonyl)- heptyl]-N-hydroxy-formamide.

N- [(2R)-2-( {N'- [2-Cyclopropyl-6-(dimethylamino)-pyrimidin-4-yl]-hydrazino}- <BR> <BR> <BR> carbonyl)-heptyl]-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N- [ (2R)-4- (2-thienyl)-2- ( {N'- [4- (trifluoromethyl)-pyrimidin-2-yl]-<BR> <BR> <BR> <BR> hydrazino}-carbonyl)-butyl]-formamide.

N-Hydroxy-N- [ (2R)-2- { [N'- (4-methyl-pyrimidin-2-yl) hydrazino] carbonyl}-4- (2- thienyl)-butyl]-formamide.

N-[(2R)-2-[(N'- {4-Ethyl-6-[ethyl (methyl) amino]-1, 3, 5-triazin-2-yl}-hydrazino)- <BR> <BR> <BR> carbonyl]-4-(2-thienyl) butyl]-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N- ( (2R)-3-oxo-2- (2-thienylmethyl)-3- { N'- [4- (trifluoromethyl)-pyrimidin-<BR> <BR> <BR> <BR> <BR> 2-yl]-hydrazino}-propyl)-formamide.

N-Hydroxy-N-[(2R)-3-[N'-(4-methyl-pyrimidin-2-yl)hydrazin o]-3-oxo-2-(2- thienylmethyl)-propyl]-formamide.

N-[(2R)-3-(N'- {4-Ethyl-6-[ethyl (methyl) amino]-1, 3, 5-triazin-2-yl} hydrazino)-3-oxo- <BR> <BR> <BR> 2- (2-thienylmethyl)-propyl]-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N-[(2R)-2-({N'-[2-methyl-6-(pyridin-2-yl) -pyrimidin-4-yl]-hydrazino}-<BR> <BR> <BR> <BR> <BR> carbonyl)-heptyl]-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N-[(2R)-2-({N'-[6-(pyridin-2-yl-methyl)-p yridazin-3-yl]-hydrazino}- carbonyl)-heptyl]-formamide.

N-Hydroxy-N- [(2R)-2-( {N'- [2-methyl-6-(morpholin-4-yl)-pyrimidin-4-yl]- hydrazino}-carbonyl)-heptyl]-formamide.

N-Hydroxy-N- {N'-[6-(morpholin-4-yl)-2-(trifluoromethyl)-pyrimidin-4-yl]- <BR> <BR> <BR> hydrazino}-carbonyl)-heptyl]-formamide.<BR> <BR> <BR> <BR> <BR> <P>N-Hydroxy-N- { (2R)-2-[(N'-{4-[methyl-(pyridin-2-yl)-amino]-pyrimidin-2-yl} -<BR> <BR> <BR> <BR> <BR> hydrazino)-carbonyl]-heptyl}-formamide.

N-Hydroxy-N- ( (2R)-2- (cyclopentylmethyl)-3- { N'- [4-cyclopropyl-6- (dimethylamino)- 1,3, 5-triazin-2-yl]-hydrazino}-3-oxopropyl)-formamide.

N-Benzo [1, 3] dioxol-5-yl-methyl-hydrazinecarboxylic acid tert-butyl ester.

N-[(R)-2-(N'-Benzo [1, 3] dioxol-5-yl-methyl-hydrazinocarbonyl)-heptyl]-N-hydroxy- formamide.

N- { (R)-2- [N'- (2, 3-Dihydro- [1, 4] dioxino [2,3-b] pyridin-7-yl-methyl) - <BR> <BR> <BR> hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <P>N- { (R) -2- [N'- (4-Dimethylamino-benzyl)-hydrazinocarbonyl]-heptyl}-N-hydrox y- formamide.

N-Hydroxy-N- ( (R)-2- {N'- [2- (5, 6,7, 8-tetrahydro- [1, 8] naphthyridin-2-yl)-ethyl]- hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

N-Hydroxy-N- [(R)-2-(N'-quinolin-2-yl-methyl-hydrazinocarbonyl)-heptyl]- formamide.

N-Hydroxy-N- { (R)-2- [N'- ( 1, 2,3, 4-tetrahydro-quinolin-2-yl-methyl) - hydrazinocarbonyl]-heptyl}-formamide.

N-Hydroxy-N- [(R)-2-(N'-quinolin-6-yl-methyl-hydrazinocarbonyl)-heptyl]- formamide.

N-[(R)-2-(N'-Benzofuran-2-yl-methyl-hydrazinocarbonyl)-he ptyl]-N-hydroxy- formamide.

N- [(R)-2-(N'-Cyclopropylmethyl-hydrazinocarbonyl)-heptyl]-N-hy droxy-formamide.

N- { (R)-2- [N'- (6-Fluoro-4H-benzo [1, 3] dioxin-8-yl-methyl)-hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

N-Hydroxy-N- { (R) -2- [N'- (4-methoxy-benzyl)-hydrazinocarbonyl]-heptyl}- formamide.

N-Hydroxy-N- { (R) -2- [N'- (2-methoxy-benzyl)-hydrazinocarbonyl]-heptyl}- formamide. <BR> <BR> <BR> <BR> <P>N-Hydroxy-N- { (R)-2- [N'- (tetrahydro-furan-3-yl-methyl)-hydrazinocarbonyl]-heptyl}- formamide. <BR> <BR> <BR> <BR> <P>N-[(R)-2-(N'-Furan-3-yl-methyl-hydrazinocarbonyl)-h eptyl]-N-hydroxy-formamide.

N-{(R)-2-[N'-(2, 3-Dihydro-benzo [1, 4] dioxin-6-yl-methyl)-hydrazinocarbonyl]- <BR> <BR> <BR> heptyl}-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <P>N- { (R) -2- [N'- (2, 3-Dihydro-benzo [1, 4] dioxin-2-yl-methyl)-hydrazinocarbonyl]-<BR> <BR> <BR> <BR> <BR> heptyl}-N-hydroxy-formamide.

N-Hydroxy-N-{(R)-2-[N'-(2-phenyl-ethyl)-hydrazinocarbonyl ]-heptyl}-formamide.

N-{(R)-2-[N'-((S)-2,3-Dihydroxy-propyl)-hydrazinocarbonyl ]-heptyl}-N-hydraoxy- formamide.

N-Hydroxy-N-{(R)-2-[N'-(5-methyl-isoxazol-3-yl-methyl)-hydra zinocarbonyl]- heptyl-formamide.

N-((R)-2- {N'-[l-(l-Benzo [1, 3] dioxol-5-yl-methanoyl)-piperidin-4-yl]- <BR> <BR> hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.<BR> <BR> <BR> <P> N- {N'-[l-(l-Benzofuran-2-yl-methanoyl)-piperidin-4-yl]-hydrazi nocarbonyl}- heptyl)-N-hydroxy-formamide.

N-Hydroxy-N- [ (R)-2- (N'- {l- [l- (7-methoxy-benzofuran-2-yl)-methanoyl]-piperidin-4- <BR> <BR> yl}-hydrazinocarbonyl)-heptyl]-formamide.<BR> <BR> <BR> <P> N- { (R)-2-[N'-(1-Benzyl-piperidin-4-yl)-hydrazinocarbonyl]-hepty l}-N-hydroxy- formamide.

N- [ (R)-2- (N'- { 1- [1- (3, 4-Dichloro-phenyl)-methanoyl]-piperidin-4-yl}- hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide. <BR> <BR> <P> N- [ (R)-2- (N'- {l- [l- (2, 3-Dichloro-phenyl)-methanoyl]-piperidin-4-yl}-<BR> <BR> <BR> hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.<BR> <BR> <BR> <P> N-Hydroxy-N- [ (R)-2- (N'- { 1- [1- (4-methyl-piperazin-1-yl)-methanoyl]-pentyl}-<BR> <BR> <BR> hydrazinocarbonyl)-heptyl]-formamide.<BR> <BR> <BR> <P> N-[(R)-2-(N'-Benzyl-hydrazinocarbonyl)-heptyl]-N-hydroxy-for mamide.

GENERAL SYNTHETIC SEQUENCE The compounds and processes of the present invention will be better understood in connection with the following synthetic schemes, which are merely illustrative of the methods by which the compounds of the invention may be prepared and are not intended to limit the scope of the invention as defined in the appended claims.

The present invention provides compounds of Formula (1) that can be prepared from the common racemic intermediate (8), or common chiral intermediates (17) and (25).

(1) Y = O, CH2 or a bond

Scheme 1 As shown in Scheme 1, intermediate (8) can be prepared by reacting the mono- substituted dialkyl malonate (2) with a base, such as potassium hydroxide, in an appropriate solvent, such as ethanol/water, to afford the mono-acid (3). Coupling of (3) with O- benzylhydroxylamine or 0- (tetrahydro-2H-pyran-2-yl) hydroxylamine in the presence of a coupling reagent, such as 1- [3- (dimethylamino) propyl] -3-ethylcarbodiimide hydrochloride (EDCI), and a base, such as 4-dimethylaminopyridine (DMAP), in an appropriate solvent, such as dichloromethane, gives the amide (4), where P is benzyl or tetrahydro-2H-pyran-2-yl.

Reduction of the ester functionality of compound (4) with a reducing agent, such as lithium borohydride, in an appropriate solvent, such as tetrahydrofuran, at room temperature provides the alcohol (5). Treatment of the alcohol (5) under Mitsunobu conditions affords the lactam (6). The same transformation may be achieved by treating (5) with triphenylphosphine, carbon tetrachloride and a base, such as triethylamine, to obtain (6). Hydrolysis of the lactam (6) using, for example, lithium hydroxide in an appropriate solvent mixture, such as THF-H2O- MeOH, gives acid (7). Formylation of the amine group of (7) is achieved using formic acid and acetic anhydride in a solvent, such as dichloromethane, to provide the formylated compound (8).

Any racemates can be resolved at the level of any intermediate during the synthesis or at the level of the final product using, for example, a chiral chromatography method, to provide compound (8) in each of two enantiomeric forms.

Alternatively, an enantiomer of intermediate (8), such as (18) in Scheme 2 or (27) in Scheme 3, can be prepared by reacting an appropriate acid chloride (9) with a chiral agent, such as Evans'chiral oxazolidinone, in the presence of a base, such as n-butyl lithium, to afford the chiral intermediate (10) in Scheme 2 or (19) in Scheme 3. Treatment of the

compound (10) or (19) with a base, such as diisopropylethylamine, in the presence of a chelating agent, such as titanium tetrachloride, in a solvent, such as tetrahydrofuran, followed by addition of an electrophile, such as benzyloxymethylchloride, provides either of two chiral compounds (11) or (20), depending on the selection of chiral auxiliary. Conversion of compound (11) or (20) to the corresponding hydroxyacid (14) or (23) can be achieved by a sequence comprising oxidative cleavage of the chiral oxazolidinone, using, for example H202 and lithium hydroxide, to the respective intermediates (12) or (21), followed by hydrogenolysis, to afford intermediates (13) or (21), respectively. Compounds (10) or (19) can also be converted to intermediates (14) or (23), respectively, in a two-step procedure. For this transformation, (10) or (19) can be treated with a base, such as diisopropylethylamine, in the presence of a chelating agent, such as titanium tetrachloride, in a solvent, such as tetrahydrofuran, followed by addition of trioxane or any other formaldehyde equivalent to provide compounds (13) or (22), which are then submitted to oxidative cleavage of the chiral oxazolidinone, using, for example H202 and lithium hydroxide, to the respective acids (14) or (23), respectively.

Coupling of the acid (14) or (23) with benzyloxyamine or 0- (tetrahydro-2H-pyran-2- yl) hydroxylamine in the presence of coupling agents, such as EDCI-DMAP, yields the amides (15) or (24), respectively. These can be cyclized to the azetidin-2-ones (16) or (25) using Mitsunobu conditions or a combination of triphenylphosphine-carbon tetrachloride- triethylamine. Hydrolysis of the azetidin-2-one (16) or (25), using for example lithium hydroxide, in an appropriate solvent, gives the corresponding acid (17) or (26), respectively.

Conversion of compound (17) or (26) to the carboxylic acid (18) or (27) can be achieved using an appropriate formylating agent, such as formic acid/acetic anhydride or methyl formate, in neat reagents or in an appropriate solvent, such as dichloromethane.

Scheme 2

Scheme 3 As shown in Scheme 4, compound (8) can be coupled to CBZNHNH2, using conditions such as DMAP-EDCI or EDCI-HOAt-NMM, and debenzylated to generate compound (28). Reaction of (28) with the halide or trifluoromethyl R1X affords (1) where R2 is H. Similarly, compounds (18) and (27) can be submitted to the same procedure to afford, respectively, (31) where R2 is H and (32) where R2 is H.

Scheme 4 Alternatively, as shown in Scheme 5, compound (28) is submitted to a reductive alkylation with the ketone R1C (O) R2 using as reductant, for example, sodium cyanoborohydride, to afford compound (1). If the aldehyde R1C (O) H is used in the reductive alkylation instead, compound (1) where R2 is H is formed. Similarly, compound (29) can be submitted to reductive alkylation with the ketone R1C (O) R2 to afford compound (31), or with the aldehyde R1C (O) H to afford compound (31) where R2 is H. Similarly, compound (30) can be submitted to reductive alkylation with the ketone R1C (O) R2 to afford compound (32), or with the aldehyde RIC (O) H to afford compound (32) where R2 is H.

Scheme 5 Alternatively, as shown in Scheme 6, the monoprotected hydrazine G1NHNH2 (33), where G1 is benzyloxycarbonyl or tert-butoxycarbonyl, can be reacted with phthalic anhydride

to yield intermediate (34). (34) can be coupled to the alcohol R10H under Mitsunobu conditions to yield (35), which upon hydrazinolysis originates hydrazine (36). Coupling of (36) to acid (8) using conditions such as DMAP/EDCI or EDCI/HOAt/NMM affords (37).

(37) can be fully deprotected in one step using hydrogenolysis when G1 is benzyloxycarbonyl and P is benzyl, in one step using acidic conditions when G1 is tert-butoxycarbonyl and P is O- (tetrahydro-2X-pyran-2-yl), or in two steps (by acid treatment and hydrogenolysis) when G1 is benzyloxycarbonyl and P is 0- (tetrahydro-2H-pyran-2-yl), or G1 is tert-butoxycarbonyl and P is benzyl. In all three cases, compound (1) where R2 is H is formed. Similarly ; compounds (18) and (27) can be submitted to the same procedure to afford, respectively, (31) where R2 is H or (32) where R2 is H.

phthalic 0 Rl 0 Rl anhydride H ROH N\ N2H4 Ri 1 G1'NNH2 G1NN \--- G1 N/--- G1-NH2 p O (33) (34) (35) (36) G1 = CBZ or BOC H2, Pd/C (G1=CBZ and P=Bn), or TFA, CH2CI2 (G1=BOC and P=THP), or Ri O TFA, CH2CI2 ; H2, Pd/C (G1=BOC and (8) + (36) 131"N', N'JL'rN'op P=Bn, or Gl =CBZ and P=THP) 30 (1), R2=H H YR CHO (37) H2, Pd/C (Gl=CBZ and P=Bn), or TFA, CH2CI2 (G1=BOC and P=THP), or R1 O TFA, CH2CI2 ; H2, Pd/C (G1=BOC and (18) + (36) P=Bn, or G1=CBZ and P=THP) G1 N i N YR CHO (38) H2, Pd/C (G1=CBZ and P=Bn), or TFA, CH2CI2 (G1=BOC and P=THP), or R1 O TFA, CH2CI2 ; H2, Pd/C (G1=BOC and II P=Bn or G1=CBZ and P=THP) G1'NN-Y'NP (32), R2=H Y CHO (39) Scheme 6 As shown in Scheme 7, coupling of the acid (8) with the hydrazine R1R2NNH2 (40), using conditions such as DMAP-EDCI or EDCI-HOAt-NMM, provides the hydrazide (41). Final deprotection (hydrogenolysis using a catalyst, such as 10% Pd/C, in an appropriate solvent, such as ethanol, in the case that P is Bn; treatment with 80% acetic acid-water at

room temperature or 40 °C in the case that P is THP) gives the desired compound (1).

Similarly, coupling of the chiral acid (18) or (27) with the hydrazine (40) provides the corresponding hydrazide (42) or (43). Final deprotection gives the final desired compound (31) or (32).

Scheme 7 Hydrazines of general structure R1R2NNH2 (40) may be purchased from available commercial sources or prepared according to literature methods by those skilled in the art. The I following examples of specific structures of hydrazine (40) and the synthetic methods used to generate them are merely illustrative and are not to be construed as a limitation of the scope of the present invention.

Hydrazines (40) where R2 is alkyl or hydrogen, and R1 has the general structure (44) may be prepared from appropriate precursors shown in Scheme 8,9 and 10.

As shown in Scheme 8, hydrazine (40) where RI is (44) can be prepared from precursor (45) by treatment with an appropriate hydrazine, such as hydrazine monohydrate, in an appropriate solvent, such as methanol. Alternatively, as shown in Scheme 9, hydrazine (40)

where R1 is (44) can be prepared from precursor (46) by oxidation to the sulfone via treatment with an appropriate oxidant such as meta-chloroperbenzoic acid (m-CPBA) in an appropriate solvent such as methylene chloride. Further treatment with an appropriate hydrazine, such as hydrazine monohydrate, in an appropriate solvent, such as methanol, then provides the desired product (40) where RI is (44). Alternatively, as shown in Scheme 10, hydrazine (40) where R1= (44) can be prepared from (47) via treatment with sodium nitrate in an appropriate solvent such as aqueous sulfuric acid to give (48). Compound (48) is then treated with an appropriate halogenating reagent such as phosphorus oxychloride at reflux followed by treatment with an appropriate hydrazine, such as hydrazine monohydrate, in an appropriate solvent, such as methanol, to provide intermediate (40) where R1 is (44). Compounds (45), (46), (47) and (48) are available from commercial sources, or can be prepared via literature methods by those skilled in the art (Pyrimidines. Brown, D. J. In"The Chemistry of Heterocyclic Compounds" vol. 52, Taylor, E. C. , ed.; Wiley: New York, 1994).

X = halogen ; L1, L2, L3 = bond, N-G5, O, S; G2, G3, G4, G5 = H, Alkyl, Acyl, Heterocyclic, Aryl, Heteroaryl.

Scheme 8

L4, L5, L6 = bond, N-G10, O ; G6, G7, G8, G10 = H, Alkyl, Acyl, Heterocyclic, Aryl, Heteroaryl ; G9 = Alkyl, Aryl.

Scheme 9 H R2 L N NH N p 1) POCI3 or POBr3 7 2 NaN02 11 I reflux'G1 NYN, NH2 G1--N aq. H SCI G-, L8 2) R2-NHNH2 G/L9 MeOH/s 13 13 G13 (47) (48) (40) ; R1= (44) L7, L8, L9 = bond, O, S ; G11, G12, G13 = H, Alkyl, Acyl, Heterocyclic, Aryl, Heteroaryl.

Scheme 10 , Hydrazines (40) where R2 is hydrogen, and R1 has the general structure (49) may be prepared from appropriate precursors shown in Schemes 11 and 12.

(49) G14, G15 = H, Alkyl, Aryl, Heteroaryl, Heterocyclic As shown in Scheme 11,4, 6-dichloropyrimidine (50) may be reacted with tert- butylcarbazate in the presence of base, such as diisopropylethylamine, at 100 °C in an appropriate solvent such as ethanol to give compound (51). The amine G14G15NH may be reacted with (51) to afford compound (52), which may be deprotected under acidic conditions, such as trifluoroacetic acid in dichloromethane, to afford compound (40), where R2 is hydrogen and R1 is (49). H H N Nyo 0 ? 14 z II W H J''\/NwH CI\ ^'CI p CINN O il H EtOH, 120 °C base, 100 °C N<N EtOH, 120 °C (50) (51) T 4 H T 4 N NN TFA, DCM N N-NH2 Gui gui N+N s (52) (40) ; R1= (49) and R2=H Scheme 11

Alternatively, as shown in Scheme 12,4, 6-dichloropyrimidine (50) may be reacted with one equivalent of amine G14G15NH in the presence of base, such as triethylamine or diisopropylethylamine, to afford compound (53), which may be treated with excess hydrazine to afford compound (40), where R2 is hydrogen and R1 is (49).

Scheme 12 Hydrazines (40) where R2 is hydrogen, and R1 has the general structure (54) may be prepared from an appropriate precursor such as (55), by treatment with anhydrous hydrazine in an appropriate solvent such as ethanol, as shown in Scheme 13.

(54) G16, G17, G18 = H, Alkyl, Aryl Scheme 13 Hydrazines (40) where R2 is hydrogen and R1 has the general structure (56) may be prepared from an appropriate precursor shown in Scheme 14.

(56) G19, G20 = H, Alkyl, Aryl As shown in Scheme 14, 4-chloro-2-methylsulfanyl-6-trifluoromethyl-pyrimidine (57) may be treated with tert-butyl carbazate at 100 °C in an appropriate solvent, such as ethanol, to give intermediate (58). Treatment of (58) with an oxidant, such as meta-chloro perbenzoic acid, produces (59), which upon treatment with amine G19G20NH in a suitable solvent such as methanol or ethanol affords (60). Deprotection under acidic conditions, such as trifluroacetic acid in dichloromethane, affords (40), where R2 is hydrogen and R1 is (56).

0 0 S N CI S ! Nw O O ! H _ \ II H /S II N N\H''O N tert-butyl carbazate N N CF3 CF3 CF3 (57) (58) (59) G19 0 19 -------- N---- NJ 2° I, N/ N/ CF3 CF3 (60) (40) ; R2=H and R1= (56)

Scheme 14 Hydrazines (40) where R2 is hydrogen and R1 has the general structure (61) may be prepared following procedures outlined in Scheme 15 (Pauldler, W. et al. , J. Het. Chem. 767- 771,1970 ; Lieber, E. et al. , J. Org. Chem. 17,518-522, 1952; Chem. Abstr. 87,68431, 1977; Taylor, E. C. , J. Org. Chem. 52, 4287-4292, 1987).

(61) G21, G22 = H, alkyl, aryl, heteroaryl

As shown in Scheme 15, compound (62) may be reacted with (63) in the presence of a mild base, such as aqueous sodium bicarbonate, to yield (64). Treatment of (64) with hydrazine under microwave conditions affords (40) where R2 is H and R1 is (61).

Alternatively, (62) may be reacted with (65) to afford (40) where R2 is H and R1 is (61).

Alternatively, (62) may be condensed with (66) to yield (67), which upon treatment with phosphorous oxychloride forms (68). Treatment of (68) with hydrazine affords (40) where R2 is H and R1 is (61). Alternatively, the oxoacid (69) may be condensed with (63) to form (70), which may be converted to (71) by reaction with oxalyl chloride or phosphorous oxychloride. Coupling of (71) with a boronic acid G22B (OH) 2 under standard Suzuki conditions affords (72), which can be reacted with hydrazine to afford (40) where R2 is H and R1 is (61) and G22 is alkyl, heteroaryl only. H G-"Y='2.. L NH 'NHH y NH .. N .. N O z Gzi N Gzy N (62) (63) (64) (62) (63) (64) (40) ; R2=H and R1= (61) 0 NH2 H ---'y ! 2 G22xNtNsNH O , G21 (65) (40) ; R2=HandR1= (61) O Ji H2N H 2 XN, NH G XN'N zon p 2 H 2 GZN. NH Ga \N (62) (66) (67) (68) H G22 N N. NH2NH2 Y NH2 zon G21 N (40) ; R2=H and R1= (61) 0 H OH 0 N S'-, (COC') 2 Cir POCI zi + H2N N 2 . N . N , N N (69) (63) (70) (71) H G2 N S G22 N N G22B (OH) 2 Y NH2NHz NHz Pd N (72) (40) ; R2=H and R1= (61) and G22=aryl, heteroaryl only

Scheme 15 Hydrazines (40) where R2 is hydrogen and R1 has the general structure (73) may be prepared following procedures outlined in Scheme 16.

(73) G23, G24, G25, G26 = H, alkyl, aryl, heteroaryl, heterocyclic

As shown in Scheme 16, cyanuric chloride (74) may be treated with one equivalent of amine (75) under mild conditions, such as 0 °C in acetone in the presence of aqueous potassium carbonate, to afford (76). Treatment of (76) with amine (77) under conditions such as 25 °C in acetone in the presence of potassium carbonate yields (78). Displacement of the remaining chloride in (78) with hydrazine affords (40) where R2 is H and RI is (73).

Scheme 16 Hydrazines (40) where R2 is hydrogen and R1 has the general structure (79) may be prepared following procedures outlined in Scheme 17 (Menicagli, R. et al., Tetrahedron, 56, 9705-9711,2000).

(79) G25, G26 = H, alkyl, aryl, heteroaryl, heterocyclic; G27 = alkyl, heterocyclic As shown in Scheme 17, cyanuric chloride (74) may be reacted with the Grignard compound (80) to form (81), which upon treatment with amine (77) affords monochloride (82). Hydrazinolysis of (82) yields (40) where R2 is H and R1 is (73).

Scheme 17 Hydrazines (40) where R2 is hydrogen and Rl has the general structure (83) may be prepared following procedures outlined in Scheme 18 (Kobe, J. et al. , Monatsh. Chem. 101, 724-735,1970 ; Janietz, D. and Bauer, M.,. Synthesis 33-34,1993).

(83) G28 = aryl, heteroaryl; G29 = alkyl, aryl, heteroaryl, heterocyclic, NG30G31 ; G30, G31 = aryl, alkyl, heteroaryl, heterocyclic As shown in Scheme 18, compound (84) may be coupled to boronic acid G28B (OH) 2 or equivalent under Suzuki coupling protocols to afford (85), which upon hydrazinolysis yields (40) where R2 is H and Rl is (83).

Scheme 18 Hydrazines (40) where R2 is hydrogen and R1 has the general structure (86) may be prepared following procedures outlined in Scheme 19.

(86) G30, G31 = alkyl, heterocyclic As shown in Scheme 19, sequential reaction of cyanuric chloride (74) with Grignard compounds G30MgX and G31MgX in a solvent such as benzene affords monochloride (87), which can be treated with hydrazide to afford (40) where R2=H and R1= (86).

Scheme 19 Hydrazines (40) where R2 is hydrogen and R1 has the general structure (88) may be prepared following procedures outlined in Scheme 20.

(88) G32 = alkyl, aryl, heteroaryl, heterocyclic; G33 = hydrogen, alkyl, aryl, heteroaryl, heterocyclic; G34 = alkyl As shown in Scheme 20, (89) can be reduced to (90) using reducing conditions such as iron and acetic acid. Sequential treatment of (90) with alkylating agents G32X and G33X (where X is halide or trifluoromethylsulfonate) affords (91). Alternatively, treatment of (90) with one equivalent of G32X affords (91) where G33 is H. Oxidation of (91) to the corresponding sulfoxide or sulfone using as oxidant such as meta-chloro perbenzoic acid, and subsequent treatment with hydrazine affords (40) where R2 is H and R1 is (88).

Scheme 20 Hydrazines (40) where R2 is hydrogen and Rl has the general structure (92) may be prepared following procedures outlined in Scheme 21 (Wolf, F. J. et al. , J. Am. Chem. Soc. 76, 3551-3553,1954 ; Hay, M. et al. , J. Med. Chem. 46, 169-182, 2003) and Scheme 22 (Ley, K. et al. , Angew. Chem. Int. Ed. 11, 1009-1010,1972).

(92) G35 = alkyl, aryl, heteroaryl, heterocyclic, alkoxy, halogen, amino; m, q = 0, 1 As shown in Scheme 21, (93) may be reacted with cyanamide in the presence of a base such as aqueous sodium hydroxide to afford (95). Alternatively, treatment of (94) with guanidine and a base such as potassium tert-butoxide, followed by acidification, affords (95) as well. Reaction of (95) with sodium nitrite in acidic solution yields (96). Conversion of (96) to the respective chloride (97) may be achieved with phosphorous oxychloride, for example. Hydrazinolysis of (97) affords (40) where R2 is H and R1 is (92) and m=0 and q=1 ; the N-oxide in this molecule may be reduced by hydrogenolysis in the presence of Pd on carbon and the resulting hydrazine may then be coupled to acid (8), (18) or (27).

Alternatively, the 1-N-oxide benzotriazine hydrazine may be coupled to the acids (8), (18) or (27), and the resulting compounds may then be submitted to hydrogenolysis in the presence of Pd on carbon in order to reduce the N-oxide group.

Br J NO G35 2 (94) 1. guanidine, KOtBu 2. HCI NH2 N NH ry. cN fY ' v NO N NaN02 Gss z Gas O (93) (95) H N CI NY NNH NYOH I N NH2NH2 1 1 ! 5 G35 1 G 5 G35 G 35 1 35 1 35 1 (96) (97) (40) ; R2=H and R1= (92) Scheme 21 Alternatively, as shown in Scheme 22, (98) may be reacted with disodium cyanamide in a solvent such as a mixture of methanol and water to afford (99), which tautomerizes to (100) in the presence of acid. Treatment of (100) with sodium nitrite in acidic media provides (101). Reaction of (101) with phosphorous oxychloride, followed by hydrazinolysis, affords (40), where R2 is H and R1 is (92) and m=q=l ; the N-oxide groups in this molecule may be reduced by hydrogenolysis in the presence of Pd on carbon and the resulting hydrazine may then be coupled to acid (8), (18) or (27). Alternatively, the 1,4-bis-N-oxide benzotriazine hydrazine may be coupled to acid (8), (18) or (27), and the resulting compound may then be reduced by hydrogenolysis in the presence of Pd on carbon.

Scheme 22 SYNTHETIC EXAMPLES The invention will now be described by reference to the following examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention.

As used herein the symbols and conventions used in these processes, schemes and examples are consistent with those used in the contemporary scientific literature, for example, the Journal of the American Chemical Society or the Journal of Biological Chemistry.

Standard single-letter or three-letter abbreviations are generally used to designate amino acid residues, which are assumed to be in the L-configuration unless otherwise noted. Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification.

Hz (Hertz); TLC (thin layer chromatography); Tr (retention time); RP (reverse phase); MeOH (methanol); i-PrOH (isopropanol); EtOH (ethanol); TEA (triethylamine); TFA (trifluoroacetic acid); THF (tetrahydrofuran); DMSO (dimethylsulfoxide); AcOEt or EtOAc (ethyl acetate); DCM (dichloromethane); DMF (N, N-dimethylformamide) ; CDI (1, 1-carbonyldiimidazole) ; HOAc (acetic acid); HOSu (N-hydroxysuccinimide) ; Ac (acetyl); HOBT (1-hydroxybenzotriazole) ; BOC (tert-butyloxycarbonyl) ;

mCPBA (meta-chloroperbenzoic acid); FMOC (9-fluorenylmethoxycarbonyl) ; DCC (dicyclohexylcarbodiimide) ; CBZ (benzyloxycarbonyl); NMM (N-methyl morpholine); HOAt (1-hydroxy-7-azabenzotriazole) ; DMAP (4-dimethylaminopyridine); Bn (benzyl); TBAF (tetra-n-butylammonium fluoride) ; THP (tetrahydro-2H-pyran-2-yl) HPLC (high pressure liquid chromatography); BOP (bis (2-oxo-3-oxazolidinyl) phosphinic chloride); EDCI (1-ethyl-3- [3-dimethylaminopropyl] carbodiimide hydrochloride) ; HBTU (O-Benzotriazole-1-yl-N, N, N', N'- tetramethyluronium hexafluorophosphate).

All references to ether are to diethyl ether; brine refers to a saturated aqueous solution of NaCl. Unless otherwise indicated, all temperatures are expressed in °C (degrees Centigrade). All reactions are conducted under an inert atmosphere at room temperature unless otherwise noted, and all solvents are highest available purity unless otherwise indicated.

'H NMR (hereinafter also"NMR") spectra were recorded on a Varian VXR-300, a Varian Unity-300, a Varian Unity-400 instrument, a Brucker AVANCE-400, a General Electric QE-300 or a Bruker AM 400 spectrometer. Chemical shifts are expressed in parts per million (ppm, 8 units). Coupling constants are in units of hertz (Hz). Splitting patterns describe apparent multiplicities and are designated as s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), br (broad).

Mass spectra were run on an open access LC-MS system using electrospray ionization. LC conditions: 4.5% to 90% CH3CN (0.02% TFA) in 3.2 min with a 0.4 min hold and 1.4 min re-equilibration; detection by MS, UV at 214 nm, and a light scattering detector (ELS). Column : 1 X 40 mm Aquasil (CIS).

For preparative (prep) hplc ; ca 50 mg of the final products were injected in 500 uL of DMSO onto a 50 X 20 mm I. D. YMC CombiPrep ODS-A column at 20 mL/min with a 10 min gradient from 10% CH 3CN (0. 1% TFA) to 90% CH3CN (0. 1% TFA) in H 20 (0. 1% TFA) and a 2 min hold. Flash chromatography was run over Merck Silica gel 60 (230-400 mesh).

Infrared (IR) spectra were obtained on a Nicolet 510 FT-IR spectrometer using a 1- mm NaCl cell. Most of the reactions were monitored by thin-layer chromatography on 0.25

mm E. Merck silica gel plates (60F-254), visualized with UV light, 5% ethanolic phosphomolybdic acid or p-anisaldehyde solution.

The following synthetic schemes are merely illustrative of the methods by which the compounds of the invention may be prepared and are not intended to limit the scope of the invention as defined in the appended claims.

The compounds disclosed in Examples 2 to 353 were prepared following the general procedures described in Example 1. The compounds disclosed in Examples 355 to 379 were prepared following the general procedures described in Example 354.

Preparation 1 (4S)-Benzyl-3-heptanoyl-oxazolidin-2-one.

To a solution of (S)- (-)-4-benzyl-2-oxazolidinone (3.3 g, 18.6 mmol) in THF (50 mL) at-78 °C was added dropwise n-BuLi (7.4 mL, 2.5M solution in hexane, 18.6 mmol). After stirring for 30 min at the same temperature, the reaction mixture was treated with heptanoyl chloride (2.76 g, 18.6 mmol). The reaction mixture was stirred and allowed to warm to 10 °C over 5 h, and quenched with saturated aqueous NH4C1 solution (100 mL). The aqueous layer was extracted with EtOAc (100 mL x 2). The combined organic layers were washed with brine, and dried over MgSO4. Removal of the solvent under reduced pressure yielded 4.63 g (86%) of the title compound. 1H NMR (400 MHz, CDC13) 8 7. 37-7.22 (m, 5H), 4.69 (m, 1H), 4.19 (m, 2H), 3.31 (dd, J = 13.4, 3.3 Hz, 1H), 2.95 (m, 2H), 2.79 (dd, J = 13.4, 9.7 Hz, 1H), 1.71 (m, 2H), 1. 42-1. 32 (m, 6H), 0.92 (t, J = 6. 8 Hz, 3H). MH+ 290.

Preparation 2 (4S)-Benzyl-3-[(2R)-benzyloxymethylheptanoyl] oxazolidin-2-one.

To a solution of (S) -4-benzyl-3-heptanoyloxazolidin-2-one (4.63 g, 16.02 mmol) and titanium (IV) chloride (1.9 mL, 16. 82 mmol) in dichloromethane (55 mL) at 0 °C was added dropwise diisopropylethylamine (3.1 mL, 17.62 mmol). After stirring at 0 °C for 1 hour, the resulting titanium enolate was reacted with benzylchloromethyl ether (TCI-America, 4.9 mL, 32.04 mmol) at 0 °C for 6 h. The reaction mixture was then quenched with water (100 mL). The aqueous layer was extracted with dichloromethane (100 mL x 2). The organic extracts were washed with brine, and dried over MgSO4. After removing the solvent under reduced pressure,

purification by flash column chromatography using an eluting system of hexane/EtOAc (5: 1) yielded 4.39 g (67%) of the title compound. 1H NMR (400 MHz, CDC13) 87. 38-7. 21 (m, 10H), 4.74 (m, 1H), 4.57 (m, 2H), 4.28-4. 13 (m, 3H), 3.82 (t, J = 8. 7 Hz, 1H), 3.68 (dd, J = 9.0, 4.9 Hz, 1H), 3.25 (dd, J = 13.5, 3.1 Hz, 1H), 2.71 (dd, J = 13.5, 9.3 Hz, 1H), 1.74 (m, 1H), 1.54 (m, 1H), 1.31-1. 28 (m, 6H), 0.89 (t, J = 6.7 Hz, 3H). MH+ 410.

Preparation 3 (3R)-Benzyloxy-2-pentylpropionic acid.

A 0.05 M solution of (S)-4-benzyl-3- [ (R)-2-benzyloxymethylheptanoyl] oxazolidin-2-one (2.0 g, 4.89 mmol) in a 3: 1 mixture of THF and H20 was treated with 30% H202 (4-5 mL, 39.12 mmol), followed by LiOH (0.48 g, 9.78 mmol) at 0 °C. The resulting mixture was stirred and allowed to warm to room temperature overnight. THF was then removed under vacuum. The residue was washed with dichloromethane (50 mL x 2) to remove (S)-4-benzyloxazolidin-2- one. The desired product was isolated by EtOAc extraction of the acidified (pH 1-2) aqueous phase. No further purification was required. Standing under high vacuum yielded 1. 16 g (95%) of the title compound. 1H NMR (400 MHz, CHCl3) 8 11. 1 (br s, 1H), 7.36 (m, 5H), 4.57 (s, 2H), 3.69 (m, 1H), 3.58 (dd, J = 9.2, 5.2 Hz, 1H), 2.74 (m, 1H), 1.66 (m, 1H), 1. 54 (m, 1H), 1.34-1. 30 (m, 6H), 0.90 (t, J = 6.7 Hz, 3H). MH+ 251.

Preparation 4 3-Hydroxy- (2R)-pentylpropionic acid.

To a solution of (R) -3-benzyloxy-2-pentyl-propionic acid (1.54 g, 6.16 mmol) in EtOH (100 mL) was added 10% Pd/C (310 mg). The reaction mixture was subjected to hydrogenation overnight at room temperature. After the reaction was completed, the reaction mixture was filtered through a pad of Celite, and washed with EtOH (50 mL x 3). Removal of the solvent provided the title compound (0.92 g, 93%). No further purification was required. 1H NMR (400 MHz, CHCL) 8 6.30 (br s, 1H), 3.81 (d, J = 5.4 Hz, 2H), 2.64 (m, 1H), 1.69 (m, 1H), 1.56 (m, 1H), 1.41-1. 27 (m, 6H), 0.91 (t, J = 7.7 Hz, 3H). MH+ 161.

Preparation 5 N-Benzyloxy-3-hydroxy- (2R)-pentylpropionamide.

To a mixture of (R) -3-hydroxy-2-pentylpropionic acid (0.92 g, 5.75 mmol), 0-benzyl hydroxylamine hydrochloride (0.92 g, 5.75 mmol) and 4- (dimethylamino) pyridine (1.41 g, 11.50 mmol) in dichloromethane (25 mL) at 0 °C was added 1- [3- (dimethylamino) propyl] -3- ethylcarbodiimide hydrochloride (1.11 g, 5.75 mmol). After stirring at room temperature overnight, the reaction was quenched with 1N aqueous HC1 solution (25 mL) and extracted using dichloromethane (25 mL x 2). The organic extracts were washed with water, brine, and dried over MgSO4. Removal of the solvent under reduced pressure yielded the title compound (1.43 g, 94%). 1H NMR (400 MHz, CHC13) 8 9.22 (br s, 1H), 7.41-7. 28 (m, 5H), 4.89 (q, J = 10.6 Hz, 2H), 3.70-3. 37 (m, 3H), 2.17 (m, 1H), 1.54 (br s, 1H), 1.27 (m, 6H), 0. 88 (t ; J = 6.9 Hz, 3H). MH+ 266.

Preparation 6 1-benzyloxy- (3R)-pentylazetidin-2-one.

To a mixture of (R) -N-benzyloxy-3-hydroxy-2-pentylpropionamide (1.41 g, 5.32 mmol) and triphenylphosphine (1.68 g, 6.39 mmol) in THF (53 mL) was added dropwise diethyl azodicarboxylate (1. 1 mL, 6.39 mmol) at 0 °C. The reaction mixture was stirred and allowed to warm to room temperature overnight. The reaction was then quenched with water (50 mL).

The aqueous layer was extracted with EtOAc (50 mL x 2). The combined organic layers were washed with brine, and dried over MgSO4. After removing the solvent under vacuum, the residue was purified by flash column chromatography (hex: EtOAc 5/1) to provide the title compound (1.17 g, 89%). 1H NMR (400 MHz, CHC13) 8 7.35-7. 25 (m, 5H), 4.87 (s, 2H), 3.28 (t, J = 4.85 Hx, 1H), 2.84 (q, J 2.35 Hz, 1H), 2.77 (m, 1H), 1.62 (m, 1H), 1.36 (m, 1H), 1.25-1. 16 (m, 6H), 0.88 (t, J = 6.9 Hz, 3H). MH+ 248.

Preparation 7 3-benzyloxyamino- (2R)-pentylpropionic acid.

To a solution of (R)-l-benzyloxy-3-pentylazetidin-2-one (0.96 g, 3.89 mmol) in a mixture of THF-H20-MeOH (50 mL, 3: 1: 1 v/v) was added lithium hydroxide monohydrate (1.91 g, 38. 9 mmol). After stirring at room temperature overnight, water (25 mL) was added to the mixture.

The solution was acidified to pH 5-6 with 3N aqueous HC1 solution. It was extracted with EtOAc (50 mL x 2). The combined organic layers were dried over MgSO4. Removal of the

solvent under vacuum provided the title compound (0.98 g, 95%). IH NMR (400 MHz, CHC13) 8 9.80 (br s, 1H), 7.37 (m, 5H), 4.75 (m, 2H), 3.14 (m, 2H), 2.74 (m, 1H), 1.70 (m, 1H), 1.53 (m, 1H), 1.38-1. 25 (m, 6H), 0.91 (t, J = 6.8 Hz, 3H). MH+ 266.

Preparation 8 (2R)-[(benzyloxyformylamino) methyl] heptanoic acid.

To a cold solution of (R) -3-benzyloxyamino-2-pentylpropionic acid (1.03 g, 3. 89 mmol) in HCO2H (19 mL) and dichloromethane (19 mL) at 0 °C was added acetic anhydride (3.9 mL, 41.2 mmol). The mixture was stirred at 0 °C for 3 hours. The volatiles were removed by evaporation under vacuum. Dichloromethane (50 mL) was added. The organic solution was washed with brine (50 mL x 2), and dried over MgSO. Filtration and evaporation under vacuum provided the title compound (1.08 g, 95%). 1H NMR (400 MHz, CHC13) 8 8.07 (br s, 1H), 7.29 (m, 5H), 4.91-4. 71 (m, 2H), 3.76 (m, 2H), 2.67 (m, 1H), 1.54 (m, 1H), 1.41 (m, 1H), 1.20 (m, 6H), 0.80 (t, J = 7.0 Hz, 3H). MH+ 294. <BR> <BR> <BR> <BR> <BR> <BR> <P> Example 1<BR> <BR> <BR> <BR> <BR> <BR> N-Hydroxy-N-[(R)-2-(N'-pyridin-2-yl-hydrazinocarbonyl)-hepty l]-formamide.

(2R)- [ (benzyloxyformylamino) methyl] heptanoic acid (1.2 mmoles), HOAt (1.3 mmoles), N'- pyridin-2-yl-hydrazine (1.2 mmoles) and NMM (5 mmoles) were dissolved in DMF and treated with EDCI (1.3 mmoles) at room temperature for 12 hours. The coupling product N- benzyloxy-N- [ (R)-2- (N'-pyridin-2-yl-hydrazinocarbonyl)-heptyl]-formamide was isolated by prep hplc of the crude reaction mixture. This compound was submitted to atmospheric pressure hydrogenation over Pd/C in methanol for 1 hour, yielding the title compound. MH+ 295.

Preparation 9 2-Hydrazino-5-ethylpyrimidine.

To a solution of 2-chloro-5-ethylpyrimidine (0.31 g, 2.2 mmol) in MeOH (5 mL) was added hydrazine monohydrate (1.0 mL, 20. 6 mmol). After stirring for 16 h at 50 °C, the solution was cooled to room temperature and purified by reverse phase HPLC to give 0.24 g (80%) of the title compound as a white solid. MH+ 139.

Preparation 10 2-Hydrazino-4-methylpyrimidine.

To a finely dispersed suspension of 2-chloropyrimidine (8.01 g, 69.9 mmol) in a 10: 1 mixture of Et2O-THF (500 mL) at-30°C was added dropwise MeLi (46 mL, 1.6M in Et20, 73.6 mmol). The reaction mixture was stirred at-30°C for 30 min, and was then warmed to 0°C and stirred for 30 min. To the reaction mixture was then added a 1: 1: 20 mixture of H2O- HOAc-THF (100 mL), and the mixture was stirred at 0°C for 10 min. To the mixture was then added a solution of DDQ (16.7 g, 73.6 mmol) in THF (100 mL), and the mixture was stirred and warmed to room temperature for 30 min. The mixture was then diluted with Et2O (300 mL) and washed with IN aq. NaOH (3x100 mL) followed by brine (300 mL). The organic phase was then dried over anhydrous MgSO4, filtered, concentrated in vacuo, and purified by flash chromatography using EtOAc-hexanes (1: 2) as eluent to afford 6.06 g of 2-chloro-4- methylpyrimidine (67%) as white crystalline plates.

To a solution of 2-chloro-4-methylpyrimidine (6.06 g, 47.1 mmol) in MeOH (40 mL) was added hydrazine monohydrate (10 mL, 206 mmol). The solution was stirred for 16 h at room temperature and then purified by reverse phase HPLC to provide 4.43 g of the title compound (76%) as a white solid. MH+ 125.

Preparation 11 2-Hydrazino-4-morpholino-6-methylpyrimidine.

To a solution of 2,4-dichloro-6-methylpyrimidine (0.41 g, 2.50 mmol) in MeOH (5 mL) was added morpholine (0.5 mL, 5.73 mmol). The solution was stirred for 30 min at room temperature, and then hydrazine monohydrate (1.0 mL, 20.6 mmol) was added. The solution was then heated at 60 °C and stirred for 16 h. The solution was then cooled to room temperature and purified by reverse phase HPLC to afford 0.31 g of the title compound (59%) as a waxy white solid. MH+ 210.

Preparation 12 2-Hydrazino-4- (2, 3, 4-trimethoxyphenyl) pyrimidine.

To a solution of 2-thiomethyl-4-chloropyrimidine (0. 3410 g, 2.12 mmol) in 1,4-dioxane (21 mL) was added 2,3, 4-trimethoxyphenylboronic acid (0.4950 g, 2.33 mmol) and aq. Na2C03 (2.3 mL, 2. 0M in water, 4.60 mmol). The mixture was sparged with dry nitrogen gas for 5 min, and then Pd (Ph3P) 4 (123 mg, 0.106 mmol) was added. The mixture was protected from light and heated at 110°C for 16 h. The mixture was then cooled to room temperature, filtered, concentrated in vacuo, and purified by flash chromatography using EtOAc-hexanes (1: 4) as eluent, to give 0.5920 g of 2-thiomethyl-4- (2, 3,4-trimethoxyphenyl) pyrimidine (95%) as a yellow solid.

To a solution of 2-thiomethyl-4- (2, 3,4-trimethoxyphenyl) pyrimidine (0.5920 g, 2.02 mmol) in CH2C12 (10 mL) was added m-chloroperbenzoic acid (1.05 g, 6.08 mmol), and the solution was stirred for 3 h at which time it was observed to be a white suspension. The suspension was concentrated in vacuo, and MeOH (10 mL) was added followed by hydrazine monohydrate (2 mL, 41.2 mmol). The resulting solution was stirred for 16 h and then concentrated to about one-half volume in vacuo. The mixture was allowed to stand for 1 h, and the resulting solid was collected by vacuum filtration and was washed with water. Drying in vacuo afforded 0.3330 g of the title compound (60%) as a light brown solid. MH+ 277.

Preparation 13 2-Hydrazino-4-morpholino-6-trifluoromethylpyrimidine.

To a solution of 2-thiomethyl-4-chloro-6-trifluoromethylpyrimidine (1.9996 g, 8.75 mmol) in MeOH (50 mL) was added morpholine (1.5 mL, 17.2 mmol). The solution was stirred overnight, concentrated in vacuo, and the resulting white solid was collected by vacuum filtration and washed with water. To a solution of the solid in CH2C12 (50 mL) was added m- chloroperbenzoic acid (4.53 g, 26.3 mmol), and the resulting solution was stirred for 2 h at which time it was observed to be a white suspension. The solvent was removed in vacuo, and then MeOH (50 mL) was added followed by hydrazine monohydrate (3.0 mL, 61.8 mmol).

The solution was stirred for 16 h, and was then concentrated to about one-half volume in vacuo. Water (100 mL) was then added to the resulting suspension, and the observed white solid was collected by vacuum filtration. This material was then washed with water and dried in vacuo to afford 1.7193 g of the title compound (75%) as a white solid. MH+ 264.

Preparation 14 2-Hydrazino-5,6, 7, 8-tetrahydroquinazoline.

To a mixture of ethyl 2-cyclohexanonecarboxylate (3.00 g, 17.6 mmol) and 2-methyl-2- thiopseudourea sulfate (3.68 g, 13.2 mmol) was added a solution of potassium carbonate (7.31 g, 52.9 mmol) in water (60 mL). The reaction solution was stirred at room temperature for 16 h, at which time it was observed to be a suspension. The white solid was collected by vacuum filtration, washed with water, and dried in vacuo. A mixture of the solid in phosphorus oxychloride (20 mL) was heated at 110°C in a sealed tube, at which time it was observed to be a solution. The solution was cooled to room temperature and was then poured over cracked ice and water (300 mL). The mixture was vigorously stirred at 0°C for 1 h, and the resulting precipitate was collected by vacuum filtration, washed with water, and dried in vacuo to afford 1.61 g of 2-thiomethyl-4-chloro-5, 6,7, 8-tetrahydroquinazoline (43%) as an off-white solid.

To a solution of 2-thiomethyl-4-chloro-5, 6,7, 8-tetrahydroquinazoline (0.5121 g, 2.39 mmol) in a 10: 1 mixture of MeOH-HOAc (30 mL) was added activated zinc dust (500 mg, 7.65 mmol).

The mixture was heated at 70°C for 1 h, and was then cooled to room temperature and filtered.

The resulting solution was concentrated in vacuo, and azeotropically dried with toluene (50 mL). The residue was partitioned between EtOAc (150 mL) and 1 N aq. HC1 (50 mL), and the organic phase was then washed with saturated aq. NaHCO3 and brine. The organic phase was then dried over anhydrous MgSO4 and concentrated in vacuo to provide 0.1461 g of 2- thiomethyl-5,6, 7,8-tetrahydroquinazoline (34%) as a purple oil.

To a solution of 2-thiomethyl-5, 6,7, 8-tetrahydroquinazoline (0.1461 g, 0.81 mmol) in CH2Cl2 (5 mL) was added m-chloroperbenzoic acid (0.462 g, 2.68 mmol). The solution was stirred at room temperature for 3 h at which time it was observed to be a suspension. The solvent was then removed in vacuo, and MeOH (5 mL) was added followed by hydrazine monohydrate (1 mL, 20.6 mmol). The solution was then heated at 50°C and stirred for 16 h. The solution was cooled to room temperature and purified by reverse phase HPLC to give 0.1126 g of the title compound (85%) as a colorless oil. MH+ 165.

Preparation 15 2-Hydrazino-4- (2-pyridyl) pyrimidine.

To a solution of 2-amino-4- (2-pyridyl) pyrimidine (10.10 g, 58.66 mmol) in 5% aqueous sulfuric acid (200 mL) was added sodium nitrate (20.24 g, 293.3 mmol) portionwise over 10 min. The solution was stirred at room temperature for 2 h and was then adjusted to pH 10 by addition of 6N aq. NaOH. The resulting mixture was then extracted with 30% i-PrOH in CHC13 (10x300 mL), and the combined organic phase was dried over anhydrous MgSO4 and concentrated in vacuo. The residue was triturated with hexanes and collected by vacuum filtration to afford 6.89 g of 4- (2-pyridyl) pyrimid-2-one (68%) as a beige solid.

A mixture of 4- (2-pyridyl) pyrimid-2-one (6.89 g, 39.8 mmol) in phosphorus oxychloride (30 mL) was heated at 110°C for 90 min in a sealed tube. The dark brown solution was then cooled to room temperature and poured over cracked ice and water (500 mL). The mixture was vigorously stirred at 0°C for 1 h, and was then adjusted to pH 14 with 6 N aq NaOH.

The mixture was extracted with CH2C12 (2x300 mL), and the combined organic phase was dried over anhydrous MgSO4 and concentrated in vacuo. To a solution of the residue in CH2Cl2 (10 mL) and MeOH (30 mL) was added hydrazine monohydrate (7.0 mL, 144.2 mmol), and the solution was stirred for 16 h at which time a white precipitate was observed.

This solid was collected by vacuum filtration, washed with water, and dried in vacuo to provide 2. 20 g of the title compound (30%) as an off-white solid. MH+ 188.

Preparation 16 (6-Morpholin-4-yl-pyrimidin-4-yl)-hydrazine.

A solution of 4,6 dichloropyrimidine (300 mg, 2 mmol), tert-butyl carbazate (280 mg, 2.1 mmol) and Hunig's base (453 . L, 2.6 mmol) in ethanol (3 ml) was stirred at 120 °C for 1 hour under microwave condition. After morpholine (700 RL, 8 mmol) was added, the mixture was then resubmitted to the same microwave condition for another hour. Evaporation of solvent under vacuum gave a white solid which was treated with TFA (3 ml) in DCM (3 ml) for 20 min. After evaporation of solvent, the residue was redissolved in methanol. Treatment with solid NaHCO3 removed the traces of TFA that might have been left over. Filtration followed by evaporation of the solvent gave a residue which was submitted to reverse-phase HPLC purification to produce (6-morpholin-4-yl-pyrimidin-4-yl)-hydrazine (200 mg, 1 mmol, 50% in 3 steps) as a white solid. MH+ 196.

Alternatlively, the same compound may be generated by stirring a solution of 4,6 dichloropyrimidine (300 mg, 2 mmol), morpholine (280 mg, 2.1 mmol) and diisopropylethylamine (453 RL, 2.6 mmol) in ethanol (3 ml) for one hour. After addition of hydrazine (370 . L, 6 mmol), the mixture was stirred at 120 °C for 1 hour under microwave condition. After evaporation of the solvent, the compound was dissolved in DMSO before submitted to prep HPLC purificaton which then gave 6-morpholin-4-yl-pyrimidin-4-yl)- hydrazine. MH+ 196.

Preparation 17 (2-Ethylamine-6-trifluoromethyl-pyrimidin-4-yl)-hydrazine.

A solution of (4-chloro-6-trifluoromethyl-pyrimidin-2-yl) -ethyl-amine (100 mg, 0.38 mmol), hydrazine (87 gel, 3.8 mmol) in ethanol was heated at 70 °C over night. Evaporation of the solvent under vacuum gave a residue which was purified by prep HPLC to give (2- ethylamine-6-trifluoromethyl-pyrimidin-4-yl)-hydrazine (74 mg, 75%). MH+ 256.

Preparation 18 [ (4-Methyl-piperazin-1-yl)-trifluoromethyl-pyrimidin-4-yl]-hy drazine.

A mixture of 4-chloro-2-methylthiol-6- (trifluomethyl) pyrimidine (228 mg, 1 mmol), tert- butyl carbazate (159 mg. 6,1. 2 mmol) in ethanol was heated to 100 °C in the microwave reactor for 20 min. Evaporation of solvent gave a white solid. The solid was treated with MCPBA in DCM at rt overnight. Evaporation of the solvent gave a white solid which was treated with 1-methylpiperazine at 140 °C for 20 min. in ethanol under microwave conditions.

Evaporation of solvents gave a solid which was treated TFA (3 ml) in DCM (3 ml) for 20 min. After the reaction was done, most of TFA and DCM was removed under vacuum. The residue was redissolved in methanol and treated with solid NaHCO3 to remove TFA residue until no gas was generated. Filtration and vacuum evaporation of the filtrate gave a residue which was purified by prep. HPLC to give [ (4-Methyl-piperazin-1-yl)-trifluoromethyl- pyrimidin-4-yl]-hydrazine (100 mg, 36%). MH+ 277.

Example 2 <BR> <BR> <BR> N-Hydroxy-N-{(R)-2-[N'-(3-methoxy-phenyl)-hydrazinocarbonyl] -heptyl}-formamide.

MH+ = 324.

Example 3 <BR> <BR> <BR> N-Hydroxy-N-{(R)-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hy drazinocarbonyl]-<BR> <BR> <BR> <BR> <BR> heptyl}-formamide.

MH+ = 364.

Example 4 <BR> <BR> <BR> N-{(R)-2-[N'-(4-Cyano-phenyl)-hydrazinocarbonyl]-heptyl}-N-h ydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <P>MH+ = 319.

Example 5 N-{(R)-2-[N'-(2,6-Dimethyl-pyrimidin-4-yl)-hydrazinocarbonyl ]-heptyl}-N-hydroxy- formamide.

MH+ = 324.

Example 6 N-Hydroxy-N-[(R)-2-(N'-quinoxalin-2-yl-hydrazinocarbonyl)-he ptyl]-formamide.

MH+ = 346.

Example 7 <BR> <BR> <BR> N-Hydroxy-N-((2R)-2-{N'-(3, 4-dihydro-quinoxalin-2-yl)-hydrazinocarbonyl}-heptyl)- formamide.

MH+ = 348.

Example 8 N-Hydroxy-N-{(R)-2-[N'-(1, 3, 4-trimethyl-1H-pyrazolo [3, 4-b] pyridin-6-yl)- hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 377.

Example 9 4-(N'-{(R)-2-[(RFOrmyl-hydroxy-amino)-methyl]-heptanoyl}-hyd razino)- benzenesulfonamide.

MH+ = 373.

Example 10

N-Hydroxy-N- [ (2R)-2- (cyclohexylmethyl)-3-oxo-3- {N'- [4- (trifluoromethyl)-pyrimidin-2-<BR> <BR> <BR> <BR> <BR> yl]-hydrazino}-propyl]-formamide.

MH+ = 390.

Example 11 <BR> <BR> <BR> N-Hydroxy-N- [ (2R)-2- (cyclopentylmethyl)-3-oxo-3- {N'- [4- (trifluoromethyl)-pyrimidin- 2-yl]-hydrazino}-propyl]-formamide.

MH+ = 376.

Example 12 <BR> <BR> <BR> N-{(R)-2-[N'-(Dimethyl-trifluoromethyl-pyrimidin-4-yl)-hydra zinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 392.

Example 13 N-Hydroxy-N-{(R)-2-[N'-(6-trifluoromethyl-pyridazin-3-yl)-hy drazinocarbonyl]- heptyl}-formamide.

MH+ = 364.

Example 14 <BR> <BR> <BR> N-Hydroxy-N-{(R)-2-[N'-(6-trifluoromethyl-pyrimidin-4-yl)-hy drazinocarbonyl]-<BR> <BR> <BR> <BR> <BR> heptyl}-formamide.

MH+ = 364.

Example 15 N-Hydroxy-N- { (R)-2- [N'- (5-methyl- [1, 2,4] triazolo [1, 5-a] pyrimidin-7-yl)- hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 350.

Example 16 N-Hydroxy-N-{(R)-2-[N'-(9H-purin-6-yl)-hydrazinocarbonyl]-he ptyl}-formamide.

MH+ = 336.

Example 17 N-{(R)-2-[N'-(5-Cyano-pyrimidin-2-yl)-hydrazinocarbonyl]-hep tyl}-N-hydroxy- formamide.

MH+ = 321.

Example 18 N-Hydroxy-N-((2R)-2-{[N'-(pyrimidin-2-yl)-hydrazino] carbonyl}-heptyl)-formamide.<BR> <P>MH+ = 296.

Example 19 N-Hydroxy-N- ( (2R)-2- (cyclobutylmethyl)-3-oxo-3- {N'- [4- (trifluoromethyl)-pyrimidin-2- yl]-hydrazino}-propyl)-formamide.

MH+ = 362.

Example 20 N-Hydroxy-N-{(R)-2-[N'-(6-imidazol-1-yl-pyrimidin-4-yl)-hydr azinocarbonyl]-heptyl}- formamide.

MH+ = 362.

Example 21 N-[(R)-2-(N'-Benzo[1, 2,4] triazin-3-yl-hydrazinocarbonyl)-heptyl]-N-hydroxy- formamide.

MH+ = 347.

Example 22 N-Hydroxy-N-{(R)-2-[N'-(7-methoxy-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- heptyl}-formamide.

MH+ = 377.

Example 23 N-Hydroxy-N-{(R)-2-[N'-(1-methyl-1H-pyrazolo [3,4-d] pyrimidin-6-yl) - hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 350.

Example 24 N-((R)-2-{N'-[6-(5-Chloro-pyridin-3-yl-oxy)-pyridazin-3-yl]- hydraiznocarbonyl}- heptyl)-N-hydroxy-formamide.

MH+ = 423.

Example 25

N-Hydroxy-N-[(2R)-2-({N'-[6-(1H-pyrrol-1-yl)-3-pyridazinyl]- hydrazino}-carbonyl)- heptyl]-formamide.

MH+ = 361.

Example 26 N-Hydroxy-N-((2R)-2-{[N'-(9-methyl-9H-purin-6-yl)-hydrazino] -carbonyl}-heptyl)- formamide.

MH+ = 350.

Example 27 N-Hydroxy-N-{(R)-2-[N-({6-morpholin-4-yl}-9H-purin-2-yl)-hyd razinocarbonyl]-<BR> heptyl}-formamide.

MH+ = 421.

Example 28 N-{(R)-2-[N'-(6-Fluoro-pyridin-2-yl)-hydrazinocarbonyl]-hept yl}-N-hydroxy- formamide.

MH+ = 313.

Example 29 N-Hydroxy-N-((2R)-2-{[N'-(1-methyl-1H-pyrazolo [3, 4-d]pyriidin-4-yl)-hydrazino]- carbonyl}-heptyl)-formamide.

MH+ = 350.

Example 30 N- { (R)-2- [N'- (4-Amino-6-isopropyl- [1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 354.

Example 31 N-{(R)-2-[N'-(2, 5-Dimethyl-4-nitro-2H-pyrazol-3-yl)-hydrazinocarbonyl]-hepty l}-N- hydroxy-formamide.

MH+ = 357.

Example 32 N-{(R)-2-[N'-(3-Chloro-l-methyl-lH-pyrazolo [3,4-d] pyrimidin-6-yl)- hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 384.

Example 33 <BR> <BR> <BR> N-{(R)-2-[N'-(6-Dimethylamino-9H-purin-2-yl)-hydrazinocarbon yl]-heptyl}-N-hydroxy- formamide.

MH+ = 379.

Example 34 N-Hydroxy-N-[(2R)-4-cyclopropyl-2-({N'-[4-(trifluoromethyl)- pyrimidin-2-yl]- hydrazino}-carbonyl)-butyl]-formamide.

MH+ = 362.

Example 35 <BR> <BR> <BR> N-Hydroxy-N- ( (2R)-2- (cyclopropylmethyl)-3-oxo-3-IN'- [4- (trifluoromethyl)-pyrimidin-<BR> <BR> <BR> <BR> <BR> 2-yl]-hydrazino}-propyl)-formamide.

MH+ = 348.

Example 36 <BR> <BR> <BR> N-Hydroxy-N-{(R)-2-[N'-methyl-N'-(4-trifluoromethyl-pyrimidi n-2-yl)-<BR> <BR> <BR> <BR> <BR> hydrazinocarbonyl]-heptyl}-formamide.<BR> <BR> <BR> <BR> <P>MH+ = 378.

Example 37 2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydr azino)-4- trifluoromethyl-pyrimidine-5-carboxylic acid methyl ester.

MH+ = 422.

Example 38 2-(N'-{(R)-2-[(Fòrmyl-hydroxy-amino)-methyl]-heptanoyl}-hyd razino)-4- trifluoromethyl-pyrimidine-5-carboxylic acid.

MH+ = 408.

Example 39 N-{(R)-2-[N'-(5-Fluoro-4-methoxy-pyrimidin-2-yl)-hydrazinoca rbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 344.

Example 40 N-{(R)-2-[N'-(4-Dimethylamino-pyrimidin-2-yl)-hydrazinocarbo nyl]-heptyl}-N- hydroxy-formamide.

MH+ = 339.

Example 41 <BR> <BR> <BR> N-Hydroxy-N-{(2R)-2-[(N'-{6-[(2-hydroxyethyl) amino]-1, 3-dihydro-2H-purin-2-<BR> <BR> <BR> <BR> <BR> ylidene}-hydrazino)-carbonyl]-heptyl}-formamide.

MH+ = 395.

Example 42 <BR> <BR> <BR> N-{(R)-2-[N'-(5-Fluoro-4-morpholin-4-yl-pyrimidin-2-yl)-hydr azinocarbonyl]-heptyl}- N-hydroxy-formamide.

MH+ = 399.

Example 43 N-{(R)-2-[N'-(5-Fluoro-4-methylamino-pyrimidin-2-yl0-hydrazn ocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 343.

Example 44 2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydr azino)-4- trifluoromethyl-pyrimidine-5-carboxylic acid dimethylamide.

MH+ = 435.

Example 45 <BR> <BR> <BR> N-Hydroxy-N-{(R)-2-[N'-(3-oxo-3, 4-dihydro-quinoxalin-2-yl)-hydrazinocarbonyl]-<BR> <BR> <BR> <BR> <BR> heptyl}-formamide.

MH+ = 362.

Example 46 <BR> <BR> <BR> N-{(R)-2-Butoxy-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hyd razinocarbonyl]-ethyl}-N- hydroxy-formamide.

MH+ = 366.

Example 47

2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydr azino)-4- trifluoromethyl-pyrimidine-5-carboxylic acid (2-fluoro-phenyl) -amide.

MH+ = 501.

Example 48 2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydr azino)-4- trifluoromethyl-pyrimidine-5-carboxylic acid tert-butylamide.

MH+ = 463.

Example 49 N-Hydroxy-N-((R)-2-{N'-[(1-piperidin-1-yl-methanoyl)-trifluo romethyl-pyrimidin-2-yl]-<BR> hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 475.

Example 50 N-{(R)-2-[N'-(5-Cyano-4-trifluoromethyl-pyrimidin-2-yl)-hydr azinocarbonyl]-heptyl}- N-hydroxy-formamide.

MH+ = 389.

Example 51 N-Hydroxy-N-[(2R)-2-({N'-[9-(4, 4, 4-trifluorobutyl)-1, 9-dihydro-2H-purin-2-ylidene]- hydrazino}-carbonyl)-heptyl]-formamide.

MH+ = 446.

Example 52 N-Hydroxy-N-((R)-2-{N'-[(1-morpholin-4-yl-methanoyl)-trifluo romethyl-pyrimidin-2-<BR> yl]-hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 477.

Example 53 2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydr azino)-4- trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide.

MH+ = 497.

Example 54 N-Hydroxy-N-[(2R)-3-[N'-(1, 2, 4-benzotriazin-3-yl)-hydrazino]-2-(cyclohexylmethyl)-3- oxopropyl]-formamide.

MH+ = 373.

Example 55 N-Hydroxy-N-((2R)-2-(cyclohexylmethyl)-3-[N'-[7-(methyloxy)- 1, 2, 4-benzotriazin-3-yl]- hydrazino}-3-oxopropyl)-formamide.

MH+ = 403.

Example 56 2-[2-((2R)-2-{[Formyl (hydroxy) amino] methyl} heptanoyl) hydrazino]-N-methyl-N-2- pyridinyl-4- (trifluoromethyl)-5-pyrimidinecarboxamide.

MH+ = 498.

Example 57 2-[2-((2R)-2-{[Formyl (hydroxy) amino] methyl} heptanoyl) hydrazino]-N-methyl-N- phenyl-4- (trifluoromethyl)-5-pyrimidinecarboxamide.

MH+ = 497.

Example 58 2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydr azino)-4- trifluoromethyl-pyrimidine-5-carboxylic acid morpholin-4-ylamide.

MH+ = 492.

Example 59 <BR> <BR> <BR> N-Hydroxy-N-((R)-2-{N'-[(N'-phenyl-hydrazinocarbonyl)-triflu oromethyl-pyrimidin-2-<BR> <BR> <BR> <BR> yl]-hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 498.

Example 60 2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydr azino)-4- trifluoromethyl-pyrimidine-5-carboxylic acid piperidin-1-ylamide.

MH+ = 490.

Example 61 2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydr azino)-4- trifluoromethyl-pyrimidine-5-carboxylic acid pyrrol-1-ylamide.

MH+ = 472.

Example 62 N-{(R)-2-[N'-(Dimethylamino-fluoro-pyrimidin-2-yl)-hydrazino carbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 357.

Example 63 <BR> <BR> <BR> N-((R)-2-{N'-[(Ethyl-methyl-amino)-fluoro-pyrimidin-2-yl]-hy drazinocarbonyl}-heptyl)- N-hydroxy-formamide.

MH+ = 371.

Example 64 N-Hydroxy-N- ( (2R)-2- (cyclopentylmethyl)-3- {N'- [7- (methyloxy)-1, 2, 4-benzotriazin-3- yl]-hydrazino}-3-oxopropyl)-formamide.

MH+ = 389.

Example 65 N-Hydroxy-N-{(R)-2-[N'-(1-methyl-lH-benzoimidazol-2-yl)-hydr azinocarbonyl]- heptyl}-formamide.

MH+ = 348.

Example 66 <BR> <BR> <BR> N-{(R)-2-[N'-(4-Azetidin-1-yl-5-fluoro-pyrimidin-2-yl)-hydra zinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 369.

Example 67 <BR> <BR> <BR> N-{(R)-2-[N'-(4-Cyclopropylamino-5-fluoro-pyrimidin-2-yl)-hy drazinocarbonyl]-<BR> <BR> <BR> <BR> <BR> <BR> heptyl}-N-hydroxy-formamide.

MH+ = 369.

Example 68 N-[(R)-2-(N-Benzo[1, 2,4] triazin-3-yl-hydrazinocarbonyl)-3-cyclopentyl-propyl]-N- hydroxy-formamide.

MH+ = 359.

Example 69

N-Hydroxy-N-{(R)-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrim idin-2-yl)-<BR> hydrazinocarbonyl]-heptyl}-formamide.<BR> <P>MH+ = 449.

Example 70 N-Hydroxy-N-[(R)-2-(N'-{[(2-hydroxy-ethyl)-methyl-amino]-tri fluoromethyl-pyrimidin- 2-yl}-hydrazinocarbonyl)-heptyl]-formamide.

MH+ = 437.

Example 71 N-Hydroxy-N-((R)-2-{N'-[(4-methyl-piperazin-1-yl)-trifluorom ethyl-pyrimidin-2-yl]- hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 462.

Example 72 N-Hydroxy-N- ( (2R)-2- (cyclohexylmethyl)-3- {N'- [4- (cyclopropylamino)-5-fluoro- pyrimidin-2-yl] hydrazino}-3-oxopropyl)-formamide.

MH+ = 395.

Example 73 N-Hydroxy-N- ( (2R)-2- (cyclopentylmethyl)-3-N'- [4- (cyclopropylamino)-5-fluoro- pyrimidin-2-yl] hydrazino}-3-oxopropyl)-formamide.

MH+ = 381.

Example 74 N-Hydroxy-N- [ (2R)-3- {N'- [4- (azetidin-1-yl)-5-fluoro-pyrimidin-2-yl]-hydrazino}-2-<BR > (cyclopentylmethyl)-3-oxopropyl]-formamide.

MH+ = 381.

Example 75 N-Hydroxy-N- [ (2R)-5-methyl-2- ( {N'- [4- (trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-<BR> carbonyl)-hexyl]-formamide.

MH+ = 364.

Example 76 N-[(R)-2-(N'-Benzo[1, 2,4] triazin-3-yl-hydrazinocarbonyl)-5-methyl-hexyl]-N-hydroxy- formamide.

MH+ = 347.

Example 77 N-Hydroxy-N-[(2R)-5-methyl-2-({N'-[7-(methloxy)-1, 2, 4-benzotriazin-3-yl]- <BR> <BR> <BR> hydrazino}-carbonyl)-hexyl]-formamide.<BR> <BR> <BR> <BR> <P>MH+ = 377.

Example 78 N-{(R)-2-[N'-(7-Chloro-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 381.

Example 79 <BR> <BR> <BR> N-Hydroxy-N- ( (2R)-2- (cyclopentylmethyl)-3- {N'- [4- (morpholin-4-yl)-6-<BR> <BR> <BR> <BR> <BR> (trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-3-oxopropyl)-fo rmamide.

MH+ = 461.

Example 80 N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[4-[(2-hydroxy ethyl)-(methyl)-amino]- 6-(trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-3-oxopropyl)- formamide.

MH+ = 449.

Example 81 N-Hydroxy-N-[(2R)-6-methyl-2-({N'-[4-(trifluoromethyl)-pyrim idin-2-yl]-hydrazino}- carbonyl)-heptyl]-formamide.

MH+ = 378.

Example 82 N-Hydroxy-N-((2R)-2-{[N'-(1, 2, 4-benzotriazin-3-yl)-hydrazino]-carbonyl}-6- methylheptyl)-formamide.

MH+ = 361.

Example 83 N-Hydroxy-N-{(R)-2-[N'-(5-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- <BR> <BR> <BR> heptyl}-formamide.<BR> <BR> <BR> <BR> <P>MH+ = 361.

Example 84 <BR> <BR> <BR> N- ( (R)-2- {N'- [ (4-Ethyl-piperazin-1-yl)-trifluoromethyl-pyrimidin-2-yl]-< ;BR> <BR> <BR> <BR> <BR> hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 476.

Example 85 N-Hydroxy-N-{(R)-2-[N'-(piperazin-1-yl-trifluoromethyl-pyrim idin-2-yl)- hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 448.

Example 86 N-{(R)-2-[N'-(7-Fluoro-benzo[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 365.

Example 87 N-Hydroxy-N-[(2R)-2-({N'-[4-(4-ethyl-1-piperazinyl)-6-(trifl ouromethyl)-pyrimidin-2- yl]-hydrazino}-carbonyl)-6-methylheptyl]-formamide.

MH+ = 490.

Example 88 <BR> <BR> <BR> N-Hydroxy-N- [ (2R)-6-methyI-2- ( {N'- [4- (piperazm-l-yI)-6- (trifluoromethyl)-pyrimidin-<BR> <BR> <BR> <BR> <BR> 2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

MH+ = 462.

Example 89 N-Hydroxy-N-[(2R)-6-methyl-2-({N'-[4-(4-methyl-piperazin-1-y l)-6-(trifluoromethyl)- pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

MH+ = 476.

Example 90 N-Hydroxy-N-((2R)-2-({N'-(7-chloro-1, 2, 4-benzotriazin-3-yl) hydrazino] carbonyl}-6- methylheptyl)-formamide.

MH+ = 395.

Example 91

N-Hydroxy-N-((2R)-6-methyl-2-{[N'-(5-methyl-1, 2, 4-benzotriazin-3-yl)-hydrazino]- carbonyl}-heptyl)-formamide.

MH+ = 375.

Example 92 N-Hydroxy-N-((2R)-2-{[N'-(7-fluoro-1, 2, 4-benzotriazin-3-yl)-hydrazino]-carbonyl}-6- methylheptyl)-formamide.

MH+ = 379.

Example 93 N-Hydroxy-N-(R)-2-{N'-[(2-methoxy-ethylamino)-trifluoromethy l-pyrimidin-2-yl]- hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 437.

Example 94 N-Hydroxy-N-[(2R)-6-methyl-2-({N'-[7-(methoxy)-1, 2, 4-benzotriazin-3-yl]- hydrazino}-carbonyl)-heptyl]-formamide.<BR> <P>MH+ = 391.

Example 95 N-Hydroxy-N-[(R)-2-(N'-{ [4-(2-hydroxy-ethyl)-piperazin-1-yl]-trifluoromethyl-<BR& gt; pyrimidin-2-yl}-hydrazinocarbonyl)-heptyl]-formamide.

MH+ = 492.

Example 96 N-Hydroxy-N-((R)-2-{N'-[(4-pyrimidin-2-yl-piperazin-1-yl)-tr ifluoromethyl-pyrimidin-<BR> 2-yl]-hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 526.

Example 97 N-Hydroxy-N-((R)-2-{N'-[(2-hydroxy-ethylamino)-trifluorometh yl-pyrimidin-2-yl]- hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 423.

Example 98 N-Hydroxy-N-{(R)-2-[N'-(7-trifluoromethyl-benzo [1, 2,4] triazin-3-yl) - hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 415.

Example 99 N-Hydroxy-N-{(R)-2-[N'-(6-methyl-benzo[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- <BR> <BR> <BR> heptyl}-formamide.<BR> <BR> <BR> <BR> <P>MH+ = 361.

Example 100 N-Hydroxy-N-{(2R)-2-(cyclopentylmethyl)-3-[N'-(5-methyl-1, 2, 4-benzotriazin-3- yl) hydrazino]-3-oxopropyl}-formamide.

MH+ = 373.

Example 101 N-Hydroxy-N-[(2R)-2({N'-[4-(trofluoromethyl)-pyrimidin-2-yl] -hydrazinio}-carbonyl)- octyl]-formamide.

MH+ = 378.

Example 102 N-Hydroxy-N-((2R)-2-{[N'-(1, 2, 4-benzotriazin-3-yl) hydrazino]-carbonyl}-octyl)- formamide.

MH+ = 361.

Example 103 N-Hydroxy-N-[(2R0-({N'-(7-(methyloxy)-1, 2, 4-benzotriazin-3-yl]-hydrazino}- carbonyl)-octyl]-formamide.

MH+ = 391.

Example 104 N-Hydroxy-N-{(R)-2-[N'-(7-methyl-benzo[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- <BR> <BR> <BR> heptyl}-formamide.<BR> <BR> <BR> <BR> <P>MH+ = 361.<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P> Example 105 N-({R)-2-[N'-(6-Chloro-benzo[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+=381.

Example 106 N-Hydroxy-N-{(R)-2-[N'-(5-methoxy-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- heptyl}-formamide.

MH+ = 377.

Example 107 N-Hydroxy-N-{(R)-2-[N'-(1-methyl-2oxo-1,2-dihydro-pyridin-4- yl)- <BR> <BR> <BR> hydrazinocarbonyl]-heptyl}-formamide.<BR> <BR> <BR> <BR> <BR> <P>MH+ = 325.

Example 108 <BR> <BR> <BR> N-Hydroxy-N-((R)-2-{N'-[(N'-pyridin-2-yl-hydrazino)-trifluor omethyl-pyrimidin-2-yl]-<BR> <BR> <BR> <BR> <BR> hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 471.

Example 109 N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-morpholin-4-yl-pyrimidin- 2-yl)- hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 395.

Example 110 <BR> <BR> <BR> N- ( (R)-2- {N'- [4- (4-Ethyl-piperazin-1-yl)-6-methyl-pyrimidin-2-yl]-hydrazinoc arbonyl}- heptyl)-N-hydroxy-formamide.

MH+ = 422.

Example 111 N-{(R)-2-[N'-(4,6-Dimethyl-pyrimidin-2-yl)-hydrazinocarbonyl ]-heptyl}-N-hydroxy- formamide.

MH+ = 324.

Example 112 N-Hydroxy-N-{(R)-2-[N'-(4-trifluoromethyl-pyridin-2-yl)-hydr azinocarbonyl]-heptyl} formamide.

MH+ = 363.

Example 113 N-Hydroxy-N-[(R)-2-(N'-isouinolin-1-yl-hydrazinocarbonyl)-he ptyl]-formamide.

MH+ = 345.

Example 114 N-Hydroxy-N-[(R)-2-(N'-quinolin-2-yl-hydrazinocarbonyl)-hept yl]-formamide.

MH+ = 345.

Example 115 N-{(R)-2-[N'-(1-Benzyl-2-oxo-1,2-dihydro-pyridin-4-yl)-hydra zinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 401.

Example 116 N-Hydroxy-N-{(R)-2-[N'-(4-oxo-4H-pyrido [1, 2-a] [1, 3,5] triazin-2-yl)- hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 363.

Example 117 N-Hydroxy-N-{(R)-2-[N'-(4-methyl-pyrimidin-2-yl)-hydrazinoca rbonyl]-heptyl}- formamide.

MH+ = 310.

Example 118 <BR> <BR> <BR> N-{(R)-2-[N'-(l-Butyl-2-oXo-1, 2-dihydro-pyridin-4-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 367.

Example 119 N-Hydroxy-N-{(R)-2-[N'-(9-methyl-4-oxo-4H-pyrido [1, 2-a] [1, 3,5] triazin-2-yl)- hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 377.

Example 120 N-Hydroxy-N-{(R)-2-[N'-(6-oxo-4-trifluoromethyl-1, 6-dihydro-pyrimidin-2-yl)- hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 380.

Example 121

N-Hydroxy-N-{(R)-2-[N'-(methyl-trifluoromethyl-pyrimidin-2-y l)-hydrazinocarbonyl]- heptyl}-formamide.

MH+ = 378.

Example 122 N-Hydroxy-N-{(R)-2-[N'-(5-trifluoromethyl-pyridin-2-yl)-hydr azinocarbonyl]-heptyl}- formamide.

MH+ = 363.

Example 123 N-{(R)-2-[N'-(6-Ethoxy-pyridin-2-yl)-hydrazinocarbonyl]-hept yl}-N-hydroxy- formamide.

MH+ = 339.

Example 124 N-Hydroxy-N- [ (R)-2- (N'-pyrido [2, 3-e]- [1, 2,4] triazin-3-yl-hydrazinocarbonyl)-heptyl]- formamide.

MH+ = 348.

Example 125 N-((R)-2-{N'-[1-(1-Ethyl-propyl)-2-oxo-1,2-dihydro-pyridin-4 -yl]-hydrazinocarbonyl}- heptyl)-N-hydroxy-formamide.

MH+ = 381.

Example 126 N-Hydroxy-N-((R)-2-{N'-[2-oxo-1-(3-trifluoromethyl-benzyl)-1 , 2-dihydro-pyridin-4-yl]-<BR> hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 469.

Example 127 N-Hydroxy-N-{(R)-2-[N'-(4-methyl-pyridin-2-yl)-hydrazinocarb onyl]-heptyl}- formamide.

MH+ = 309.

Example 128 N-Hydroxy-N-{(R)-2-[N'-(6-methoxy-pyridin-2-yl)-hydrazinocar bonyl]-heptyl}- formamide.

MH+ = 325.

Example 129 N-Hydroxy-N-{(R)-2-[N'-(2-oXo-1-quinolin-8-yl-methyl-1, 2-dihydro-pyridin-4-yl)- hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 452.

Example 130 N-Hydroxy-N-[(R)-2-(N'-{2-oxo-1-[2-(5, 6,7, 8-tetrahydro- [1, 8] naphthyridin-2-yl)-ethyl]- dihydro-pyridin-4-yl}-hydrazinocarbonyl)-heptyl]-formamide.

MH+ = 471.

Example 131 N-I (R)-2- [N'- (4, 6-Bis-ethylamino- [1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 383.

Example 132 N-{(R)-2-[N'-(Bis-dimethylamino-[1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 383 Example 133 N-I (R)-2- [N'- (4, 6-Di-morpholin-4-yl- [1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 467.

Example 134 N-Hydroxy-N-((R)-2-{N'-[4-(4-methyl-piperazin-1-yl)-6-prpyla mino-[1, 3,5] triazin-2- yl]-hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 452.

Example 135 N-{(R)-2-[N'-(Dimethylamino-morpholin-4-yl-[1, 3,5] triazin-2-yl)-hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

MH+ = 425.

Example 136 N-Hydroxy-N-{(R)-2-[N'-(6-methyl-pyridin-2-yl)-hydrazinocarb onyl]-heptyl}- formamide.

MH+ = 309.

Example 137 N-Hydroxy-N-((R)-2-{N'-[5-(5-phenyl-[1, 3,4] oxadiazol-2-yl)-pyridin-2-yl]- hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 439.

Example 138 N-{(R)-2-[N'-(7-tert-Butyl-1, 4-dioxo-1, 2,3, 4-tetrahydro-pyrido [3,4-d] pyridazin-5-yl) - hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ = 435.

Example 139 N- ( (R)-2-INI- [4-Ethylamino-6- (4-methyl- [1, 4] diazepan-1-yl)- [1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 452.

Example 140 N-((4)-2-{N'-[4-Ethylamino-6-(4-ethyl-piperazin-1-yl)-[1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 452.

Example 141 <BR> <BR> <BR> N-Hydroxy-N-{(R)-2-[N'-(6-trifluoromethyl-pyridin-2-yl)-hydr azinocarbonyl]-heptyl}- formamide.

MH+ = 363.

Example 142 N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-morpholin-4-yl-methyl-pyr imidin-2-yl)- hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 409.

Example 143

N-Hydroxy-N-I (R)-2- [N'- (4-methyl-6-morpholin-4-yl- [1, 3,5] triazin-2-yl)- hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 396.

Example 144 N-Hydroxy-N-{(2R)-2-(cyclopentylmethyl)-3-[N'-(4, 6-dimethyl-2-pyrimidinyl)- hydrazino]-3-oxopropyl}-formamide.

MH+ = 336.

Example 145 N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-pyrrolidin-1-yl-methykl-p yrimidin-2-yl)- hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 393.

Example 146 <BR> <BR> <BR> N-{(R)-2-[N'-(4-Dimethylaminomethyl-6-methyl-pyrimidin-2-yl) -hydrazinocarbonyl]-<BR> <BR> <BR> <BR> <BR> heptyl}-N-hydroxy-formamide.

MH+ = 367.

Example 147 <BR> <BR> <BR> N-Hydroxy-N- ( (R)-2- {N'- [4-methyl-6- (4-methyl-piperazin-1-yl-methyl)-pyrimidin-2-yl]-<BR> <BR> <BR> <BR> <BR> hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 422.

Example 148 N-Hydroxy-N-{(R)-2-[N'-(5-methyl-pyridin-2-yl)-hydrazinocarb onyl]-heptyl}- formamide.

MH+ = 309.

Example 149 N-((R)-2-{N'-[Dimethylamino-(4-methyl-[1, 4] diazepan-1-yl)- [1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 452.

Example 150 N-Hydroxy-N-{(R)-2-[N'-(4-methyl-6-pyrrolidin-1-yl-[1, 3,5] triazin-2-yl)- hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 380.

Example 151 N-Hydroxy-N-((R)-2-{N'-[4-methyl-6-)4-pyrrolidin-1-yl-piperi din-1-yl)-[1, 3,5] triazin-2- yl]-hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 463.

Example 152 N-((R)-2-{N'[(Ethyl-methyl-amino)-methyl-[1, 3,5] triazin-2-yl]-hydrazinocarbonyl}- heptyl)-N-hydroxy-formamide.

MH+ = 368.

Example 153 N-((R)-2-{N'-[(4-(4-Ethyl-piperazin-1-yl)-6-methyl-[1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 423.

Example 154 N-Hydroxy-N- [ (2R)-7, 7, 7-trifluoro-2-({N'-[4-(trifluoromethyl)-pyrimidin-2-yl]- hydrazino}-carbonyl)-heptyl]-formamide.

MH+ = 418.

Example 155 N-Hydroxy-N- ( (2R)-7, 7, 7-trifluoro-2- { [N'- (5-methyl-1, 2, 4-benzotriazin-3-yl)- hydrazino]-carbonyl}-heptyl)-formamide.

MH+ = 415.

Example 156 N-Hydroxy-N- ( (2R)-7, 7, 7-trifluoro-2- { [N'- (7-methyl-1, 2, 4-benzotriazin-3-yl)- <BR> <BR> <BR> hydrazino]-carbonyl}-heptyl) f-ormamide.<BR> <BR> <BR> <BR> <P>MH+ = 415.

Example 157 N-Hydroxy-N- { (R)-2- [N'- (4-methyIammo-6-morphoHn-4-yl- [l, 3, 5]-2-yl)- hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 411.

Example 158 N-((R)-2-{N'-[4-(4-Ethyl-piperazin-1-yl)-6-methylamino-[1, 3,5] triazin-2-yl]- <BR> <BR> <BR> hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <P>MH+ = 438.

Example 159 N- { (R)-2- [N'- (4-Ethylamino-6-morpholin-4-yl- [1, 3,5] triazin-2-yl)-hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

MH+ = 425.

Example 160 N-Hydroxy-N-{(R)-2-[N'-(4, 6, 7-trimethyl-7, 8-dihydro-pterin-2-yl)-hydrazinocarbonyl]- <BR> <BR> <BR> heptyl}-formamide.<BR> <BR> <BR> <BR> <BR> <P>MH+ = 392.

Example 161 N-Hydroxy-N-{(R)-2-[N'-(4, 6, 7-trimethyl-pteridin-2-yl)-hydrazinocarbonyl]-heptyl}- formamide.

MH+ = 390.

Example 162 N-Hydroxy-N-{(R)-2-[N'-(methoxymethoxymethyl-trifluoromethyl -pyrimidin-2-yl)- hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 438.

Example 163 N-Hydroxy-N- ( (R)-2-f N'- [4-methyl-6- (l-piperidin-1-yl-methanoyl)-pyrimidin-2-yl]- hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 421.

Example 164 2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydr azino)-6-methyl- pyrimidine-4-carboxylic acid cyclopropylamide.

MH+ = 393.

Example 165

2-(N'-{(R)-2-[(Fromyl-hydroxy-amino)-methyl]-heptanoyl}-hydr azino)-6-methylk- pyrimidine-4-carboxylic acid diisopropylamide.

MH+ = 437.

Example 166 N-{(R)-2-[N'-(5-Cyano-pyridin-2-yl)-hydrazinocarbonyl]-hepty l}-N-hydroxy- formamide.

MH+ = 320.

Example 167 N- { (R)-2- [N'- (4, 6-Diethyl- [1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy- formamide.

MH+ = 353.

Example 168 <BR> <BR> <BR> N-{(R)-4-Cyclopentyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl )-hydrazinocarbonyl]-<BR> <BR> <BR> <BR> <BR> butyl}-N-hydroxy-formamide.

MH+ = 390.

Example 169 N-{(R)-4-Cyclopentyl-2-[N'-(7-methyl-benzo[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- butyl}-N-hydroxy-formamide.

MH+ = 387.

Example 170 N-{(R)-4-Cyclopentyl-2-[N'-(5-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- butyl}-N-hydroxy-formamide.

MH+ = 387.

Example 171 <BR> <BR> <BR> N-Hydroxy-N- ( (R)-2-IN'- [6- (4-methyl-piperazin-1-yl-methyl)-pyridin-2-yl]-<BR> <BR> <BR> <BR> <BR> hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 407.

Example 172 N-((R)-2-[N'-(5-(4,6-Dimethyoxy-pyrimidin-2-yl)-pyridin-2-yl ]-hydrazinocarbonyl}- heptyl)-N-hydroxy-formamide.

MH+ = 433.

Example 173 N- { (R)-2- [N'- (Diethylamino-methyl- [1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 382.

Example 174 N-Hydroxy-N-[(R)-2-(N'-{[(2-methoxy-ethyl)-methyl-aminio]-me thyl-[1, 3,5] triazin-2-yl}- hydrazinocarbonyl)-heptyl]-formamide.

MH+ = 397.

Example 175 N- ( (R)-l-IN'- [4- (2, 6-Dimethyl-morpholin-4-yl)-6-methyl- [1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 424.

Example 176 <BR> <BR> <BR> N-{(R)-2-[N'-(5-Fluoro-4-methyl-6-morpholin-4-yl-pyrimidin-2 -yl)-hydrazinocarbonyl]-<BR> <BR> <BR> <BR> heptyl}-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <P>MH+ = 413.

Example 177 N-I (R)-2- [N'- (4-Ethyl-6-morpholin-4-yl- [1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-heptyl}- N-hydroxy-formamide.

MH+ = 410.

Example 178 N- { (R)-2- [N'- (Ethyl-methyl-amino)- [1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 382.

Example 179 N-((R)-2-{N'-[4-Ethyl-6-(4-ethyl-piperazin-1-yl)-[1, 3,5] triazin-2-yl]-hydrazinocarbonyl}- heptyl)-N-hydroxy-formamide.

MH+ = 437.

Example 180 N- ( (R)-2- {N'- [5-Fluoro-4-methyl-6- (4-methyl-piperazin-1-yl)-pyrimidin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 426.

Example 181 N-I (R)-2- [N'- (Dimethylamino-ethyl- [1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 368.

Example 182 N-((R)-2-{N'-[5-Fluoro-4-methyl-6-(4-methyl-[1, 4] diazepan-1-yl)-pyrimidin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 440.

Example 183 <BR> <BR> <BR> N-{(R)-4-Cyclopentyl-2-[N'-(morpholin-4-yl-trifluoromethyl-p yrimidin-2-yl)-<BR> <BR> <BR> <BR> <BR> hydrazinocarbonyl]-butyl}-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <P> MH+ = 475.

Example 184 N- [ (R)-2- (N'-IEthyl- [ (2-methoxy-ethyl)-methyl-amino]- [1, 3,5] triazin-2-yl}- hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

MH+ = 412.

Example 185 N-{(R)-2-[N'-(Dimethylamino-methyl-pyrimidin-2-yl)-hydrazino carbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 353.

Example 186 <BR> <BR> <BR> N-{(R)-2-[N'-(4-Cyclopropylamino-6-methyl-pyrimidin-2-yl)-hy drazinocarbonyl]-<BR> <BR> <BR> <BR> <BR> heptyl}-N-hydroxy-formamide.

MH+ = 365.

Example 187

N-{(R)-2-Cyclohexyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl) -hydrazinocarbonyl]- ethyl}-N-hydroxy-formamide.

MH+ = 376.

Example 188 N-{(R)-2-Cyclohexyl-2-[N'-(7-methoxy-benzo[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- ethyl}-N-hydroxy-formamide.

MH+ = 389.

Example 189 N-{(R)-2-Cyclohexyl-2-[N'-(5-methyl-benzo[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- ethyl}-N-hydroxy-formamide.

MH+ = 373.

Example 190 <BR> <BR> <BR> N-{(R)-4, 4-Dimethyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazin ocarbonyl]-<BR> <BR> <BR> <BR> <BR> pentyl}-N-hydroxy-formamide.

MH+ 364.

Example 191 N-{(R)-4,4-Dimethyl-2-[N'-(7-methyl-benzo[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- <BR> <BR> <BR> pentyl}-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <P>MH+ = 361.

Example 192 N-{(R)-4,4-Dimethyl-2-[N'-(5-methyl-benzo[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- <BR> <BR> <BR> pentyl}-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <P>MH+ = 361.

Example 193 <BR> <BR> <BR> N-{(R)-4, 4-Dimethyl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2 -yl)-<BR> <BR> <BR> <BR> <BR> hydrazinocarbonyl]-pentyl}-N-hydroxy-formamide.

MH+ = 449.

Example 194 N-((R)-2-{N'-[Ethyl-(methyl-pyridin-2-yl-amino)-[1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+=431.

Example 195 N-{(R)-2-[N'-(4-Cyclopropylamino-6-ethyl-[1, 3,5] triazin-2-yl)-hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

MH+ = 380.

Example 196 N-Hydroxy-N-[(R)-2-[N'-(5-methyl-benzo[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-3-(1- methyl-cyclopentyl)-propyl]-formamide.

MH+ = 387.

Example 197 N-Hydroxy-N-[(R)-2-[N'-(7-methoxy-benzo[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-3- (1- methyl-cyclopentyl)-propyl]-formamide.

MH+ = 403 Example 198 N-Hydroxy-N-{(R)-3-(1-methyl-cyclopentyl)-2-[N'-(4-trifluoro methyl-pyrimidin-2-yl)- hydrazinocarbonyl]-propyl}-formamide.

MH+ = 390.

Example 199 N-Hydroxy-N-{(R)-2-[N'-(4-isopropyl-6-morpholin-4-yl-[1, 3,5] triazin-2-yl)- hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 424.

Example 200 <BR> <BR> <BR> N-Hydroxy-N-{(2R)-2-(cyclopentylmethyl)-3-[N'-(4-methyl-2-py rimidinyl)-hydrazino]-<BR> <BR> <BR> <BR> <BR> 3-oxopropyl}-formamide.

MH+ = 322.

Example 201 N-Hydroxy-N- [ (2R)-6, 6, 6-trifluoro-2- ( {N'- [4- (trifluoromethyl)-pyrimidin-2-yl]- hydrazino}-carbonyl)-hexyl]-formamide.

MH+ = 404.

Example 202 N-{(R)-2-[N'-(5, 7-Dimethyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 375.

Example 203 N-I (R)-2- [N'- (3, 6-Dimethyl-pyrazin-2-yl)-hydrazinocarbonyl]-heptyl}-N-hydrox y- formamide.

MH+ = 324.

Example 204 N-((R)-2-{N'-[4-(4-Ethyl-piperazine-1-yl)-6-isopropylo-[1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 451.

Example 205 N-({R)-2-[N'-(4-Dimethylamino-6-isopropylo-[1, 3,5] triazin-2-yl)-hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

MH+ = 382.

Example 206 N-Hydroxy-N-{(R)-2-[N'-(methyl-trifluoromethyl-pyridin-2-yl) -hydrazinocarbonyl]- heptyl}-formamide.

MH+ = 377.

Example 207 2-(N'-{(R)-2-[ormyl-hydroxy-amino)-methyl]-heptanoyl}-hydraz ino)-6, N, N-trimethyl- isonicotinamide.

MH+ = 380.

Example 208 N-Hydroxy-N [ (2R)-2- ( {N'- [3-amino-6- (trifluoromethyl)-pyridin-2-yl]-hydrazino}- carbonyl)-heptyl]-formamide.

MH+ = 378.

Example 209

N-Hydroxy-N-[(R)-2-(N'-{4-isopropyl-6-[(2-methoxy-ethyl)-met hyl-amino]- [1, 3,5] triazin-2-yl}-hydrazinocarbonyl)-heptyl]-formamide.

MH+ = 426.

Example 210 N-{(R)-3-Cyclopentyl-2-[N[-(4-ethyl-6-morpholin-4-yl-[1, 3,5] triazin-2-yl)- hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.

MH+ = 422.

Example 211 N-Hydroxy-N-{(R)-2-[N'-(4-morpholin-4-yl-propyl-[1, 3,5] triazin-2-yl)- hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 424.

Example 212 N-((R)-2-{N'-[4-(4-Ethyl-piperazin-1-yl)-6-propyl-[1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 451.

Example 213 N-I (R)-5, 5-Dimethyl-2- [N' (4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-<BR > hexyl}-N-hydroxy-formamide.

MH+ = 378.

Example 214 N-{(R)-5, 5-Dimethyl-2-[N'-(7-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- hexyl}-N-hydroxy-formamide.

MH+ = 375.

Example 215 N-I (R)-5, 5-Dimethyl-2- [N'- (5-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- hexyl}-N-hydroxy-formamide.

MH+ = 375.

Example 216 N-{(R)-5, 5-Dimethyl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimidin-2 -yl)-<BR> hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

MH+ = 463.

Example 217 <BR> <BR> <BR> N-{(R)-4-Ethyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydr azino carbonyl]-hexyl}-N- hydroxy-formamide.

MH+ = 378.

Example 218 N-{(R)-4-Ethyl-2-[N'-(7-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-hexyl}-N- hydroxy-formamide.

MH+ = 375.

Example 219 N-{(R)-4-Ethyl-2-[N'-(morpholin-4-yl-trifluoromethyl-pyrimid in-2-yl)- hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

MH+ = 463.

Example 220 N-((R)-3-Cyclopentyl-2-{N'-[4-ethyl-6-(4-ethyl-piperazin-1-y l)-[1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-pyopyl)-N-hydroxy-formamide.

MH+ = 449.

Example 221 N-{(R)-3-Cyclopentyl-2-[N'-(4-cyclopropylamino-6-ethyl-[1, 3,5] triazin-2-yl)- hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.

MH+ = 392.

Example 222 N-{(R)-4-Ethyl-2-[N'-(5-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-hexyl}-N- hydroxy-formamide.

MH+ = 375.

Example 223 N-Hydroxy-N-[(R)-2-(N'-{[(2-methoxy-ethyl)-methyl-amino]-pro pyl-[1, 3,5] triazin-2-yl}- hydrazinocarbonyl)-heptyl]-formamide.

MH+ = 426.

Example 224 N- { (R)-2- [N'- (Dimethylamino-propyl- [1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 382.

Example 225 N-I (R)-2- [N'- (4-Ethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-heptyll-N-hydrox y- formamide.

MH+ = 324.

Example 226 N-Hydroxy-N-{(R)-2-[N'-(4-isopropyl-pyrimidin-2-yl)-hydrazin ocarbonyl]-heptyl}- formamide.

MH+ = 338.

Example 227 N-I (R)-2- [N'- (4-Cyclopropyl-6-morpholin-4-yl- [1, 3,5] triazin-2-yl)-hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

MH+ = 422.

Example 228 N-Hydroxy-N-[(2R)-2-({N'-[4-(pyridin-2-yl)-pyrimidin-2-yl]-h ydrazino}-carbonyl)- heptyl]-formamide.

MH+ = 373.

Example 229 N-((R)-2-{N'-[4-Cyclopropyl-6-(4-ethyl-piperazin-1-yl)-[1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 449.

Example 230 N-I (R)-2- [N'- (Cyclopropyl-dimethylamino- [1, 3,5] triazin-2-yl)-hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

MH+ = 380.

Example 231

N- ( (R)-2-INI- [Cyclopropyl- (ethyl-methyl-amino)- [1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 394.

Example 232 N-{(R)-2-[N'-(4-Cyclopropyl-6-pyrrolidin-1-yl [1, 3,5] triazin-2-yl)-hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

MH+ = 406.

Example 233 N-{(R)-2-[N'-(4,6-Dicyclopropyl-[1, 3, 5]triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 377.

Example 234 N-Hydroxy-N-[(R)-2-[N'-(5-methyl-benzo[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-3- (2- methyl-cyclopentyl)-propyl]-formamide.

MH+ = 387.

Example 235 N-[(R)-2-[N'-(Dimethylamino-ethyl-[1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-3- (2-methyl- cyclopentyl)-propyl]-N-hydroxy-formamide.

MH+ = 394.

Example 236 <BR> <BR> <BR> N-Hydroxy-N- [ (R)-2- [N'- (4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-3- (2- methyl-cyclopentyl)-propyl]-formamide.

MH+ = 390.

Example 237 N-{(R)-2-[N'-(5-Ethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-hep tyl}-N-hydroxy- formamide.

MH+ = 324.

Example 238 N-Hydroxy-N-{(2R)-2-(cyclopentylmethyl)-3-[N'-(7-methyl-1, 2,4-benzotriazin-3-yl)- hydrazino]-3-oxopropyl}-formamide.

MH+ = 373.

Example 239 N-Hydroxy-N- [ (2R)-2- (cyclopentylmethyl)-3- (N'-14-ethyl-6- [ethyl (methyl) amino]-1, 3,5- triazin-2-yl}-hydrazino)-3-oxopropyl]-formamide.

MH+ = 394.

Example 240 N-Hydroxy-N- ( (2R)-2- (cyclopentylmethyl)-3- {N'- [4- (dimethylamino)-6-ethyl-1, 3,5- triazin-2-yl]-hydrazino}-3-oxopropyl)-formamide.

MH+ = 380.

Example 241 N- ( (R)-2- {N'- [4-Ethyl-6- (4-isopropyl-piperazin-1-yl)- [1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 451.

Example 242 N-Hydroxy-N-[(2R)-3-[N'-(6-chloro-1, 2, 4-benzotriazin-3-yl)-hydrazino]-2- (cyclopentylmethyl)-3-oxopropyl]-formamide.

MH+ = 393.

Example 243 N-I (R)-4, 4-Dimethyl-2- [N'- (4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]- hexyl}-N-hydroxy-formamide.

MH+ = 378.

Example 244 N-{(R)-4, 4-Dimethyl-2-[N'-(7-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- hexyl}-N-hydroxy-formamide.

MH+ = 375.

Example 245 N-{(R)-4, 4-Dimethyl-2-[N'-(5-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- <BR> <BR> <BR> hexyl}-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <BR> <P>MH+ = 375.

Example 246<BR> <BR> <BR> <BR> <BR> N-{(R)-4, 4-Dimethyl-2-[N'-(morpholin"4-yl-trifluoromethyl-pyrimidin-2 -yl)-<BR> <BR> <BR> <BR> <BR> hydrazinocarbonyl]-hexyl}-N-hydroxy-formamide.

MH+ = 463.

Example 247 N-Hydroxy-N-{(R)-2-[N'-(5-phenyl-[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-heptyl}- formamide.

MH+ = 373.

Example 248 <BR> <BR> <BR> N-{(R)-2-[N'-(4-Ethyl-6-morpholin-4-yl-pyrimidin-2-yl)-hydra zinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 409.

Example 249 <BR> <BR> <BR> N- ( (R)-2- {N'- [4-Ethyl-6- (4-methyl-piperazin-1-yl)-pyrimidin-2-yl]-hydrazinocarbonyl} - heptyl)-N-hydroxy-formamide.

MH+ = 422.

Example 250 <BR> <BR> <BR> N-{(R)-2-[N'-(5-Ethyl-4-methyl-pyrimidin-2-yl)-hydrazinocarb onyl]-heptyl}-N-hydroxy- formamide.

MH+ = 338.

Example 251 N-((R)-2-{N'-[4-Ethyl-6-(4-propyl-piperazin-1-yl)-[1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 451.

Example 252 N-Hydroxy-N- ( (R)-2- {N'- [6- (4-pyrimidin-2-yl-piperazin-1-yl-methyl)-pyridin-2-yl]- hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 471.

Example 253

N-Hydoryx-N-((R)-2-{N'-[6-(3-[1, 2,4] triazol-1-yl-methyl- [1, 2,4] triazol-1-yl)-pyridin-2- yl]-hydraznocarbonyl}-heptyl)-formamide.

MH+ = 443.

Example 254 N-{(R)-3-Bicyclo [2.2. 1] hept-7-yl-2- [N'- (4-trifluoromethyl-pyrimidin-2-yl)- hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.

MH+ = 402.

Example 255 N-{(R)-3-Bicyclo [2.2. 1] hept-7-yl-2- [N'- (morpholin-4-yl-trifluoromethyl-pyrimidin-2-yl)- hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.

MH+ = 487.

Example 256 N-hydroxy-N-[(R)-2-(N'-pyridin-3-yl-hydrazinocarbonyl)-hepty l]-formamide.

MH+ = 295.

Example 257 4-{4-Ethyl-6-[2-((2R)-2-{[formyl (hydroxy) amino]-methyl}-heptanoyl)-hydrazino]-1, 3,5- triazin-2-yl}-1-methyl-1-propylpiperazin-1-ium iodide.

MH+ = 465.

Example 258 N-{(R)-3-Bicyclo [2.2. 1] hept-7-yl-2- [N'- (5-methyl-benzo [1, 2, 4] triazin-3-yl)- hydrazinocarbonyl]-propyl}-N-hydroxy-formamide.

MH+ = 399.

Example 259 N-I (R)-2- [N'- (4-Azetidin-1-yl-6-ethyl- [1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 380.

Example 260 <BR> <BR> <BR> N-I (R)-2-Cyclopentyl-2- [N'- (4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-<BR > <BR> <BR> <BR> <BR> ethyl}-N-hydroxy-formamide.

MH+ = 362.

Example 261 N-{(R)-2-Cyclopentyl-2-[N'-(morpholin-4-yl-4-trifluoromethyl -pyrimidin-2-yl)- hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

MH+ = 447.

Example 262 N-{(R)-2-Cyclopentyl-2-[N'-(4-methyl-pyridin-2-yl)-hydrzinoc arbonyl]-ethyl}-N- hydroxy-formamide.

MH+ = 307.

Example 263 N-{(R)-2-Cyclopentyl-2-[N'-(dimethylamino-ethyl-[1, 3,5] triazin-2-yl) - hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

MH+ = 366.

Example 264 N-{(R)-2-Cyclopentyl-2-[N'-(7-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- ethyl}-N-hydroxy-formamide.

MH+ = 359.

Example 265 N-{(R)-2-Cyclopentyl-2-[N'-(5-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- ethyl}-N-hydroxy-formamide.

MH+ = 359.

Example 266 N-Hydroxy-N-{(R)-2-[N'-(5-methyl-benzo[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-2- (4- methyl-cyclohexyl)-ethyl}-formamide.

MH+ = 387.

Example 267 N-Hydroxy-N-{(R)-2-[N'-(7-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-2- (4- methyl-cyclohexyl)-ethyl}-formamide.

MH+ = 387.

Example 268

N-Hydroxy-N-{(R)-2-(4-methyl-cyclohexyl)-2-[N'-(4-trifluorom ethyl-pyrimidin-2-yl)-<BR> hydrazinocarbonyl]-ethyl}-formamide.

MH+ = 390.

Example 269 N-Hydroxy-N-I (R)-2- (4-methyl-cyclohexyl)-2- [N'- (morpholin-4-yl-trifluoromethyl-' pyrimidin-2-yl)-hydrazinocarbonyl]-ethyl}-formamide.

MH+ = 475.

Example 270 N-Hydroxy-N-I (R)-2- (4-methyl-cyclohexyl)-2- [N'- (4-methyl-pyridin-2-yl)-<BR> hydrazinocarbonyl]-ethyl}-formamide.

MH+ = 335.

Example 271 N- { (R)-2- [N'- (Dimethylamino-ethyl- [1, 3,5] triazin-2-yl)-hydrazinocarbonyl]-2- (4-methyl- cyclohexyl)-ethyl}-N-Hydroxy-formamide.

MH+ = 394.

Example 272 N-{(R)-2-[N'-(6, 7-Dihydro-5 H-cyclopentapyrimidin-2-yl)-hydrazinocarbonyl]-heptyl}- N-hydroxy-formamide.

MH+ = 336.

Example 273 N-((R)-2-[N'-[4-Ethyl-6-((S)-2-hydroxymethyl-pyrrolidin-1-yl )-[1, 3,5] triazin-2-yl]- hydrazinocarbonyl]-heptyl)-N-hydroxy-formamide.

MH+ = 424.

Example 274 N-{(R)-2-[N'-(Dimethylamino-pyridin-3-yl-pyrimidin-2-yl)-hyd razinocarbonyl]-heptyl}- N-hydroxy-formamide.

MH+ = 416.

Example 275 N-{(R)-2-[N'-(Diemthylamino-pyridin--4yl-primidin-2-yl)-hydr azinocarbonyl]-heptyl}- N-hydroxy-formamide.

MH+ = 416.

Example 276 N-Hydroxy-N-{(R)-2-N'-(5, 6,7, 8-tetrahydro-benzo [1, 2,4] triazin-3-yl)- <BR> <BR> <BR> hydrazinocarbonyl]-heptyl}-formamide.<BR> <BR> <BR> <BR> <BR> <BR> <P> MH+ = 351.

Example 277 N-{(R)-2-[N'-(5,6-Diethyl-[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-heptyl}-N-hydroxy- formamide.

MH+ = 353.

Example 278 N-Hydroxy-N-{(R)-2-[N'-[5-(4-hydroxy-phenyl)-[1, 2,4] triazin-3-yl]-hydrazinocarbonyl}- heptyl)-formamide.

MH+=389.

Example 279 N-[(R)-2-(N'-{[(2-Dimethylamino-ethyl)-methyl-amino]-ethyl-[ 1, 3,5] triazin-2-yl}- hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

MH+ = 425.

Example 280 N-{(R)-2-[N'-(2-Dimethylamino-quinazolin-4-yl)-hydrazinocarb onyl]-heptyl}-N- hydroxy-formamide.

MH+ = 389.

Example 281 <BR> <BR> <BR> N-Hydroxy-N-{(R)-2-[N'-(3-methanesulfonyl-4, 6-dimethyl-pyridin-2-yl)-<BR> <BR> <BR> <BR> <BR> <BR> hydrazinocarbonyl]-heptyl}-formamide.

MH+ = 401.

Example 282 N-((R)-2-{N'-[4-Ethyl-6-(3-hydroxy-piperidin-1-yl)-[1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 424.

Example 283 N- [ (R)-2- (N'- [4, 5'] Bipyrimidinyl-2-yl-hydrazinocarbonyl)-heptyl]-N-hydroxy- formamide.

MH+ = 374.

Example 284 N-((R)-2-{N'-[(Cyclopropyl-methyl-amino)-ethyl-[1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 394.

Example 285 N-((R)-2-{N'-[4-Ethyl-6-((R)-3-hydroxy-pyrrolidin-1-yl)-[1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 410.

Example 286 N-Hydroxy-N- [ (R)-2- (N'- [3, 3'] Bipyridinyl-5-yl-hydrazinocarbonyl)-heptyl]-formamide.

MH+ = 372.

Example 287 <BR> <BR> <BR> N-Hydroxy-N-[(R)-2-(N'-(5-morpholin-4-yl-pyridin-3-yl)-hydra zinocarbonyl)-heptyl]- formamide.

MH+ = 380.

Example Example 288 <BR> <BR> N-Hydroxy-N-{(R)-2-[N'-(4-pyridin-3-yl-pyrimidin-2-yl)-hydra zinocarbonyl]-heptyl}- formamide.

MH+ = 373.

Example 289 N-Hydroxy-N-{(R)-2-[N'-(5, 6,7, 8-tetrahydro-quinazolin-2-yl)-hydrazinocarbonyl]- heptyl}-formamide.

MH+ = 350.

Example 290 N- [ (R)-2- (N'-I [Cyclopropyl-l- (I-methyl-piperidin-4-yl)-amino]-ethyl- [1, 3,5] triazin-2- yl}-hydrazinocarbonyl)-heptyl]-N-hydroxy formamide.

MH+ = 477.

Example 291 N-((R)-2-{N'-[4-((R)-3-Dimethylamino-pyrrolidin-1-yl)-6-ethy l-[1, 3,5] triazin-2-yl]- <BR> <BR> <BR> hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <P>MH+ = 437.

Example 292 N-Hydroxy-N-[(R)-2-(N'-[5-(1H-pyrrol-2-yl)-pyridin-3-yl]-hyd razinocarbonyl)-heptyl]- formamide.

MH+ = 360.

Example 293 <BR> <BR> <BR> N-Hydroxy-N- [ (R)-2- (N'- [ (4-methyl-piperazin-1-yl)-trifluoromethyl-pyrimidin-4-yl]- hydrazinocarbonyl)-heptyl]-formamide.

MH+ = 462.

Example 294 N-Hydroxy-N-[(R)-2-(N'-(5-Furan-3-yl-pyridin-3-yl)-hydrazino carbonyl)-heptyl]- formamide.

MH+ = 361.

Example 295 <BR> <BR> <BR> N-{(R)-5, 5-Dimethyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl)-hydrazin ocarbonyl]-<BR> <BR> <BR> heptyl}-N-hydroxy-formamide.

MH+ = 392.

Example 296 N-{(R)-5,5-Dimethyl-2-[N'-(7-methyl-benzo[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

MH+ = 389.

Example 297 <BR> <BR> <BR> N-I (R)-5, 5-Dimethyl-2- (4-methyl-pyridin-2-yl)-hydrazinocarbonyl]-heptyll-N-hydroxy - formamide.

MH+ = 337.

Example 298 <BR> <BR> <BR> N-{(R)-2-Cycloheptyl-2-[N'-(4-trifluoromethyl-pyrimidin-2-yl )-hydrazinocarbonyl]-<BR> <BR> <BR> <BR> <BR> ethyl}-N-hydroxy-formamide.

MH+ = 390.

Example 299 N-{(R)-2-Cycloheptyl-2-[N'-(4-methyl-pyridin-2-yl)-hydrazino carbonyl]-ethyl}-N- hydroxy-formamide.

MH+ = 335.

Example 300 N-{(R)-2-Cycloheptyl-2-[N'-(dimethylamino-ethyl-[1, 3,5] triazin-2-yl)- hydrazinocarbonyl]-ethyl}-N-hydroxy-formamide.

MH+ = 394.

Example 301 N-{(R)-2-Cycloheptyl-2-[N'-(7-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- ethyl}-N-hydroxy-formamide.

MH+ = 387.

Example 302 N- ( (R)-2- {N'- [4-Ethyl-6- (4-hydroxy-piperidin-1-yl)- [1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 424.

Example 303 N-{(R)-5, 5-Dimethyl-2-[N'-(5-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

MH+ = 389.

Example 304 N-{(R)-2-[N'-(4-Dimethylamino-quinazolin-2-yl)-hydrazinocarb onyl]-heptyl}-N- hydroxy-formamide.

MH+ = 389.

Example 305

N-Hydroxy-N-{(R)-2-[N'-(4-pyridin-4-yl-pyrimidin-2-yl)-hydra zinocarbonyl]-heptyl}- formamide.

MH+ = 373.

Example 306 N-Hydroxy-N-((R)-2-{N'-[4-(3-hydroxymethyl-phenyl)-pyrimidin -2-yl]- hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 402.

Example 307 N-Hydroxy-N-((R)-2-{N'-[4-(4-hydroxymethyl-phenyl)-pyrimidin -2-yl]- hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 402.

Example 308 N-((R)-2-{N'-[4-Ethyl-6-(3-emthoxy-piperidin-1-yl)-[1, 3,5] triazin-2-yl]- <BR> <BR> <BR> hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.<BR> <BR> <BR> <BR> <BR> <P>MH+ = 438.

Example 309 N-Hydroxy-N-I (R)-2- [N'- (7-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-2- (4- methyl-cyclohexyl)-ethyl}-formamide.

MH+ = 387.

Example 310 N-[(R)-2-{N'-[Ethyl-(ethy-methylamino)-[1, 3,5] triazin-2-yl]-hydrazinocarbonyl}-2- (4- methyl-cyclohexyl)-ethyl}-N-hydroxy-formamide.

MH+ = 408.

Example 311 N-[(R)-2-{N'-[Ethyl-(ethyl-methylamino)-[1, 3,5] triazin-2-yl]-hydrazinocarbonyl}-2- (4- methyl-cyclohexyl)-ethyl}-N-hydroxy-formamide.

MH+ = 408.

Example 312 N-Hydroxy-N-{(R)-2-[N'-(7-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]-2- (4- methyl-cyclohexyl)-ethyl}-formamide.

MH+ = 387.

Example 313 N- ( (R)-2-INI- [4- (2, 6-Dimethoxy-phenyl)-pyrimidin-2-yl]-hydrazinocarbonyl}-hepty l)-N- hydroxy-formamide.

MH+ = 432.

Example 314 N-((R)-2-{N'-[4-Ethyl-6-((R)-3-methoxy-pyrrolidin-1-yl)-[1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 424.

Example 315 N-((R)-2-{N'-[4-Ethyl-6-(4-methoxy-piperidin-1-yl)-[1, 3,5] triazin-2-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 438.

Example 316 N-Hydroxy-N-[(R)-2-(N'-(6-pyrrolidin-1-yl-pyrimidin-4-yl)-hy drazinocarbonyl)-heptyl]- formamide.

MH+ = 365.

Example 317 N-Hydroxy-N- [ (R)-2- (N'- [6- (4-methyl-piperazin-1-yl)-pyrimidin-4-yl])- hydrazinocarbonyl)-heptyl]-formamide.

MH+ ='394.

Example 318 N-{(R)-2-[N'-(6-Dimethylamino-pyrimidin-4-yl)-hydrazinocarbo nyl]-heptyl}-N- hydroxy-formamide.

MH+ = 339.

Example 319 N-{(R)-2-[N'-(Pyridin-4-yl-trifluoromethyl-pyrimidin-4-yl)-h ydrazinocarbonyl)-heptyl]- N-hydroxy-formamide.

MH+ = 441.

Example 320 N-{(R)-2-[N'-(Pyridin-3-yl-trifluoroemthyl-pyrimidin-4-yl)-h ydrazinocarbonyl]-heptyl}- N-hydroxy-formamide.

MH+ = 441.

Example 321 <BR> <BR> <BR> N-{(R)-2-[N'-(2-Ethylamino-6-trifluoromethyl-pyrimidin-4-yl) -hydrazinocarbonyl]-<BR> <BR> <BR> <BR> <BR> heptyl}-N-hydroxy-formamide.

MH+ = 407.

Example 322 N-Hydroxy-N-((R)-2-{N'-[5-(4-methoxy-phenyl)-[1, 2,4] triazin-3-yl]-hydrazinocarbonyl}- heptyl)-formamide.

MH+ = 403.

Example 323 N-Hydroxy-N-((R)-2-{N'-[4-(2, 3, 4-trimethoxy-phenyl)-pyrimidin-2-yl]- hydrazinocarbonyl}-heptyl)-formamide.

MH+ = 462.

Example 324 <BR> <BR> <BR> N-I (R)-4, 4-Dimethyl-2- [N'- (4-trifluoromethyl-pyrimidin-2-yl)-hydrazinocarbonyl]-<BR > <BR> <BR> <BR> <BR> heptyl}-N-hydroxy-formamide.

MH+ = 392.

Example 325 N-{(R)-4, 4-Dimethyl-2-[N'-(7-methyl-benzo [1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

MH+ = 389.

Example 326 N-{(R)-4,4-Dimethyl-2-[N'-(5-methyl-benzo[1, 2,4] triazin-3-yl)-hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

MH+ = 389.

Example 327

N-{(R)-4, 4-Dimethyl-2-[N'-(4-methyl-pyridin-2-yl)-hydrazinocarbonyl]- heptyl}-N- hydroxy-formamide.

MH+ = 337.

Example 328 <BR> <BR> <BR> N-Hydroxy-N-{(R)-2-[N'-(6-morpholin-4-yl-pyrimidin-4-yl)-hyd razinocarbonyl]-<BR> <BR> <BR> <BR> <BR> heptyl}-formamide.

MH+ = 381.

Example 329 N-Hydroxy-N-[(R)-2-(N'-{5-[4-(2-hydroxy-ethoxy)-phenyl]-[1, 2,4] triazin-3-yl}- hydrazinocarbonyl)-heptyl]-formamide.' MH+ = 433.

Example 330 <BR> <BR> <BR> N-{(R)-2-[N'-(4-Furan-2-yl-pyrimidin-2-yl)-hydrazinocarbonyl ]-heptyl}-N-hydroxy- formamide.

MH+ = 362.

Example 331 <BR> <BR> <BR> N- ( (R)-2- {N'- [4- (3, 5-Dimethyl-isoxazol-4-yl)-pyrimidin-2-yl]-hydrazinocarbonyl} - heptyl)-N-hydroxy-formamide.

MH+ = 391.

Example 332 <BR> <BR> <BR> N-Hydroxy-N-{(R)-2-[N'-(4-methyl-1-oxy-pyridin-2-yl)-hydrazi nocarbonyl]-heptyl}- formamide.

MH+ = 325.

Example 333 2-(N'-{(R)-2-[(Formyl-hydroxy-amino)-methyl]-heptanoyl}-hydr azino)-6-methyl- nicotinic acid.

MH+ = 353.

Example 334 N-Hydroxy-N-{(R)-2-[N'-(3-methoxy-pyridin-2-yl)-hydrazinocar bonyl]-heptyl}- formamide.

MH+ = 325.

Example 335 <BR> <BR> <BR> N-Hydroxy-N- { (2R)-2- [ (N'- {4- [4- (methylsulfonyl) phenyl]-pyrimidin-2-yl}-hydrazino)-<BR> <BR> <BR> <BR> <BR> carbonyl]-heptyl}-formamide.

MH+ = 450.

Example 336 N-Hydroxy-N-[(2R)-2-({N'-[4-(furan-3-yl)-pyrimidin-2-yl]-hyd razino}-carbonyl)- heptyl]-formamide.

MH+ = 362.

Example 337 <BR> <BR> <BR> N- [ (2R)-2- ( {N'- [4- (2-aminophenyl)-pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl] -N- hydroxy-formamide.

MH+ = 387.

Example 338 N-Hydroxy-N- [ (2R)-2- ( {N'- [5- (5-methyl-1, 3, 4-oxadiazol-2-yl)-4-(trifluoroemthyl)- pyrimidin-2-yl]-hydrazino}-carbonyl)-heptyl]-formamide.

MH+ = 446.

Example 339 N-Hydroxy-N-((2R)-2-(cyclopentylmethyl)-3-{N'-[5-(5-methyl-1 , 3, 4-oxadiazol-2-yl)-4- (trifluoromethyl)-pyrimidin-2-yl]-hydrazino}-3-oxopropyl)-fo rmamide.

MH+ = 458.

Example 340 <BR> <BR> <BR> N-[(2R)-2-({N'-[6-(dimethylamino)-2-methyl-pyrimidin-4-yl]-h ydrazino}-carbonyl)- heptyl]-N-hydroxy-formamide.

MH+ = 353.

Example 341 <BR> <BR> <BR> N-[(2R)-2-({N'-[2-Cyclopropyl-6-(dimethylamino)-pyrimidin-4- yl]-hydrazino}-<BR> <BR> <BR> <BR> <BR> <BR> carbonyl)-heptyl]-N-hydroxy-formamide.

MH+ = 379.

Example 342 <BR> <BR> <BR> N-Hydroxy-N- [ (2R)-4- (2-thienyl)-2- ( {N'- [4- (trifluoromethyl)-pyrimidin-2-yl]-<BR> <BR> <BR> <BR> <BR> hydrazino}-carbonyl)-butyl]-formamide.

MH+ = 404.

Example 343 <BR> <BR> <BR> N-Hydroxy-N-[(2R)-2-{[N'-(4-methyl-pyrimidin-2-yl) hydrazino] carbonyl}-4-(2-thienyl)- butyl]-formamide.

MH+ = 350 Example 344 N-[(2R)-2-[(N'-{4-Ethyl-6-[ethyl(methyl)amino]-1, 3, 5-triazin-2-yl}-hydrazino)- carbonyl]-4- (2-thienyl) butyl]-N-hydroxy-formamide.

MH+ = 422.

Example 345 <BR> <BR> <BR> N-Hydroxy-N- ( (2R)-3-oxo-2- (2-thienylmethyl)-3- {N'- [4- (trifluoromethyl)-pyrimidin-2- yl]-hydrazino}-propyl)-formamide.

MH+ = 390.

Example 346 <BR> <BR> <BR> N-Hydroxy-N-[(2R)-3-[N'-(4-methyl-pyrimidin-2-yl) hydrazino]-3-oxo-2-(2-<BR> <BR> <BR> <BR> <BR> thienylmethyl)-propyl]-formamide.

MH+ = 336.

Example 347 N-[(2R)-3-(N'-{4-Ethyl-6-[ethyl(methyl)amino]-1, 3, 5-triazin-2-yl} hydrazino)-3-oxo-2- (2- thienylmethyl)-propyl]-N-hydroxy-formamide.

MH+ = 408. <BR> <BR> <BR> <BR> <BR> <BR> <P> Example 348<BR> <BR> <BR> <BR> <BR> N-Hydroxy-N-[(2R)-2-({N'-[2-methyl-6-(pyridin-2-yl)-pyrimidi n-4-yl]-hydrazino}- carbonyl)-heptyl]-formamide.

MH+ = 387.

Example 349

N-Hydroxy-N-[(2R)-2-({N'-[6-(pyridin-2-yl-methyl)-pyridazin- 3-yl]-hydrazino}-<BR> <BR> <BR> <BR> <BR> carbonyl)-heptyl]-formamide.

MH+ = 387.

Example 350 N-Hydroxy-N-[(2R)-2-({N'-[2-methyl-6-(morpholin-4-yl)-pyrimi din-4-yl]-hydrazino}- carbonyl)-heptyl]-formamide.

MH+ = 395.

Example 351 <BR> <BR> <BR> N-Hydroxy-N-[(2R)-2-({N'-[6-(morpholin-4-yl)-2-(trifluoromet hyl)-pyrimidin-4-yl]-<BR> <BR> <BR> <BR> <BR> hydrazino}-carbonyl)-heptyl]-formamide.

MH+ = 449.

Example 352 N-Hydroxy-N-{(2R)-2-[(N'-{4-[methyl-(pyridin-2-yl)-amino]-py rimidin-2-yl}- hydrazino)-carbonyl]-heptyl}-formamide.

MH+ = 402.

Example 353 N-Hydroxy-N- ( (2R)-2- (cyclopentylmethyl)-3-f N'- [4-cyclopropyl-6- (dimethylamino)- 1, 3, 5-triazin-2-yl]-hydrazino}-3-oxopropyl)-formamide.

MH+ = 392.

Preparation 19 (1, 3-oxo-1, 3-dihydro-isoindol-2-yl)-carbamic acid tert-butyl ester.

To a mixture of tert-butyl carbazate (5.15 g, 38.97 mmol) and phthalic anhydride (5.77 g, 38.97 mmol) was added CHCl3 (70 mL). The reaction mixture was refluxed for 18 h.

Removal of the solvent under reduced pressure yielded 8.20 g (80%) of the title compound as a white solid. MH+ 263.

Preparation 20 Benzo [1, 3] dioxol-5-yl-methyl- (1, 3-dioxo-1, 3-dihydro-isoindol-2-yl)-carbamic acid dimethyl-ethyl ester.

To a solution of (1, 3-dioxo-1, 3-dihydro-isoindol-2-yl) -carbamic acid tert-butyl ester (0.31 g, 1.18 mmol), piperonyl alcohol (0. 18 g, 1.18 mmol) and triphenylphosphine (0.40 g, 1.54 mmol) in THF (12 mL) at 0 °C was added dropwise diisopropyl azodicarboxylate (0.30 mL, 1.54 mmol). The reaction mixture was stirred and allowed to warm up to room temperature overnight. Removal of the solvent under reduced pressure, followed by purification by hplc yielded 0.28 g (60%) of the title compound. MH+ 397.

Preparation 21 N-Benzo [1, 3] dioxol-5-yl-methyl-hydrazinecarboxylic acid tert-butyl ester.

To N-benzo [1, 3] dioxol-5-yl-methyl- (1, 3-dioxo-1, 3-dihydro-isoindol-2-yl) -carbamic acid dimethyl-ethyl ester (0.28 g, 0.71 mmol) in EtOH (3.6 mL) was added hydrazine monohydrate (0.14 mL, 2. 84 mmol) in one portion at room temperature. The reaction mixture was stirred for 21 hrs. Toluene (5 mL) was added to the mixture, and the white solid was collected by filtration. The filtrate was evaporated in vacuo. Further standing under high vacuum yielded 0.17 g (89%) of the title compound. MH+ 267.

Preparation 22 N-Benzo [1, 3] dioXol-4-yl-methyl-N'-{(R)-2-[(benzyloxy-formyl-amino)-methy l]- heptanoyl}-hydrazinecarboxylic acid tert-butyl ester.

To a mixture of N-benzo [1, 3] dioxol-5-yl-methyl-hydrazinecarboxylic acid tert-butyl ester (168 mg, 0. 632 mmol), (R)-2-[(benzyloxy-formyl-amino)-methyl]-heptanoic acid (185 mg, 0.632 mmol), 4-dimethylaminopyridine (100 mg, 0.822 mmol) in methylene chloride (7 mL) was added 1- (3-dimethylaminopropyl)-3-ethylcarbodiimde hydrochloride (158 mg, 0. 822 mmol) at room temperature. The reaction mixture was stirred for 19h at room temperature and then treated with aqueous 1N HCl solution. Separation of the organic layer, drying over anhydrous MgSO4 and removal of the solvent provided the title compound No further purification was required. MH+ 542.

Preparation 23 N-[(R)-2-(N'-Benzo [1, 3] dioxol-5-yl-methyl-hydrazinocarbonyl)-heptyl]-N-benzyloxy- formamide.

To the crude N-benzo [1, 3] dioxol-4-ylmethyl-N'-{R-2-[(benzyloxy-formyl-amino)-methyl]- heptanoyl}-hydrazinecarboxylic acid tert-butyl ester obtained in Preparation 12 was added 5% TFA in methylene dichloride (20 mL) at room temperature. The resulting solution was stirred for 6 hours, and then washed with saturated aqueous NaHCO3 solution (20 mL x 3). The organic layer was separated and dried (MgSO4). Filtration and evaporation provided the title compound (0.221 g, 79% in two steps). MH+ 442.

Example 354 N-[(R)-2-(N'-Benzo[1, 3] dioxol-5-yl-methyl-hydrazinocarbonyl)-heptyl]-N-hydroxy- formamide.

To a solution of N-[(R)-2-(N'Benzo [1, 3] dioxol-5-yl-methyl-hydrazinocarbonyl)-heptyl]-N- benzyloxy-formamide (0.221 g, 0.501 mmol) in EtOH (10 mL) was added 10% Pd/C (50 mg).

The mixture was subjected to hydrogenation for 5 h at room temperature. The mixture was filtered through Celite. The filtrate was evaporated and purified by HPLC to afford the title compound (0.10 g, 57%) in a white solid. MH+ 352.

Example 355 N-f (R)-2- [N'- (2, 3-Dihydro- [1, 4] dioxino [2,3-b] pyridin-7-yl-methyl)-hydrazinocarbonyl]- heptyl}-N-hydroxy-formamide.

MH+ 366.

Example 356 N-{(R)-2-[N'-(4-Dimethylamino-benzyl)-hydrazinocarbonyl]-hep tyl}-N-hydroxy- formamide.

MH+ 351.

Example 357 N-Hydroxy-N- ( (R)-2- {N'- [Z- (5, 6,7, 8-tetrahydro-[1,8]naphthyridin-2-yl)-ethyl]- hydrazinocarbonyl]-heptyl}-N-hydroxy-formamide.

MH+ 378.

Example 358 <BR> <BR> <BR> <BR> N-Hydroxy-N-[(R)-2-(N'-quinolin-2-yl-methyl-hydrazinocarbony l)-heptyl]-formamide.

MH+ 359.

Example 359 N-Hydroxy-N-{(R)-2-[N'-(1, 2,3, 4-tetrahydro-quinolin-2-yl-methyl)-hydrazinocarbonyl]- heptyl}-formamide.

MH+ 363.

Example 360 N-Hydroxy-N-[(R)-2-(N'-quinolin-6-yl-methyl-hydrazinocarbony l)-heptyl]-formamide.

MH+ 359.

Example 361 N- [ (R)-2- (N'-Benzofuran-2-yl-methyl-hydrazinocarbonyl)-heptyl]-N-hydr oxy- formamide.

MH+ 348.

Example 362 <BR> <BR> <BR> N-[(R)-2-(N'-Cyclopropylmethyl-hydrazinocarbonyl)-heptyl]-N- hydroxy-formamide.

MH+ 272.

Example 363 N-{(R)-2-[N'-(6-Fluoro-4H-benzo[1, 3] dioxin-8-yl-methyl)-hydrazinocarbonyl]-heptyl}- N-hydroxy-formamide.

MH+ 384 Example 364 <BR> <BR> <BR> N-Hydroxy-N-{(R)-2-[N'-(4-methoxy-benzyl)-hydrazinocarbonyl] -heptyl}-formamide.

MH+ = 338.

Example 365 N-Hydroxy-N-{(R)-2-[N'-(2-methoxy-benzyl)-hydrazinocarbonyl] -heptyl}-formamide.

MH+ = 338.

Example 366 <BR> <BR> <BR> N-Hydroxy-N-{(R)-2-[N'-(tetrahydro-furan-3-yl-methyl)-hydraz inocarbonyl]-heptyl}- formamide.

MH+ = 302.

Example 367 N-[(R)-2-(N'-FFuran-3-yl-methyl-hydrazinocarbonyl)-heptyl]-N -hydroxy-formamide.

MH+ = 298.

Example 368 N-{(R)-2-[N'-(2, 3-Dihydro-benzo [1, 4] dioxin-6-yl-methyl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 366.

Example 369 N-{(R)-2-[N'-(2, 3-Dihydro-benzo [1, 4] dioxin-2-yl-methyl)-hydrazinocarbonyl]-heptyl}-N- hydroxy-formamide.

MH+ = 366.

Example 370 N-Hydroxy-N-{(R)-2-[N'-(2-phenoxy-ethyl)-hydrazinocarbonyl]- heptyl}-formamide.

MH+ = 338.

Example 371 N-{(R)-2-[N'-((S)-2, 3-Dihydroxy-propyl)-hydrazinocarbonyl]-heptyl}-N-hydroxy- formamide.

MH+ = 292.

Example 372 <BR> <BR> <BR> N-Hydroxy-N-{(R)-2-[N'-(5-methyl-isoxazol-3-yl-methyl)-hydra zinocarbonyl]-heptyl}- formamide.

MH+ = 313.

Example 373 N-((R)-2-{N'-[l-(l-Benzo [1, 3] dioxol-5-yl-methanoyl)-piperidin-4-yl]- hydrazinocarbonyl}-heptyl)-N-hydroxy-formamide.

MH+ = 449.

Example 374 N- ( (R)-2- {N'- [1- (1-Benzofuran-2-yl-methanoyl)-piperidin-4-yl]-hydrazinocarbo nyl}- heptyl)-N-hydroxy-formamide.

MH+ = 445.

Example 375 N-Hydroxy-N-[(R)-2-(N'-{1-[1-(7-methoxy-benzofuran-2-yl)-met hanoyl]-piperidin-4-yl}- hydrazinocarbonyl)-heptyl]-formamide.

MH+ = 475.

Example 376 N-{(R)-2-[N'-(1-Benzyl-piperidin-4-yl0-hydraiznocarbonyl]-he ptyl}-N-hydroxy- formamide.

MH+ = 391.

Example 377 N- [ (R)-2- (N'-11- [I- (3, 4-Dichloro-phenyl)-methanoyl]-piperidin-4-yll- hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

MH+ = 474.

Example 378 N-[(R)-2-(N'-{1-[1-(2,3-Dichloro-phenyl)-methanoyl]-piperidi n-4-yl}- hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

MH+ = 474.

Example 379 <BR> <BR> <BR> N-Hydroxy-N- [ (R)-2- (N'- {l- [l- (4-methyl-piperazm-l-yI)-methanoyl]-pentyl}-<BR> <BR> <BR> <BR> <BR> hydrazinocarbonyl)-heptyl]-formamide.<BR> <BR> <BR> <BR> <BR> <P>MH+ = 414.

Preparation 24 N-[(R)-2-(Hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide.

To a solution of N'-{(R)-2-[(Benzyloxyformylamino) methyl] heptanoyl]-hydrazinecarboxylic acid benzyl ester (1 mmol) in EtOH (10 mL) was added 10% Pd/C (50 mg). The mixture was

subjected to hydrogenation for 5 hours at room temperature and then filtered through Celite.

The filtrate was evaporated and purified by hplc to afford N- [ (R)-2- (Hydrazinocarbonyl)- heptyl] -N-hydroxy-formamide as a glass. MH+ 218.

Example 380 N-[(R)-2-(N'-Benzyl-hydrazinocarbonyl)-heptyl]-N-hydroxy-for mamide.

N-[(R)-2-(Hydrazinocarbonyl)-heptyl]-N-hydroxy-formamide (50 mg, 0.23 mmoles) and benzaldehyde (24 mg, 0.23 mmoles) were dissolved in emthanol (2mL) under argon in the presence of 4Å molecular sieves (50 mg), stirred for 1 hour and cooled to 0 °C. To the mixture was added one crystal of methyl orange indicator and enough methanolic HCl to keep the solution acidic (red color). Sodium cyanoborohydride (17 mg, 0.28 mmoles) was added, along with enough methanolic HCl to keep the solution acidic (red indicator). The system was warmed to room temperature, stirred for two days, neutralized with sodium bicarbonate solution, and extracted with ethyl acetate (3x). The organic layer was dried over anhydrous sodium sulfate, concentrated to dryness and purified by prep hplc to afford the title compound.

MH+ 308.

COMPOSITIONS, ADMINISTRATION AND BIOLOGICAL ASSAYS Compounds of Formula (1) and their pharmaceutically acceptable salts may be administered in a standard manner for antibiotics, for example orally, parenterally, sub- lingually, dermally, transdermally, rectally, via inhalation or via buccal administration.

Compositions of Formula (1) and their pharmaceutically acceptable salts which are active when given orally can be formulated as syrups, tablets, capsules, creams and lozenges.

A syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavoring or coloring agent. Where the composition is in the form of a tablet, any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, acacia, stearic acid, starch, lactose and sucrose. Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example, using the aforementioned carriers in a hard gelatin capsule shell. Where the composition is in the form of a soft gelatin shell capsule, any pharmaceutical carrier

routinely used for preparing dispersions or suspensions may be considered, for example, aqueous gums, celluloses, silicates or oils, and incorporated in a soft gelatin capsule shell.

Typical parenteral compositions consist of a solution or suspension of a compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example, polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil or sesame oil.

Typical compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane.

A typical suppository formulation comprises a compound of Formula (1) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example, polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogs.

Typical dermal and transdermal formulations comprise a conventional aqueous or non- aqueous vehicle, for example, a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.

Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer a single dose.

Each dosage unit for oral administration contains suitably from 0.1 mg to 500 mg/Kg, and preferably from 1 mg to 100 mg/Kg, and each dosage unit for parenteral administration contains suitably from 0.1 mg to 100 mg/Kg, of a compound of Formula (1) or a pharmaceutically acceptable salt thereof calculated as the free acid. Each dosage unit for intranasal administration contains suitably 1-400 mg and preferably 10 to 200 mg per person.

A topical formulation contains suitably 0.01 to 5.0% of a compound of Formula (1).

The daily dosage regimen for oral administration is suitably about 0.01 mg/Kg to 40 mg/Kg of a compound of Formula (1) or a pharmaceutically acceptable salt thereof calculated as the free acid. The daily dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg of a compound of Formula (1) or a pharmaceutically acceptable salt thereof calculated as the free acid. The daily dosage regimen for intranasal administration and oral inhalation is suitably about 10 to about 500 mg/person. The active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit the desired activity.

No unacceptable toxicological effects are expected when compounds of the present invention are administered in accordance with the present invention.

The biological activity of the compounds of Formula (1) are demonstrated by the following test: Biological Assay.

S. aureus or E. coli PDF activity is measured at 25°C, using a continuous enzyme- linked''assay developed by Lazennec & Meinnel ("Formate dehydrogenase-coupled spectrophotometric assay of peptide deformylase", Anal. Biochem. 1997,244, pp. 180-182), with minor modifications. The reaction mixture is contained in 50 uL with 50 mM potassium phosphate buffer (pH 7.6), 15 mM NAD, 0.25 U formate dehydrogenase. The substrate peptide, f-Met-Ala-Ser, is included at the KM concentration. The reaction is triggered with the addition of 10 nM Defl enzyme, and absorbance is monitored for 20 min at 340 nm.

Antimicrobial Activity Assay.

Whole-cell antimicrobial activity was determined by broth microdilution using the National Committee for Clinical Laboratory Standards (NCCLS) recommended procedure, Document M7-A4, "Methods for Dilution Susceptibility Tests for Bacteria that Grow Aerobically" (incorporated by reference herein). The compound was tested in serial two-fold dilutions ranging from 0.06 to 64 mcg/ml. A panel of 12 strains were evaluated in the assay.

This panel consisted of the following laboratory strains: Staphylococcus aureus Oxford, Staphylococcus aureus WCUH29, Enterococcus faecalis I, Enterococcus faecalis 7, Haemophilus influenzae Ql, Haemophilus influenzae NEMC1, Moraxella catarrhalis 1502, Streptococcus pneumoniae 1629, Streptococcus pneumoniae N1387, Streptococcus pneumoniae N1387, E. coli 7623 (AcrABEFD+) and E. coli 120 (AcrAB-). The minimum inhibitory concentration (MIC) was determined as the lowest concentration of compound that inhibited visible growth. A mirror reader was used to assist in determining the MIC endpoint.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication

were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration, it is believed that one skilled in the area can, using the preceding description, utilize the present invention to its fullest extent. Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.